UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended June 30, 2015

VECTOR GROUP LTD.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation

incorporation or organization)

1-5759

Commission File Number

65-0949535 (I.R.S. Employer Identification No.)

4400 Biscayne Boulevard Miami, Florida 33137 305-579-8000

(Address, including zip code and telephone number, including area code, of the principal executive offices)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes o No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

x Large accelerated filer

o Accelerated filer

o Non-accelerated filer (Do not check if a smaller reporting company)

o Smaller reporting company

Indicate by check mark whether the Registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. o Yes x No

At July 29, 2015, Vector Group Ltd. had 116,830,619 shares of common stock outstanding.

VECTOR GROUP LTD.

FORM 10-Q

TABLE OF CONTENTS

<u>Page</u>

PART I. FINANCIAL INFORMATION

Item 1. Vector Group Ltd. Condensed Consolidated Financial Statements (Unaudited):	
Condensed Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014	<u>2</u>
Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2015 and June 30, 2014	<u>3</u>
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2015 and June 30, 2014	<u>4</u>
Condensed Consolidated Statement of Stockholders' (Deficiency) Equity for the six months ended June 30, 2015	<u>6</u>
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2015 and June 30, 2014	<u>Z</u>
Notes to Condensed Consolidated Financial Statements	<u>8</u>
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>46</u>
Item 3. Quantitative and Qualitative Disclosures About Market Risk	<u>58</u>
Item 4. Controls and Procedures	<u>58</u>
PART II. OTHER INFORMATION	
Item 1. Legal Proceedings	<u>60</u>
Item 1A. Risk Factors	<u>60</u>
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	<u>62</u>
Item 6. Exhibits	<u>63</u>
<u>SIGNATURE</u>	<u>64</u>

VECTOR GROUP LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in Thousands, Except Per Share Amounts) Unaudited

		June 30, 2015		December 31, 2014	
ASSETS:					
Current assets:					
Cash and cash equivalents	\$	238,323	\$	326,365	
Investment securities available for sale		342,577		346,043	
Accounts receivable - trade, net		18,022		23,328	
Inventories		98,576		90,323	
Income taxes receivable, net		—		3,282	
Restricted assets		2,324		2,595	
Other current assets		45,236		36,718	
Total current assets		745,058		828,654	
Property, plant and equipment, net		79,448		84,112	
Real estate held for sale, net		23,043		10,643	
Long-term investments		46,219		40,292	
Investments in real estate ventures		199,026		163,460	
Restricted assets		20,220		12,013	
Goodwill and other intangible assets, net		267,000		269,972	
Prepaid pension costs		26,635		25,032	
Other assets		56,194		58,893	
Total assets	\$	1,462,843	\$	1,493,071	
LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY:					
Current liabilities:					
Current portion of notes payable and long-term debt	\$	6,074	\$	52,640	
Current portion of fair value of derivatives embedded within convertible debt	-		-	884	
Current payments due under the Master Settlement Agreement		62,626		26,322	
Current portion of employee benefits		931		931	
Income taxes payable, net		3,723		1,743	
Litigation accruals		3,477		3,149	
Deferred income taxes, net		28,322		28,479	
Other current liabilities		125,523		126,755	
Total current liabilities		230,676		240,903	
Notes payable, long-term debt and other obligations, less current portion		872,999		860,711	
Fair value of derivatives embedded within convertible debt		156,783		168,502	
Non-current employee benefits		49,705		49,314	
Deferred income taxes, net		49,709 98,180		43,514 94,510	
Payments due under the Master Settlement Agreement		25,809		25,809	
Litigation accruals		23,444		25,700	
Difer liabilities		6,913			
Total liabilities		1,464,509		5,570 1,471,019	
Commitments and contingencies (Note 7)					
Stockholders' (deficiency) equity:					
Preferred stock, par value \$1.00 per share, 10,000,000 shares authorized Common stock, par value \$0.10 per share, 250,000,000 and 250,000,000 shares authorized, 120,975,866 and 118,646,261 shares issued and 116,830,619 and 114,501,014 shares outstanding		11,683		11,450	
Additional paid-in capital		_		—	
Accumulated deficit		(115,570)		(90,160)	
Accumulated other comprehensive income		33,758		34,540	
Less: 4,145,247 and 4,145,247 shares of common stock in treasury, at cost		(12,857)		(12,857)	
Total Vector Group Ltd. stockholders' deficiency		(82,986)		(57,027)	
Non-controlling interest		81,320		79,079	
Total stockholders' (deficiency) equity		(1,666)		22,052	
Total liabilities and stockholders' (deficiency) equity	\$	1,462,843	\$	1,493,071	

The accompanying notes are an integral part of the condensed consolidated financial statements.

VECTOR GROUP LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Thousands, Except Per Share Amounts) Unaudited

	Three Months Ended June 30,				Six Months End June 30,			
		2015		2014		2015		2014
Revenues:								
Tobacco*	\$	254,890	\$	250,556	\$	482,975	\$	483,948
Real estate		161,022		153,488		293,278		261,532
E-Cigarettes		261		2,569	_	680		8,369
Total revenues		416,173		406,613		776,933		753,849
Expenses:								
Cost of sales:								
Tobacco*		174,867		179,773		331,897		347,939
Real estate		103,870		97,763		188,228		165,087
E-Cigarettes		467		1,746		1,097		5,293
Total cost of sales		279,204		279,282		521,222		518,319
Operating, selling, administrative and general expenses		79,679		67,023		153,623		131,000
Litigation settlement and judgment expense		1,250		_		2,093		1,500
Operating income		56,040		60,308		99,995		103,030
Other income (expenses):								
Interest expense		(31,761)		(44,183)		(63,507)		(79,636)
Change in fair value of derivatives embedded within convertible debt		5,256		1,970		11,716		320
Acceleration of interest expense related to debt conversion				(439)				(4,118)
Equity income (loss) from real estate ventures		1,856		(1,808)		2,194		(256)
Equity (loss) income on long-term investments		(1,657)		(273)		(1,694)		633
(Loss) gain on sale of investment securities available for sale		(190)		(18)		12,839		(71)
Other, net		1,525		3,575		3,421		5,701
Income before provision for income taxes		31,069		19,132		64,964		25,603
Income tax expense		11,364		6,101		24,043		9,043
Net income		19,705		13,031		40,921		16,560
Net income attributed to non-controlling interest		(1,837)		(5,106)		(2,097)		(6,055)
Net income attributed to Vector Group Ltd.	\$	17,868	\$	7,925	\$	38,824	\$	10,505
Per basic common share:								
Net income applicable to common shares attributed to Vector Group Ltd.	\$	0.15	\$	0.08	\$	0.34	\$	0.10
Per diluted common share:								
Net income applicable to common shares attributed to Vector Group Ltd.	\$	0.15	\$	0.08	\$	0.34	\$	0.10
Cash distributions and dividends declared per share	\$	0.40	\$	0.38	\$	0.80	\$	0.76

* Revenues and cost of sales include excise taxes of \$108,912, \$109,695, \$206,271 and \$212,108, respectively.

The accompanying notes are an integral part of the condensed consolidated financial statements.

VECTOR GROUP LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

	Three Mc	onths Er e 30,	nded	Six Mon Jun	iths End	led
	 2015		2014	 2015		2014
Net income	\$ 19,705	\$	13,031	\$ 40,921	\$	16,560
Net unrealized (losses) gains on investment securities available for sale:						
Change in net unrealized (losses) gains	(9,623)		(2,886)	6,517		3,108
Net unrealized losses (gains) reclassified into net income	190		18	(12,839)		71
Net unrealized (losses) gains on investment securities available for sale	 (9,433)		(2,868)	 (6,322)		3,179
Net unrealized gains on long-term investments accounted for under the equity method:						
Change in net unrealized gains	1,176		5,282	1,190		8,614
Net unrealized losses reclassified into net income	1,624		_	1,624		_
Net unrealized gains on long-term investments accounted for under the equity method	2,800		5,282	2,814		8,614
Net change in forward contracts	16		15	32		32
Net change in pension-related amounts						
Net loss arising during the year	1,607		_	1,607		_
Amortization of loss	254		147	521		295
Net change in pension-related amounts	 1,861		147	 2,128		295
Other comprehensive (loss) income	 (4,756)		2,576	 (1,348)		12,120
Income tax effect on:						
Change in net unrealized (losses) gains on investment securities	3,979		1,193	(2,694)		(1,780)
Net unrealized losses (gains) reclassified into net income on investment securities	(78)		(7)	5,309		(29)
Change in unrealized gains on long-term investments accounted for under the equity method	(478)		(2,184)	(484)		(3,554)
Net unrealized losses reclassified into net income on long-term investments accounted for under the equity method	(672)		_	(672)		_
Forward contracts	(7)		(6)	(13)		(12)
Pension-related amounts	(769)		(61)	(880)		74
Income tax provision on other comprehensive income	1,975		(1,065)	 566		(5,301)
Other comprehensive (loss) income, net of tax	(2,781)		1,511	(782)		6,819
Comprehensive income	16,924		14,542	 40,139		23,379
Comprehensive income attributed to non-controlling interest	(1,837)		(5,106)	(2,097)		(6,055)
Comprehensive income attributed to Vector Group Ltd.	\$ 15,087	\$	9,436	\$ 38,042	\$	17,324

The accompanying notes are an integral part of the condensed consolidated financial statements.

VECTOR GROUP LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIENCY) EQUITY (Dollars in Thousands, Except Per Share Amounts) Unaudited

			Additional		Accumulated Other			
	Commor	n Stock	Paid-In	Accumulated	Comprehensive	Treasury	Non-controlling	
	Shares	Amount	Capital	Deficit	Income	Stock	Interest	Total
Balance, January 1, 2015	114,501,014	\$11,450	\$ —	\$ (90,160)	\$ 34,540	\$ (12,857)	\$ 79,079	\$ 22,052
Net income	_	_	_	38,824	_	_	2,097	40,921
Total other comprehensive loss	_	—	—	_	(782)	_	—	(782)
Total comprehensive income	_	_	_	_	_	_	_	40,139
Distributions and dividends on common stock	_	—	(29,292)	(64,234)	—	_	—	(93,526)
Note conversions, net of taxes \$367	2,227,552	223	25,299	_	_	_	_	25,522
Exercise of stock options	102,053	10	1,209	—	—	—	_	1,219
Tax benefit of options exercised	—	—	384	—		—	_	384
Stock-based compensation	—	—	2,400	—	_	—	_	2,400
Contributions made by non-controlling interest	—	—	—	—		—	144	144
Balance as of June 30, 2015	116,830,619	\$11,683	\$	\$ (115,570)	\$ 33,758	\$ (12,857)	\$ 81,320	\$ (1,666)

The accompanying notes are an integral part of the condensed consolidated financial statements.

VECTOR GROUP LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands, Except Per Share Amounts) Unaudited

	Six Months Ended June 30, 2015	Six Months Ended June 30, 2014
Net cash provided by operating activities	\$ 83,885	\$ 53,995
Cash flows from investing activities:		
Sale of investment securities	118,261	49,296
Maturities of investment securities	1,737	_
Purchase of investment securities	(113,595)	(110,419)
Proceeds from sale or liquidation of long-term investments	148	549
Purchase of long-term investments	(5,000)	(7,000)
Investments in real estate ventures	(34,857)	(12,534)
Distributions from investments in real estate ventures	_	3,539
Increase in cash surrender value of life insurance policies	(1,118)	(395)
Increase in restricted assets	(7,934)	(371)
Issuance of notes receivable	(4,410)	(250)
Proceeds from sale of fixed assets	3	4
Capital expenditures	(5,379)	(10,144)
Repayments of notes receivable	1,106	933
Purchase of subsidiaries	_	(250)
Pay downs of investment securities	3,530	—
Proceeds from sale of preferred securities	1,000	_
Investments in real estate held for sale	(12,502)	_
Net cash used in investing activities	(59,010)	(87,042)
Cash flows from financing activities:		
Proceeds from issuance of debt	22	413,916
Deferred financing costs	(625)	(12,360)
Repayments of debt	(3,374)	(8,051)
Borrowings under revolver	126,727	429,188
Repayments on revolver	(144,492)	(437,736)
Dividends and distributions on common stock	(92,778)	(80,963)
Distributions to non-controlling interest	_	(3,075)
Proceeds from exercise of Vector options	1,219	3,405
Tax benefit of options exercised	384	680
Net cash (used in) provided by financing activities	(112,917)	305,004
Net (decrease) increase in cash and cash equivalents	(88,042)	271,957
Cash and cash equivalents, beginning of period	326,365	234,466
Cash and cash equivalents, end of period	\$ 238,323	\$ 506,423

The accompanying notes are an integral part of the condensed consolidated financial statements.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) <u>Basis of Presentation</u>:

The condensed consolidated financial statements of Vector Group Ltd. (the "Company" or "Vector") include the accounts of VGR Holding LLC ("VGR Holding"), Liggett Group LLC ("Liggett"), Vector Tobacco Inc. ("Vector Tobacco"), Liggett Vector Brands LLC ("Liggett Vector Brands"), Zoom E-Cigs LLC ("Zoom"), New Valley LLC ("New Valley") and other less significant subsidiaries. New Valley includes the accounts of Douglas Elliman Realty, LLC ("Douglas Elliman") and other less significant subsidiaries. All significant intercompany balances and transactions have been eliminated.

Liggett and Vector Tobacco are engaged in the manufacture and sale of cigarettes in the United States. Zoom is engaged in the sale of electronic cigarettes in the United States. New Valley is engaged in the real estate business.

The unaudited, interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and, in management's opinion, contain all adjustments, consisting only of normal recurring items, necessary for a fair statement of the results for the periods presented. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission. The consolidated results of operations for interim periods should not be regarded as necessarily indicative of the results that may be expected for the entire year.

Revisions to December 31, 2014 Consolidated Balance Sheet. The Company has revised its December 31, 2014 Consolidated Balance Sheet, which originally presented deferred income tax assets and liabilities (current and noncurrent) on a gross basis, rather than a net basis. The revisions conform to ASC 740-10-45-6 which states all current deferred tax liabilities and assets shall be offset and presented as a single amount and all noncurrent deferred tax liabilities and assets shall be offset and presented as a single amount and all noncurrent deferred tax liabilities and assets shall be offset and presented as a single amount. The Company assessed the materiality of this error on previously issued financial statements and concluded that the error was immaterial.

The revisions are presented in the table below:

	December 31, 2014					
	s Previously Reported	Revision		As Rev	vised	
Deferred income taxes	\$ 29,192	\$	(29,192)	\$	—	
Total current assets	 857,846		(29,192)	828	3,654	
Deferred income taxes	51,129		(51,129)		_	
Total assets	\$ 1,573,392	\$	(80,321)	\$ 1,493	3,071	
Deferred income taxes, net	\$ 57,671	\$	(29,192)	\$ 28	3,479	
Total current liabilities	270,095		(29,192)	240),903	
Deferred income taxes, net	145,639		(51,129)	94	4,510	
Total liabilities	 1,551,340		(80,321)	1,471	,019	
Total stockholders' equity	22,052			22	2,052	
Total liabilities and stockholders' equity	\$ 1,573,392	\$	(80,321)	\$ 1,493	3,071	

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

(b) <u>Distributions and Dividends on Common Stock</u>:

The Company records distributions on its common stock as dividends in its condensed consolidated statement of stockholders' (deficiency) equity to the extent of retained earnings and accumulated paid-in capital. Any amounts exceeding retained earnings are recorded as a reduction to additional paid-in capital. Any amounts then exceeding accumulated paid-in capital are recorded as an increase to accumulated deficit.

(c) <u>Revenue Recognition</u>:

Tobacco and E-Cigarettes sales: Revenues from sales are recognized upon the shipment of finished goods when title and risk of loss have passed to the customer, there is persuasive evidence of an arrangement, the sale price is fixed or determinable and collectibility is reasonably assured. The Company provides an allowance for expected sales returns, net of any related inventory cost recoveries. Certain sales incentives, including promotional price discounts, are classified as reductions of net sales. The Company includes federal excise taxes on tobacco sales in revenues and cost of goods sold. Since the Company's primary line of business is tobacco, the Company's financial position and its results of operations and cash flows have been and could continue to be materially adversely affected by significant unit sales volume declines at the Company and industry levels, regulation, litigation and defense costs, increased tobacco costs or reductions in the selling price of cigarettes in the near term.

Real estate sales: Revenue is recognized only when persuasive evidence of an arrangement exists, the price is fixed or determinable, the transaction has been completed and collectibility of the resulting receivable is reasonably assured. Real estate and mortgage commissions earned by the Company's real estate and mortgage brokerage businesses are recorded as revenue on a gross basis upon the closing of a real estate transaction as evidenced when the escrow or similar account is closed, the transaction documents have been recorded and funds are distributed to all appropriate parties. Commissions and royalties expenses are recognized concurrently with related revenues. Property management fees earned are recorded as revenue when the related services are performed.

(d) <u>Earnings Per Share ("EPS")</u>:

Information concerning the Company's common stock has been adjusted to give retroactive effect to the 5% stock dividend paid to Company stockholders on September 26, 2014. All per share amounts and references to share amounts have been updated to reflect the retrospective effect of the stock dividends.

Net income for purposes of determining basic and diluted EPS was as follows:

	Three Months Ended			Six Months Ended			
	June 30,			Jun	e 30,		
		2015		2014	2015		2014
Net income attributed to Vector Group Ltd.	\$	17,868	\$	7,925	\$ 38,824	\$	10,505
Expense attributed to participating securities		(529)		(231)	(1,151)		(309)
Net income attributed to Vector Group Ltd. available to common stockholders	\$	17,339	\$	7,694	\$ 37,673	\$	10,196

Basic and diluted EPS were calculated using the following shares:

	Three Month	is Ended	Six Months	s Ended
	June 3	0,	June	30,
	2015	2014	2015	2014
Weighted-average shares for basic EPS	112,337,817	101,598,939	111,881,314	100,470,719
Plus incremental shares related to stock options and non-vested restricted stock	199,112	106,321	195,488	117,908
Weighted-average shares for diluted EPS	112,536,929	101,705,260	112,076,802	100,588,627

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

The following were outstanding during the three and six months ended June 30, 2015 and 2014, but were not included in the computation of diluted EPS because the effect was anti-dilutive.

	Three Months Ended June 30,			Six Mont June	ıded
	2015		2014	2015	2014
Weighted-average number of shares issuable upon conversion of debt	 23,709,978		34,117,652	 24,128,414	 30,560,906
Weighted-average conversion price	\$ 20.61	\$	18.11	\$ 20.45	\$ 16.72

(e) <u>Fair Value of Derivatives Embedded within Convertible Debt</u>:

The Company has estimated the fair market value of the embedded derivatives based principally on the results of a valuation model. The estimated fair value of the derivatives embedded within the convertible debt is based principally on the present value of future dividend payments expected to be received by the convertible debt holders over the term of the debt. The discount rate applied to the future cash flows is estimated based on a spread in the yield of the Company's debt when compared to risk-free securities with the same duration. A readily determinable fair market value of the embedded derivatives is not available. The valuation model assumes future dividend payments by the Company and utilizes interest rates and credit spreads for secured to unsecured debt, unsecured to subordinated debt and subordinated debt to preferred stock to determine the fair value of the derivatives embedded within the convertible debt. The valuation also considers other items, including current and future dividends and the volatility of the Company's stock price. At June 30, 2015, the range of estimated fair market values of the Company's embedded derivatives was between \$155,272 and \$158,324. The Company recorded the fair market value of its embedded derivatives at the midpoint of the range at \$156,783 as of June 30, 2015. At December 31, 2014, the range of estimated fair market values of the Company's embedded derivatives was between \$167,593 and \$171,215. The Company recorded the fair market value of its embedded derivatives was between \$167,593 and \$171,215. The Company recorded the fair market value of its embedded derivatives was between \$167,593 and \$171,215. The Company recorded the fair market value of its embedded derivatives could change significantly based on future market conditions. (See Note 6.)

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

(f) <u>Other Income, Net</u>:

Other income, net consisted of:

	Three Months Ended June 30,					Six Months Ended June 30,			
	2	2015		2014		2015		2014	
(Loss) gain on warrants	\$	(369)	\$	45	\$	(483)	\$	(123)	
Interest and dividend income		1,858		1,189		3,607		2,189	
Accretion of interest income from debt discount on notes receivable		10		10		74		76	
Gain on long-term investment		24		—		224		—	
Out-of-period adjustment				—		—		1,231	
Acceleration of closing fee related to termination of Douglas Elliman joint venture		—		2,335		_		2,335	
Other income (expense)		2		(4)		(1)		(7)	
Other income, net	\$	1,525	\$	3,575	\$	3,421	\$	5,701	

The out-of-period adjustment related to a non-accrual of a receivable from Douglas Elliman in the fourth quarter of 2013 and would have increased the Company's gain on acquisition of Douglas Elliman in 2013. The Company assessed the materiality of this error on all previously issued financial statements and concluded that the error was immaterial to all previously issued financial statements. The impact of correcting this error in 2014 was not material to the Company's 2014 consolidated financial statements.

(g) <u>Other Current Liabilities</u>:

Other current liabilities consisted of:

	June	30, 2015	December 31, 2014
Accrued promotional expenses	\$	18,215	\$ 20,191
Accrued excise and payroll taxes payable, net		20,885	23,172
Accrued interest		27,746	28,321
Commissions payable		13,442	9,523
Accrued salary and benefits		12,110	16,009
Other current liabilities		33,125	29,539
Total other current liabilities	\$	125,523	\$ 126,755



(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

(h) <u>Goodwill and Other Intangible Assets</u>:

The components of "Goodwill and other intangible assets, net" were as follows:

	June 30, 2015	J	December 31, 2014
Goodwill	\$ 70,791	\$	70,791
Indefinite life intangibles:			
Intangible asset associated with benefit under the MSA	107,511		107,511
Trademark - Douglas Elliman	80,000		80,000
Intangibles with a finite life, net	8,698		11,670
		_	
Total goodwill and other intangible assets, net	\$ 267,000	\$	269,972
		_	

(i) <u>New Accounting Pronouncements</u>:

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"), which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. Upon adoption, the Company will apply the new guidance on a retrospective basis and adjust the balance sheet of each individual period presented to reflect the period-specific effects of applying the new guidance. This guidance is effective for the Company beginning January 1, 2016. The Company is evaluating the effect that this guidance will have on its consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation: Amendments to the Consolidation Analysis ("ASU 2015-02"). ASU 2015-02 amends the consolidation requirements and significantly changes the consolidation analysis required. ASU 2015-02 requires management to reevaluate all legal entities under a revised consolidation model specifically (1) modify the evaluation of whether limited partnership and similar legal entities are Variable Interest Entities ("VIEs"), (2) eliminate the presumption that a general partner should consolidate a limited partnership, (3) affect the consolidation analysis of reporting entities that are involved with VIEs particularly those that have fee arrangements and related party relationships, and (4) provide a scope exception from consolidation guidance for reporting entities with interests in legal entities that are required to comply with or operate in accordance with requirements that are similar to those in Rule 2a-7 of the Investment Act of 1940 for registered money market funds. The guidance is effective for the Company beginning January 1, 2016. Early adoption is permitted. The Company is evaluating the effect that this guidance will have on its consolidated financial statements.

In May 2014, the FASB issued Accounting Standards Update No. 2014-9, "Revenue from Contracts with Customers (Topic 606)," ("ASU 2014-9"). ASU 2014-9 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. As currently issued, the new standard is effective beginning January 1, 2019; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or with the cumulative effect of initially applying it recognized at the date of initial application. The Company has not yet selected a transition method nor has it determined the impact of the new standard on its condensed consolidated financial statements.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

2. **INVENTORIES**

Inventories consist of:

	June 30, 2015	De	cember 31, 2014
Leaf tobacco	\$ 57,576	\$	49,948
Other raw materials	4,041		3,532
Work-in-process	592		879
Finished goods	67,619		62,876
E-Cigarettes	243		3,079
Inventories at current cost	130,071		120,314
LIFO adjustments	(31,495)		(29,991)
	\$ 98,576	\$	90,323

All of the Company's inventories at June 30, 2015 and December 31, 2014 are reported under the LIFO method. The \$31,495 LIFO adjustment as of June 30, 2015 decreases the current cost of inventories by \$19,821 for Leaf tobacco, \$900 for Other raw materials, \$41 for Work-in-Process, \$10,637 for Finished goods and \$96 for E-Cigarettes. The \$29,991 LIFO adjustment as of December 31, 2014 decreased the current cost of inventories by \$19,841 for Leaf tobacco, \$861 for Other raw materials, \$39 for Work-in-Process, \$9,054 for Finished goods and \$96 for E-Cigarettes.

The Company has a leaf inventory management program whereby, among other things, it is committed to purchase certain quantities of leaf tobacco. The purchase commitments are for quantities not in excess of anticipated requirements and are at prices, including carrying costs, established at the commitment date. At June 30, 2015, Liggett had tobacco purchase commitments of approximately \$13,917 and E-Cigarettes purchase commitments of \$300. The Company has a single source supply agreement for fire safe cigarette paper through 2019.

The Company capitalizes the incremental prepaid cost of the MSA in ending inventory. Each year, the Company capitalizes in inventory that portion of its MSA liability that relates to cigarettes shipped to the public warehouses but not sold. The amount of capitalized MSA cost in "Finished goods" inventory was \$15,381 and \$14,369 at June 30, 2015 and December 31, 2014, respectively.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

3. INVESTMENT SECURITIES AVAILABLE FOR SALE

The components of investment securities available for sale at June 30, 2015 were as follows:

	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Marketable equity securities	\$ 71,275	\$ 88,746	\$ (1,747)	\$ 158,274
Mutual funds invested in fixed income securities	62,399		(1,958)	60,441
Marketable debt securities	124,019	109	(266)	123,862
Total investment securities available for sale	\$ 257,693	\$ 88,855	\$ (3,971)	\$ 342,577

The components of investment securities available for sale at December 31, 2014 were as follows:

	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Marketable equity securities	\$ 63,041	\$ 92,244	\$ (1,093)	\$ 154,192
Mutual funds invested in fixed income securities	61,485	—	(1,659)	59,826
Marketable debt securities	130,311	2,557	(843)	132,025
Total investment securities available for sale	\$ 254,837	\$ 94,801	\$ (3,595)	\$ 346,043

The table below summarizes the maturity dates of marketable debt securities at June 30, 2015.

Investment Type:	Ma	arket Value	Under 1 Year	1 Yea	ar up to 5 Years	Mor	e than 5 Years
U.S. Government securities	\$	33,886	\$ _	\$	33,886	\$	_
Corporate securities		51,937	6,685		44,840		412
U.S. mortgage-backed securities		6,757	839		5,751		167
Commercial mortgage-backed securities		15,758	5,084		4,614		6,060
U.S. asset-backed securities		13,393	2,080		9,852		1,461
Index-linked U.S. bonds		2,131	—		2,131		_
Total marketable debt securities by maturity dates	\$	123,862	\$ 14,688	\$	101,074	\$	8,100

4. LONG-TERM INVESTMENTS

Long-term investments consisted of the following:

	Ju	June 30, 2015		nber 31, 2014
Investment partnerships	\$	36,540	\$	31,541
Real estate partnership		551		698
Long-term investments at cost		37,091		32,239
Investment partnership accounted for under the equity method		9,128		8,053
	\$	46,219	\$	40,292

Long-term investments consisted of the following investments accounted for at cost:

		June 30, 2015			December			er 31, 2014	
	(Carrying		Fair		Carrying		Fair	
		Value		Value		Value		Value	
Investment partnerships	\$	36,540	\$	46,093	\$	31,541	\$	38,039	
Real estate partnership		551		762		698		1,108	
	\$	37,091	\$	46,855	\$	32,239	\$	39,147	

Long-term investment partnership accounted for under the equity method:

	June 30, 2015	D	ecember 31, 2014
Investment partnership	\$ 9,128	\$	8,053

The Company recorded equity losses of \$1,657 and \$273 for the three months ended June 30, 2015 and June 30, 2014, respectively. The Company recorded an equity loss of \$1,694 and equity income of \$633 for the six months ended June 30, 2015 and June 30, 2014, respectively. The carrying value of the investment partnership was approximately \$9,128 and \$8,053 as of June 30, 2015 and December 31, 2014, respectively, which approximated the investment's fair value.

5. NEW VALLEY LLC

Residential Brokerage Business Acquisition. New Valley is engaged in the real estate business and is seeking to acquire additional real estate properties and operating companies. The Company owns a 70.59% interest in Douglas Elliman and the condensed consolidated financial statements of the Company include the account balances of Douglas Elliman.

Investments in real estate ventures. New Valley also holds equity investments in various real estate projects domestically and internationally. The components of "Investments in real estate ventures" were as follows:

	J.	June 30, 2015		-		mber 31, 2014
	¢	E 027	¢	E 0.27		
Milanosesto Holdings (Sesto Holdings)	\$	5,037	\$	5,037		
Land Development		5,057		5,037		
10 Madison Square Park West (1107 Broadway)		7,407		6,383		
The Marquand		13,500		12,000		
11 Beach Street		12,004		12,328		
20 Times Square (701 Seventh Avenue)		12,737		12,481		
111 Murray Street		27,203		27,319		
357 West (160 Leroy Street)		1,753		1,467		
PUBLIC Chrystie House (Chrystie Street)		5,297		3,300		
The Dutch (25-19 43rd Avenue)		980		733		
Queens Plaza (23-10 Queens Plaza South)		11,146		11,082		
87 Park (8701 Collins Avenue)		5,736		6,144		
125 Greenwich Street		9,110		9,308		
West Hollywood Edition (9040 Sunset Boulevard)		5,604		5,604		
76 Eleventh Avenue		17,000		_		
Monad Terrace		6,200		_		
Condominium and Mixed Use Development		135,677		108,149		
Maryland Portfolio		2,916		3,234		
ST Portfolio		16,910		15,283		
Apartment Buildings		19,826		18,517		
Park Lane Hotel		19,529		19,341		
Hotel Taiwana		8,206		7,629		
Coral Beach and Tennis Club		3,025		2,816		
Hotels		30,760		29,786		
The Plaza at Harmon Meadow		5,958		_		
Commercial		5,958		_		
Other		1,768		1,971		
Investments in real estate ventures	\$	199,026	\$	163,460		

Condominium and Mixed Use Development:

Condominium and mixed use developments investments range in ownership percentage from 5% to 49.5%. New Valley recorded net equity income of \$138 and \$675 for the three and six months ended June 30, 2015, respectively. The \$675 equity

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

income for the six months ended June 30, 2015 was primarily related to New Valley's proportionate share of three units at the Marquand offset by equity losses from the other condominiums and mixed use development projects. New Valley recorded equity income of \$7 and \$2,299 for the three and six months ended June 30, 2014, respectively. The \$2,299 equity income for the six months ended June 30, 2014 was primarily related to the sale of a commercial unit at 10 Madison Square Park West.

During the six months ended June 30, 2015, New Valley made capital contributions totaling \$27,091 primarily related to 76 Eleventh Avenue and Monad Terrace. During the six months ended June 30, 2014, New Valley made capital contributions totaling \$10,737 related to 11 Beach Street, 111 Murray Street, PUBLIC Chrystie House, Queens Plaza and 20 Times Square. New Valley contributed its proportionate share of additional capital along with contributions by the other investment partners. New Valley's investment percentages did not change.

During the six months ended June 30, 2015, New Valley received a distribution of \$236 from its investment in Chelsea Eleven, which sold its last unit in 2012, for excess amounts held back in 2012 for final expenses of the investment. During the six months ended June 30, 2014, New Valley received distributions of \$5,189 primarily related to 10 Madison Square Park West, 11 Beach Street and 20 Times Square.

New Valley's maximum exposure to loss, net of non-controlling interest, as a result of its investments in condominium and mixed use developments was \$132,842 at June 30, 2015.

Apartment Buildings:

Apartment buildings investments range in ownership percentage from 7.6% to 16.3%. New Valley recorded equity income of \$1,848 and \$1,801 for the three and six months ended June 30, 2015, respectively, primarily related to the ST Portfolio apartment portfolio. In 2015, ST Portfolio sold one (Phoenix, Arizona) of its three remaining Class A multi-family buildings and the proceeds were used to pay down debt. New Valley recorded net equity losses of \$217 and \$164 for the three and six months ended June 30, 2014, respectively, primarily related to equity losses of ST Portfolio. New Valley received distributions of \$493 and \$250 during the six months ended June 30, 2015 and 2014, respectively, primarily related to NV Maryland. New Valley's maximum exposure to loss as a result of its investment in apartment buildings was \$19,826 at June 30, 2015.

Hotels:

Hotel investments range in ownership percentage from 5% to 49%. New Valley recorded net equity losses of \$261 and \$1,006 for the three and six months ended June 30, 2015, respectively, related to hotel operations. New Valley recorded net equity losses of \$857 and \$2,171 for the three and six months ended June 30, 2014, respectively. New Valley made capital contributions totaling \$1,980 for the six months ended June 30, 2015, primarily related to Coral Beach and Tennis Club and Park Lane. New Valley made capital contributions totaling \$589 for the six months ended June 30, 2014, primarily related to Coral Beach. New Valley's maximum exposure to loss as a result of its investments in hotels was \$30,760 at June 30, 2015.

Commercial:

Commercial ventures include a contribution by New Valley of \$5,931 for a 49% interest in a joint venture which purchased a shopping center, The Plaza at Harmon Meadow, in New Jersey at the end of March 2015. The joint venture is a variable interest entity, however, New Valley is not the primary beneficiary of the joint venture. New Valley will account for its interest in the joint venture under the equity method of accounting. New Valley recorded equity income of \$27 for the three and six months ended June 30, 2015 related to shopping center rental operations. New Valley's maximum exposure to loss as a result of its investments in commercial ventures was \$5,958 at June 30, 2015.

Other:

Other investments in real estate ventures relate to an investment in a mortgage company and an insurance company partially owned by Douglas Elliman.



(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

Real Estate Held for Sale:

The components of "Real estate held for sale, net" were as follows:

	June 30, 2015	December 31, 2014
Escena, net	\$ 10,541	\$ 10,643
Sagaponack	12,502	—
Real estate held for sale, net	\$ 23,043	\$ 10,643

Escena. The assets of "Escena, net" are as follows:

	June 30, 2015	D	ecember 31, 2014
Land and land improvements	\$ 8,953	\$	8,953
Building and building improvements	1,873		1,865
Other	1,575		1,568
	12,401		12,386
Less accumulated depreciation	(1,860)		(1,743)
	\$ 10,541	\$	10,643

New Valley recorded operating losses of \$173 and \$287 for the three months ended June 30, 2015 and 2014, respectively, from Escena. New Valley recorded operating income of \$552 and \$233 for the six months ended June 30, 2015 and 2014, respectively, from Escena.

Investment in Indian Creek. In March 2013, New Valley invested \$7,616 for an 80% interest in Timbo LLC ("Indian Creek") which owns a residential real estate project located on Indian Creek, Florida. As a result of the 80% ownership interest, the consolidated financial statements of the Company included the balances of Indian Creek.

In May 2014, the Indian Creek property was sold for \$14,400 and New Valley received a distribution of approximately \$7,100. New Valley recognized income of approximately \$2,400 from the sale for the three and six months ended June 30, 2014.

Investment in Sagaponack. In April 2015, New Valley invested \$12,502 in a residential real estate project located in Sagaponack, NY. The project is wholly owned and the balances of the project are included in the consolidated financial statements of the Company. As of June 30, 2015, the assets of Sagaponack consist of land and land improvements of \$12,502.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

6. NOTES PAYABLE, LONG-TERM DEBT AND OTHER OBLIGATIONS

Notes payable, long-term debt and other obligations consist of:

	_	June 30, 2015	Ι	December 31, 2014
Vector:				
7.75% Senior Secured Notes due 2021, including premium of \$8,656 and \$9,275	\$	608,656	\$	609,275
6.75% Variable Interest Senior Convertible Note due 2015		—		25,000
7.5% Variable Interest Senior Convertible Notes due 2019, net of unamortized discount of \$140,259 and \$146,634*		89,741		83,366
5.5% Variable Interest Senior Convertible Debentures due 2020, net of unamortized discount of \$92,747 and \$98,831*		166,003		159,919
Liggett:				
Revolving credit facility		—		17,767
Term loan under credit facility		3,442		3,589
Equipment loans		10,873		13,966
Other		358		469
Total notes payable, long-term debt and other obligations		879,073		913,351
Less:				
Current maturities		(6,074)		(52,640)
Amount due after one year	\$	872,999	\$	860,711

* The fair value of the derivatives embedded within the 6.75% Variable Interest Senior Convertible Note (\$0 at June 30, 2015 and \$884 at December 31, 2014, respectively), the 7.5% Variable Interest Senior Convertible Notes (\$80,283 at June 30, 2015 and \$87,638 at December 31, 2014, respectively) and the 5.5% Variable Interest Senior Convertible Debentures (\$76,500 at June 30, 2015 and \$80,864 at December 31, 2014, respectively), is separately classified as a derivative liability in the condensed consolidated balance sheets.

6.75% Variable Interest Senior Convertible Note due 2015 - Vector:

On February 3, 2015, the holder of the 6.75% Variable Interest Senior Convertible Note due 2015, converted the remaining \$25,000 principal balance of the \$50,000 Note into 2,227,552 of the Company's common shares. The debt conversion resulted in a reduction of debt and an increase to equity in the amount of \$25,000.

Revolving Credit Facility and Term Loan Under Credit Facility - Liggett:

As of June 30, 2015, a total of \$3,442 was outstanding under the revolving and term loan portions of the credit facility. Availability, as determined under the facility, was approximately \$56,558 based on eligible collateral at June 30, 2015.

Shares of Common Stock per \$1,000 Principal Amount due on Convertible Notes:

The conversion rates for all convertible debt outstanding as of June 30, 2015 and December 31, 2014, are summarized below:

		June 30,	2015		December	31, 2014
	Conve	ersion Price	Shares per \$1,000	Conv	version Price	Shares per \$1,000
6.75% Variable Interest Senior Convertible Note due 2014	\$	—	—	\$	11.22	89.1021
7.5% Variable Interest Senior Convertible Notes due 2019	\$	16.78	59.5946	\$	16.78	59.5946
5.5% Variable Interest Senior Convertible Debentures due 2020	\$	25.87	38.6563	\$	25.87	38.6563

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

Non-Cash Interest Expense - Vector:

	Three Months Ended June 30, 2015 2014					Six Months Ended			
						June 2015	2014 - 2014		
Amortization of debt discount, net	\$	6,213	\$	7,563	\$	11,840	\$	20,019	
Amortization of deferred finance costs		1,022		1,055		1,988		1,763	
Accelerated interest expense on 6.75% Variable Interest Senior Convertible Note converted		_		_		_		3,679	
Accelerated interest expense on 6.75% Variable Interest Senior Convertible Exchange Notes converted				439		_		439	
	\$	7,235	\$	9,057	\$	13,828	\$	25,900	

Fair Value of Notes Payable and Long-Term Debt:

	June 3	0, 20 1	15		December	31, 2	2014
	 Carrying		Fair	(Carrying		Fair
	Value		Value		Value		Value
Notes payable and long-term debt	\$ 879,073 (1)	\$	1,282,056	\$	913,351 (1)	\$	1,313,711

⁽¹⁾ The carrying value does not include the carrying value of the embedded derivative. See Note 9.

Notes payable and long-term debt are carried on the condensed consolidated balance sheet at amortized cost. The fair value determination disclosed above are classified as Level 2 under the fair value hierarchy disclosed in Note 9 if such liabilities were recorded on the condensed consolidated balance sheet at fair value. The estimated fair value of the Company's notes payable and long-term debt has been determined by the Company using available market information and appropriate valuation methodologies including the evaluation of the Company's credit risk as described in the Company's Form 10-K. However, considerable judgment is required to develop the estimates of fair value and, accordingly, the estimate presented herein is not necessarily indicative of the amount that could be realized in a current market exchange.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

7. CONTINGENCIES

Tobacco-Related Litigation:

Overview. Since 1954, Liggett and other United States cigarette manufacturers have been named as defendants in numerous direct, third-party and purported class actions predicated on the theory that cigarette manufacturers should be liable for damages alleged to have been caused by cigarette smoking or by exposure to secondary smoke from cigarettes. The cases have generally fallen into the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs ("Individual Actions"); (ii) lawsuits by individuals requesting the benefit of the *Engle* ruling ("*Engle* progeny cases"); (iii) smoking and health cases primarily alleging personal injury or seeking court-supervised programs for ongoing medical monitoring, as well as cases alleging that use of the terms "lights" and/or "ultra lights" constitutes a deceptive and unfair trade practice, common law fraud or violation of federal law, purporting to be brought on behalf of a class of individual plaintiffs ("Class Actions"); and (iv) health care cost recovery actions brought by various foreign and domestic governmental plaintiffs and non-governmental plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits ("Health Care Cost Recovery Actions"). With the commencement of new cases, the defense costs and the risks relating to the unpredictability of litigation increase. The future financial impact of the risks and expenses of litigation are not quantifiable. For the three months ended June 30, 2015 and 2014, Liggett incurred tobacco product liability legal expenses and other litigation costs totaling \$5,713 and \$5,174. These are included in the operating, selling, administrative and general expenses in the Condensed Statement of Operations.

Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending cases. Management reviews on a quarterly basis with counsel all pending litigation and evaluates whether an estimate can be made of the possible loss or range of loss that could result from an unfavorable outcome. An unfavorable outcome or settlement of pending tobacco-related litigation could encourage the commencement of additional litigation. Damages awarded in some tobacco-related litigation can be significant.

Bonds. Although Liggett has been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts are on appeal, there remains a risk that such relief may not be obtainable in all cases. This risk has been reduced given that a majority of states now limit the dollar amount of bonds or require no bond at all. To obtain stays on judgments pending current appeals, Liggett has secured approximately \$12,268 and \$4,768 in bonds as of June 30, 2015 and December 31, 2014, respectively.

In June 2009, Florida amended its existing bond cap statute by adding a \$200,000 bond cap that applies to all *Engle* progeny cases in the aggregate and establishes individual bond caps for individual *Engle* progeny cases in amounts that vary depending on the number of judgments in effect at a given time. In several cases, plaintiffs challenged the constitutionality of the bond cap statute, but to date the courts have upheld the constitutionality of the statute. It is possible that the Company's consolidated financial position, results of operations, and cash flows could be materially adversely affected by an unfavorable outcome of such challenges.

Accounting Policy. The Company and its subsidiaries record provisions in their consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except as disclosed in this Note 7: (i) management has concluded that it is not probable that a loss has been incurred in any of the pending tobacco-related cases; or (ii) management is unable to reasonably estimate the possible loss or range of loss that could result from an unfavorable outcome of any of the pending tobacco-related cases and, therefore, management has not provided any amounts in the consolidated financial statements for unfavorable outcomes, if any. Legal defense costs are expensed as incurred.

Cautionary Statement About Engle Progeny Cases. Judgments have been entered against Liggett and other industry defendants in *Engle* progeny cases. A number of the judgments have been affirmed on appeal and satisfied by the defendants. As of June 30, 2015, 21 *Engle* progeny cases where Liggett was a defendant at trial resulted in verdicts. Fourteen verdicts were returned in favor of the plaintiffs (although in two of these cases (*Irimi* and *Cohen*), the court granted defendants' motion for a new trial and another (*Putney*) was reversed on appeal) and seven in favor of Liggett. In certain cases, the judgments entered have been joint and several with other defendants. In four of the cases, punitive damages were awarded against Liggett. Except as discussed in this Note 7 regarding the cases where an adverse verdict was entered against Liggett and that remain on appeal, management is unable to estimate the possible loss or range of loss from the remaining *Engle* progeny cases as there are currently

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

multiple defendants in each case and, in most cases, discovery has not occurred or is limited. As a result, the Company lacks information about whether plaintiffs are in fact *Engle* class members (non-class members' claims are generally time-barred), the relevant smoking history, the nature of the alleged injury and the availability of various defenses, among other things. Further, plaintiffs typically do not specify their demand for damages.

Although Liggett has generally been successful in managing litigation, litigation is subject to uncertainty and significant challenges remain, including with respect to the remaining *Engle* progeny cases. There can be no assurances that Liggett's past litigation experience will be representative of future results. Judgments have been entered against Liggett in the past, in Individual Actions and *Engle* progeny cases, and several of those judgments were affirmed on appeal and satisfied by Liggett. It is possible that the consolidated financial position, results of operations and cash flows of the Company could be materially adversely affected by an unfavorable outcome or settlement of any of the remaining smoking-related litigation. Liggett believes, and has been so advised by counsel, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended. Liggett may, however, enter into settlement discussions in particular cases if it believes it is in its best interest to do so, including the remaining *Engle* progeny cases. As of June 30, 2015, Liggett (and in certain cases the Company) had, on an individual basis, settled 163 *Engle* progeny cases for approximately \$3,456 in the aggregate. Two of those settlements occurred in the second quarter of 2015. In October 2013, Liggett announced a settlement of the claims of over 4,900 *Engle* progeny plaintiffs (see *Engle* Progeny Settlement below).

Individual Actions

As of June 30, 2015, there were 52 Individual Actions pending against Liggett and, in certain cases, the Company, where one or more individual plaintiffs allege injury resulting from cigarette smoking, addiction to cigarette smoking or exposure to secondary smoke and seek compensatory and, in some cases, punitive damages. These cases do not include approximately 300 *Engle* progeny cases or the approximately 100 individual cases pending in West Virginia state court as part of a consolidated action. The following table lists the number of Individual Actions by state:

State	Number of Cases
Florida	28
Maryland	10
New York	8
Louisiana	2
West Virginia	2
Missouri	1
Ohio	1

The plaintiffs' allegations of liability in cases in which individuals seek recovery for injuries allegedly caused by cigarette smoking are based on various theories of recovery, including negligence, gross negligence, breach of special duty, strict liability, fraud, concealment, misrepresentation, design defect, failure to warn, breach of express and implied warranties, conspiracy, aiding and abetting, concert of action, unjust enrichment, common law public nuisance, property damage, invasion of privacy, mental anguish, emotional distress, disability, shock, indemnity, violations of deceptive trade practice laws, the federal Racketeer Influenced and Corrupt Organizations Act ("RICO"), state RICO statutes and antitrust statutes. In many of these cases, in addition to compensatory damages, plaintiffs also seek other forms of relief including treble/multiple damages, medical monitoring, disgorgement of profits and punitive damages. Although alleged damages often are not determinable from a complaint, and the law governing the pleading and calculation of damages varies from state to state and jurisdiction to jurisdiction, compensatory and punitive damages have been specifically pleaded in a number of cases, sometimes in amounts ranging into the hundreds of millions and even billions of dollars.

Defenses raised in Individual Actions include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, lack of design defect, statute of limitations, equitable defenses such as "unclean hands" and lack of benefit, failure to state a claim and federal preemption.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

Engle Progeny Cases

Engle Case. In May 1994, *Engle* was filed against Liggett and others in Miami-Dade County, Florida. The class consisted of all Florida residents who, by November 21, 1996, "have suffered, presently suffer or have died from diseases and medical conditions caused by their addiction to cigarette smoking." In July 1999, after the conclusion of Phase I of the trial, the jury returned a verdict against Liggett and other cigarette manufacturers on certain issues determined by the trial court to be "common" to the causes of action of the plaintiff class. The jury made several findings adverse to the defendants including that defendants' conduct "rose to a level that would permit a potential award or entitlement to punitive damages." Phase II of the trial was a causation and damages trial for three of the class plaintiffs and a punitive damages trial on a class-wide basis before the same jury that returned the verdict in Phase I. In April 2000, the jury awarded compensatory damages of \$12,704 to the three class plaintiffs, to be reduced in proportion to the respective plaintiff's fault. In July 2000, the jury awarded approximately \$145,000,000 in punitive damages, including \$790,000 against Liggett.

In May 2003, Florida's Third District Court of Appeal reversed the trial court and remanded the case with instructions to decertify the class. The judgment in favor of one of the three class plaintiffs, in the amount of \$5,831, was overturned as time barred and the court found that Liggett was not liable to the other two class plaintiffs.

In July 2006, the Florida Supreme Court affirmed the decision vacating the punitive damages award and held that the class should be decertified prospectively, but determined that the following Phase I findings are entitled to res judicata effect in *Engle* progeny cases: (i) that smoking causes lung cancer, among other diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants placed cigarettes on the market that were defective and unreasonably dangerous; (iv) that defendants concealed material information knowing that the information was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to conceal or omit information regarding the health effects of cigarettes that were defective; and (vii) that defendants were negligent. The Florida Supreme Court decision also allowed former class members to proceed to trial on individual liability issues (using the above findings) and compensatory and punitive damage issues, provided they filed their individual lawsuits by January 2008. In December 2006, the Florida Supreme Court added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations made by defendants. In October 2007, the United States Supreme Court denied defendants' petition for writ of certiorari.

Pursuant to the Florida Supreme Court's July 2006 ruling in *Engle*, which decertified the class on a prospective basis, and affirmed the appellate court's reversal of the punitive damages award, former class members had until January 2008 in which to file individual lawsuits. As a result, Liggett and the Company, and other cigarette manufacturers, were named defendants in thousands of *Engle* progeny cases in both federal and state courts in Florida. Although the Company was not named as a defendant in the *Engle* case, it was named as a defendant in substantially all of the *Engle* progeny cases where Liggett was named as a defendant.

Engle Progeny Settlement. In October 2013, the Company entered into a settlement with approximately 4,900 *Engle* progeny plaintiffs and their counsel. Pursuant to the terms of the settlement, Liggett agreed to pay a total of approximately \$110,000, with approximately \$61,600 paid in a lump sum and the balance to be paid in installments over 14 years, starting in February 2015. In exchange, the claims of over 4,900 plaintiffs were dismissed with prejudice against the Company and Liggett. Due to the settlement, in 2013 the Company recorded a charge of \$86,213, of which \$25,213 is related to certain payments discounted to their present value. The present value of the installment payments was computed using an 11% annual discount rate. The Company recorded an additional charge of \$643 in the first quarter of 2015 for additional cases joining the settlement and the restructuring of certain payments related to several previously settled cases. The installment payments total approximately \$48,000 on an undiscounted basis. The Company's future payments will be approximately \$3,400 per annum through 2028, with a cost of living increase beginning in 2021.

Notwithstanding the comprehensive nature of the *Engle* Progeny Settlement, approximately 300 plaintiffs' claims remain outstanding. Therefore, the Company and Liggett may still be subject to periodic adverse judgments which could have a material adverse affect on the Company's consolidated financial position, results of operations and cash flows.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

As of June 30, 2015, the following *Engle* progeny cases have resulted in judgments against Liggett:

Date	Case Name	County	Liggett Compensatory Damages (as adjusted) ⁽¹⁾	Liggett Punitive Damages	Status ⁽²⁾
June 2002	Lukacs v. R.J. Reynolds	Miami-Dade	\$12,418	\$-	Liggett satisfied the judgment and the case is concluded.
August 2009	Campbell v. R.J. Reynolds	Escambia	156	-	Liggett satisfied the judgment and the case is concluded.
March 2010	Douglas v. R.J. Reynolds	Hillsborough	1,350	_	Liggett satisfied the judgment and the case is concluded.
April 2010	Clay v. R.J. Reynolds	Escambia	349	1,000	Liggett satisfied the judgment and the case is concluded.
April 2010	Putney v. R.J. Reynolds	Broward	3,008	-	On June 12, 2013, the Fourth District Court of Appeal reversed and remanded the case for further proceedings. Plaintiff filed a motion for rehearing which was denied. Both sides sought discretionary review from the Florida Supreme Court. The appeal is stayed pending the outcome of Hess.
April 2011	Tullo v. R.J. Reynolds	Palm Beach	225	—	Liggett satisfied the judgment and the case is concluded, other than an issue with respect to the calculation of interest on the judgment and the amount of costs owed by Liggett.
January 2012	Ward v. R.J. Reynolds	Escambia	1	_	Liggett satisfied the judgment and other than an issue regarding attorneys' fees, the case is concluded.
May 2012	Calloway v. R.J. Reynolds	Broward	1,947	7,600	A joint and several judgment for \$16,100 was entered against R.J. Reynolds, Philip Morris, Lorillard and Liggett. On appeal to the Fourth District Court of Appeal. Oral argument occurred June 16, 2015.
December 2012	Buchanan v. R.J. Reynolds	Leon	2,035	-	A joint and several judgment for \$5,500 was entered against Liggett and Philip Morris. Judgment was affirmed by the First District Court of Appeal, but the court certified an issue of conflict with another case. The defendants sought discretionary review by the Florida Supreme Court. The appeal is stayed pending the outcome of Hess.
May 2013	Cohen v. R.J. Reynolds	Palm Beach	205	—	Defendants' motion seeking a new trial was granted by the trial court. Plaintiff appealed to the Fourth District Court of Appeal.
August 2013	Rizzuto v. R.J. Reynolds	Hernando	3,479	—	Liggett settled its portion of the judgment for \$1,500 and the case is concluded as to Liggett.
August 2014	Irimi v. R.J. Reynolds	Broward	31	—	Judgment was entered against Liggett for \$31. In January 2015, the trial court granted defendants' motion for a new trial. Plaintiff appealed to the Fourth District Court of Appeal.
October 2014	Lambert v. R.J. Reynolds	Pinellas	3,600	9,500	A final judgment was entered against Liggett for \$13,100. Liggett was the only defendant at trial. On appeal to the Second District Court of Appeal.
November 2014	Boatright v. R.J. Reynolds	Polk	_	300	In November 2014, the jury awarded compensatory damages in the amount of \$15,000 with 15% fault apportioned to plaintiff and 85% to Philip Morris. The jury further assessed punitive damages against Philip Morris for \$19,700 and Liggett for \$300. Post-trial motions were denied. A joint and several judgment was entered in the amount of \$12,750 on the compensatory damages. Judgment was entered against Liggett for \$300 in punitive damages. On appeal to the Second District Court of Appeal.
June 2015	Caprio v. R.J. Reynolds	Broward	28	0	In February 2015, the jury answered certain questions on the verdict form, but were deadlocked as to others. The court entered a partial judgment and ordered a new trial on the remaining issues, including comparative fault and punitive damages. On appeal to the Fourth District Court of Appeal.
	Tota	al Damages Awarded:	28,832	18,400	
	Amounts p	aid or compromised:	(17,978)	(1,000)	
	Damages	remaining on Appeal:	\$10,854	\$17,400	

 Damages remaining on Appeal:
 \$10,854
 \$17,400

 (1) Compensatory damages are adjusted to reflect the jury's allocation of comparative fault. The amounts listed above do not include attorneys' fees or statutory interest.

(2) See Exhibit 99.1 for a more complete description of the cases currently on appeal.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

Through June 30, 2015, Liggett paid \$20,312, including interest and legal fees, to satisfy the judgments in seven *Engle* progeny cases (*Lukacs*, *Campbell*, *Douglas*, *Clay*, *Tullo*, *Ward and Rizzuto*).

The Company's potential range of loss in the *Putney*, *Calloway*, *Buchanan*, *Cohen*, *Irimi*, *Lambert*, *Boatright* and *Caprio* cases is between \$0 and \$28,254 in the aggregate, plus interest and legal fees. In determining the range of loss, the Company considers potential settlements as well as future appellate relief. Except as disclosed elsewhere in this Note 7, the Company is unable to determine a range of loss related to the remaining *Engle* progeny cases. No amounts have been expensed or accrued in the condensed consolidated financial statements for the cases described above. However, as cases proceed through the appellate process, the Company will consider accruals on a case-by-case basis if an unfavorable outcome becomes probable and the amount can be reasonably estimated.

Appeals of Engle Progeny Judgments. In December 2010, in the Martin case, a state court case against R.J. Reynolds, the First District Court of Appeal held that the trial court correctly construed the Florida Supreme Court's 2006 decision in *Engle* in instructing the jury on the preclusive effect of the Phase I *Engle* findings. In July 2011, the Florida Supreme Court declined to review the First District Court of Appeal's decision. In March 2012, the United States Supreme Court declined to review the *Campbell* case and two other *Engle* progeny cases. The Martin decision has led to additional adverse rulings by other state appellate courts.

In *Jimmie Lee Brown*, a state court case against R.J. Reynolds, the trial court tried the case in two phases. In the first phase, the jury determined that the smoker was addicted to cigarettes that contained nicotine and that his addiction was a legal cause of his death, thereby establishing he was an *Engle* class member. In the second phase, the jury determined whether the plaintiff established legal cause and damages with regard to each of the underlying claims. The jury found in favor of plaintiff in both phases. In September 2011, the Fourth District Court of Appeal affirmed the judgment entered in plaintiff's favor and approved the trial court's procedure of bifurcating the trial. The Fourth District Court of Appeal agreed with *Martin* that individual post-*Engle* plaintiffs need not prove conduct elements as part of their burden of proof, but disagreed with *Martin* to the extent that the First District Court of Appeal only required a finding that the smoker was a class member to establish legal causation as to addiction and the underlying claims. The Fourth District Court of Appeal held that in addition to establishing class membership, *Engle* progeny plaintiffs must also establish legal causation and damages as to each claim asserted. In so finding, the Fourth District Court of Appeal's decision in *Jimmie Lee Brown* is in conflict with *Martin*.

In the *Rey* case, a state court case, the trial court entered final summary judgment on all claims in favor of the Company, Liggett and Lorillard based on what has been referred to in the *Engle* progeny litigation as the "Liggett Rule." The Liggett Rule stands for the proposition that a manufacturer cannot have liability to a smoker under any asserted claim if the smoker did not use a product manufactured by that particular defendant. The Liggett Rule is based on the entry of final judgment in favor of Liggett/Brooke Group in *Engle* on all of the claims asserted against them by class representatives Mary Farnan and Angie Della Vecchia, even though the Florida Supreme Court upheld, as res judicata, the generic finding that Liggett/Brooke Group engaged in a conspiracy to commit fraud by concealment. In September 2011, the Third District Court of Appeal affirmed in part and reversed in part holding that the defendants were entitled to summary judgment on all claims asserted against them other than the claim for civil conspiracy. Defendants' further appellate efforts were unsuccessful.

In March 2012, in *Douglas*, the Second District Court of Appeal issued a decision affirming the judgment of the trial court in favor of the plaintiff and upholding the use of the *Engle* jury findings but certified to the Florida Supreme Court the question of whether granting res judicata effect to the *Engle* jury findings violates defendants' federal due process rights. In March 2013, the Florida Supreme Court affirmed the use of *Engle* jury findings and determined that there is no violation of the defendants' due process rights. This was the first time the Florida Supreme Court addressed the merits of an *Engle* progeny case. In October 2013, the United States Supreme Court declined to review the decision and Liggett satisfied the judgment. To date, the United States Supreme Court has declined to review any *Engle* progeny decisions.

In *Hess*, a case pending in Broward County, the jury returned a verdict finding that decedent relied to his detriment on an omission by the defendant before May 5, 1982 (twelve years prior to the filing of the *Engle* Complaint). Defendant moved for judgment as a matter of law on plaintiff's fraudulent concealment claim on the basis that the claim was barred by Florida's statute of repose. The trial court denied the motion and was reversed by the Fourth District Court of Appeal, which held that any *Engle* progeny claim for a fraud committed before May 5, 1982 is barred. In April 2015, the Florida Supreme Court reversed the Fourth District Court of Appeal decision and reinstated the jury verdict. The Florida Supreme Court held that *Engle* defendants cannot raise a statute of repose defense to claims for concealment or conspiracy. Defendant moved for rehearing.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

On April 8, 2015, in *Graham v. R.J. Reynolds Tobacco Co.*, the Eleventh Circuit found meritorious a defense that, in *Engle* progeny cases, federal law impliedly preempts use of the preserved *Engle* findings to establish claims for strict liability or negligence. The plaintiff moved for rehearing.

Liggett Only Cases. There are currently three cases pending where Liggett is the only remaining defendant. These cases consist of three Individual Actions. In one of the Individual Actions, *Hausrath* (NY state court), plaintiff moved to restore the case to the active docket calendar after it was removed by the court. The motion was granted, affirmed on appeal and remanded to the trial court for further proceedings. There has been no recent activity in the other two Individual Actions. Cases where Liggett is the only defendant could increase as a result of the remaining *Engle* progeny cases.

Class Actions

As of June 30, 2015, there were four actions pending for which either a class had been certified or plaintiffs were seeking class certification where Liggett is a named defendant, including one alleged price fixing case. Other cigarette manufacturers are also named in these actions.

Plaintiffs' allegations of liability in class action cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violation of deceptive trade practice laws and consumer protection statutes and claims under the federal and state anti-racketeering statutes. Plaintiffs in the class actions seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief.

Defenses raised in these cases include, among others, lack of proximate cause, individual issues predominate, assumption of the risk, comparative fault and/or contributory negligence, statute of limitations and federal preemption.

In November 1997, in *Young v. American Tobacco Co.*, a purported personal injury class action was commenced on behalf of plaintiff and all similarly situated residents in Louisiana who, though not themselves cigarette smokers, allege they were exposed to secondhand smoke from cigarettes that were manufactured by the defendants, including Liggett, and suffered injury as a result of that exposure. The plaintiffs seek to recover an unspecified amount of compensatory and punitive damages. No class certification hearing has been held. In 2013, plaintiffs' filed a motion to stay the case. The defendants did not oppose the motion and the stay was entered by the court.

In February 1998, in *Parsons v. AC & S Inc.*, a class was commenced on behalf of all West Virginia residents who allegedly have personal injury claims arising from exposure to cigarette smoke and asbestos fibers. The complaint seeks to recover \$1,000 in compensatory and punitive damages individually and unspecified compensatory and punitive damages for the class. The case is stayed due to the December 2000 bankruptcy of three of the defendants.

In February 2000, in *Smith v. Philip Morris*, a case pending in Kansas, a class was commenced against cigarette manufacturers alleging they conspired to fix cigarette prices in violation of antitrust laws. Plaintiffs seek to recover an unspecified amount in actual and punitive damages. Class certification was granted in November 2001. In January 2012, the trial court heard oral argument on defendants' motions for summary judgment and in March 2012, the court granted the motions and dismissed plaintiffs' claims with prejudice. In July 2014, the court of appeals affirmed the lower court's decision. In August 2014, plaintiffs filed a petition for review with the Kansas Supreme Court which was denied in June 2015.

Although not technically a class action, in *In Re: Tobacco Litigation (Personal Injury Cases)*, a West Virginia state court consolidated approximately 750 individual smoker actions that were pending prior to 2001 for trial of certain common issues. In January 2002, the court severed Liggett from the trial of the consolidated action. After two mistrials, on May 15, 2013, the jury rejected all but one of the plaintiffs' claims, finding for the plaintiffs on the claim that ventilated filter cigarettes sold between 1964 and 1969 should have included instructions on how to use them. The issue of damages was reserved for further proceedings. The court entered judgment in October 2013, dismissing all claims except the ventilated filter claim. The judgment was affirmed on appeal and remanded to the trial court for further proceedings. In April 2015 the plaintiffs filed a petition for writ of certiorari to the United States Supreme Court and the Supreme Court declined review. On July 13, 2015, the trial court ruled on the scope of the remaining ventilated cigarette filter claim and determined that only 30 plaintiffs have viable claims against the non-Liggett defendants and the trial court set tentative dates for consolidated trials of those claims for June 13, 2016 and December 4, 2016. With respect to Liggett, the trial court requested that Liggett and plaintiffs brief whether any claims against Liggett survive given the outcome of the first phase of the trial. Briefing of that issue is underway. When the case proceeds against Liggett, it is estimated that Liggett could be a defendant in less than 25 of the remaining individual cases.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

Class action suits have been filed in a number of states against cigarette manufacturers, alleging, among other things, that use of the terms "lights" and "ultra lights" constitutes unfair and deceptive trade practices. In December 2008, the United States Supreme Court, in *Altria Group v. Good*, ruled that the Federal Cigarette Labeling and Advertising Act did not preempt the state law claims asserted by the plaintiffs and that they could proceed with their claims under the Maine Unfair Trade Practices Act. The *Good* decision resulted in the filing of additional "lights" class action cases in other states against other cigarette manufacturers. Although Liggett was not a defendant in the *Good* case, and is not currently a defendant in any other "lights" class actions, an adverse ruling or commencement of additional "lights" related class actions could have a material adverse effect on the Company.

In addition to the cases described above, numerous class actions remain certified against other cigarette manufacturers. Adverse decisions in these cases could have a material adverse affect on Liggett's sales volume, operating income and cash flows.

Health Care Cost Recovery Actions

As of June 30, 2015, there was one remaining Health Care Cost Recovery Action pending against Liggett, *Crow Creek Sioux Tribe v. American Tobacco Company*, a South Dakota case filed in 1997, where the plaintiff seeks to recover damages based on various theories of recovery as a result of alleged sales of tobacco products to minors. The case is inactive. Other cigarette manufacturers are also named as defendants.

The claims asserted in health care cost recovery actions vary, but can include the equitable claim of indemnity, common law claims of negligence, strict liability, breach of express and implied warranty, breach of special duty, fraud, negligent misrepresentation, conspiracy, public nuisance, claims under state and federal statutes governing consumer fraud, antitrust, deceptive trade practices and false advertising, and claims under RICO. Although no specific damage amounts are typically pleaded, it is possible that requested damages might be in the billions of dollars. In these cases, plaintiffs typically assert equitable claims that the tobacco industry was "unjustly enriched" by their payment of health care costs allegedly attributable to smoking and seek reimbursement of those costs. Relief sought by some, but not all, plaintiffs include punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees.

Department of Justice Lawsuit.

In September 1999, the United States government commenced litigation against Liggett and other cigarette manufacturers in the United States District Court for the District of Columbia. The action sought to recover an unspecified amount of health care costs paid and to be paid by the federal government for lung cancer, heart disease, emphysema and other smoking-related illnesses allegedly caused by the fraudulent and tortious conduct of defendants, to restrain defendants and co-conspirators from engaging in alleged fraud and other allegedly unlawful conduct in the future, and to compel defendants to disgorge the proceeds of their unlawful conduct. Claims were asserted under RICO.

In August 2006, the trial court entered a Final Judgment against each of the cigarette manufacturing defendants, except Liggett. In May 2009, the United States Court of Appeals for the District of Columbia affirmed most of the district court's decision. The United States Supreme Court denied review. As a result, the cigarette manufacturing defendants, other than Liggett, are now subject to the trial court's Final Judgment which ordered the following relief: (i) an injunction against "committing any act of racketeering" relating to the manufacturing, marketing, promotion, health consequences or sale of cigarettes in the United States; (ii) an injunction against participating directly or indirectly in the management or control of the Council for Tobacco Research, the Tobacco Institute, or the Center for Indoor Air Research, or any successor or affiliated entities of each; (iii) an injunction against "making, or causing to be made in any way, any material false, misleading, or deceptive statement or representation or engaging in any public relations or marketing endeavor that is disseminated to the United States' public and that misrepresents or suppresses information concerning cigarettes"; (iv) an injunction against conveying any express or implied health message through use of descriptors on cigarette packaging or in cigarette advertising or promotional material, including "lights," "ultra lights," and "low tar," which the court found could cause consumers to believe one cigarette brand is less hazardous than another brand; (v) the issuance of "corrective statements" in various media regarding the adverse health effects of smoking, the addictiveness of smoking and nicotine, the lack of any significant health benefit from smoking "low tar" or "lights" cigarettes, defendants' manipulation of cigarette design to ensure optimum nicotine delivery and the adverse health effects of exposure to

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

environmental tobacco smoke; (vi) the disclosure of defendants' public document websites and the production of all documents produced to the government or produced in any future court or administrative action concerning smoking and health; (vii) the disclosure of disaggregated marketing data to the government in the same form and on the same schedules as defendants now follow in disclosing such data to the Federal Trade Commission for a period of ten years; (viii) certain restrictions on the sale or transfer by defendants of any cigarette brands, brand names, formulas or cigarette business within the United States; and (ix) payment of the government's costs in bringing the action. In June 2014, the court approved a consent agreement between the defendants and the Department of Justice regarding the "corrective statements" to be issued by the defendants. The implementation of the "corrective statements" is uncertain as the defendants appealed the specific language of the statements.

It is unclear what impact, if any, the Final Judgment will have on the cigarette industry as a whole. To the extent that the Final Judgment leads to a decline in industry-wide shipments of cigarettes in the United States or otherwise results in restrictions that adversely affect the industry, Liggett's sales volume, operating income and cash flows could be materially adversely affected.

Upcoming Trials

As of June 30, 2015, there were 14 *Engle* progeny cases scheduled for trial through June 30, 2016, where Liggett (and/or the Company) is a named defendant. Trial dates are, however, subject to change.

MSA and Other State Settlement Agreements

In March 1996, March 1997 and March 1998, Liggett entered into settlements of smoking-related litigation with 45 states and territories. The settlements released Liggett from all smoking-related claims made by those states and territories, including claims for health care cost reimbursement and claims concerning sales of cigarettes to minors.

In November 1998, Philip Morris, Brown & Williamson, R.J. Reynolds and Lorillard (the "Original Participating Manufacturers" or "OPMs") and Liggett (together with any other tobacco product manufacturer that becomes a signatory, the "Subsequent Participating Manufacturers" or "SPMs") (the OPMs and SPMs are hereinafter referred to jointly as the "Participating Manufacturers") entered into the Master Settlement Agreement (the "MSA") with 46 states, the District of Columbia, Puerto Rico, Guam, the United States Virgin Islands, American Samoa and the Northern Mariana Islands (collectively, the "Settling States") to settle the asserted and unasserted health care cost recovery and certain other claims of the Settling States. The MSA received final judicial approval in each Settling State.

As a result of the MSA, the Settling States released Liggett from:

- all claims of the Settling States and their respective political subdivisions and other recipients of state health care funds, relating to: (i) past conduct
 arising out of the use, sale, distribution, manufacture, development, advertising and marketing of tobacco products; (ii) the health effects of, the
 exposure to or research, statements or warnings about, tobacco products; and
- all monetary claims of the Settling States and their respective subdivisions and other recipients of state health care funds relating to future conduct
 arising out of the use of, or exposure to, tobacco products that have been manufactured in the ordinary course of business.

The MSA restricts tobacco product advertising and marketing within the Settling States and otherwise restricts the activities of Participating Manufacturers. Among other things, the MSA prohibits the targeting of youth in the advertising, promotion or marketing of tobacco products; bans the use of cartoon characters in all tobacco advertising and promotion; limits each Participating Manufacturer to one tobacco brand name sponsorship during any 12-month period; bans all outdoor advertising, with certain limited exceptions; prohibits payments for tobacco product placement in various media; bans gift offers based on the purchase of tobacco products without sufficient proof that the intended recipient is an adult; prohibits Participating Manufacturers from licensing third parties to advertise tobacco brand names in any manner prohibited under the MSA; and prohibits Participating Manufacturers from using as a tobacco product brand name any nationally recognized non-tobacco brand or trade name or the names of sports teams, entertainment groups or individual celebrities.

The MSA also requires Participating Manufacturers to affirm corporate principles to comply with the MSA and to reduce underage use of tobacco products and imposes restrictions on lobbying activities conducted on behalf of Participating Manufacturers. In addition, the MSA provides for the appointment of an independent auditor to calculate and determine the amounts of payments owed pursuant to the MSA.

Under the payment provisions of the MSA, the Participating Manufacturers are required to make annual payments of \$9,000,000 (subject to applicable adjustments, offsets and reductions). These annual payments are allocated based on unit volume

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

of domestic cigarette shipments. The payment obligations under the MSA are the several, and not joint, obligation of each Participating Manufacturer and are not the responsibility of any parent or affiliate of a Participating Manufacturer.

Liggett has no payment obligations under the MSA except to the extent its market share exceeds a market share exemption of approximately 1.65% of total cigarettes sold in the United States. Vector Tobacco has no payment obligations under the MSA except to the extent its market share exceeds a market share exceeds a market share exceeds a of total cigarettes sold in the United States. Liggett and Vector Tobacco's domestic shipments accounted for 3.4% of the total cigarettes sold in the United States in 2014. If Liggett's or Vector Tobacco's market share exceeds their respective market share exemption in a given year, then on April 15 of the following year, Liggett and/or Vector Tobacco, as the case may be, must pay on each excess unit an amount equal (on a per-unit basis) to that due from the OPMs for that year. On December 31, 2014, Liggett and Vector Tobacco pre-paid \$100,000 of their approximate \$117,800 2014 MSA obligation. Liggett and Vector Tobacco paid the remaining \$17,800 on April 15, 2015.

Certain MSA Disputes

NPM Adjustment. In March 2006, an economic consulting firm selected pursuant to the MSA determined that the MSA was a "significant factor contributing to" the loss of market share of Participating Manufacturers, to non-participating manufacturers, for 2003. This is known as the "NPM Adjustment." The economic consulting firm subsequently rendered the same decision with respect to 2004 and 2005. In March 2009, a different economic consulting firm made the same determination for 2006. As a result, the manufacturers are entitled to potential NPM Adjustments to each of their 2003 - 2006 MSA payments. The Participating Manufacturers are also entitled to potential NPM Adjustments to their 2007 - 2014 payments pursuant to agreements entered into between the OPMs and the Settling States under which the OPMs agreed to make certain payments for the benefit of the Settling States, in exchange for which the Settling States stipulated that the MSA was a "significant factor contributing to" the loss of market share of Participating Manufacturers for each of those years. A Settling State that has diligently enforced its qualifying escrow statute in the year in question may be able to avoid allocation of the NPM Adjustment to the payments made by the manufacturers for the benefit of that Settling State.

For 2003 - 2014, Liggett and Vector Tobacco, as applicable, disputed that they owed the Settling States the NPM Adjustments as calculated by the independent auditor. As permitted by the MSA, Liggett and Vector Tobacco paid subject to dispute, withheld payment or paid into a disputed payment account the amounts associated with these NPM Adjustments.

Notwithstanding provisions in the MSA requiring arbitration, litigation was filed in 49 Settling States involving the application of the NPM Adjustment for 2003 and whether it was to be determined through litigation or arbitration. These actions related to the potential NPM Adjustment for 2003, which the independent auditor under the MSA previously determined to be as much as \$1,200,000 for all Participating Manufacturers. All but one of the 48 courts that decided the issue ruled that the 2003 NPM Adjustment dispute was arbitrable.

In response to a proposal from the OPMs and many of the SPMs, 45 of the Settling States, representing approximately 90% of the allocable share of the Settling States, entered into an agreement providing for a nationwide arbitration of the dispute with respect to the NPM Adjustment for 2003. In exchange, the OPMs and SPMs agreed to a 20% reduction in amounts recovered for the NPM Adjustment for 2003. In June 2010, the three person arbitration panel was selected. In November 2011, the Participating Manufacturers advised the arbitration panel that they were not contesting diligent enforcement of 16 Settling States for 2003. Substantive hearings commenced in April 2012 and were completed in June 2013.

In December 2012, the Participating Manufacturers entered into a "term sheet" with 20 Settling States setting out terms for settlement of the NPM Adjustment for 2003 - 2012 and addressing the NPM Adjustment with respect to those states for future years. Certain of the non-settling states objected to the settlement. In March 2013, the arbitration panel entered a Stipulated Partial Settlement and Award which, among other things, overruled the objections of the non-settling states and directed the independent auditor to implement certain terms of the term sheet effective with the MSA payments for 2012 due April, 2013. In May 2013, two additional states joined the settlement and in June 2014, another two states joined the settlement. Several non-settling states filed motions in state courts attempting to vacate the settlement award. In Idaho, a trial court denied that state's motion to vacate, and the Idaho Supreme Court affirmed that denial. In Colorado, a trial court also denied that state's motion to vacate; Colorado did not appeal. Several of the other non-settling state challenges to the settlement have been dismissed by those states and the others are currently stayed or inactive. Although certain terms of the settlement were implemented by the independent auditor on April 15, 2013, no assurance can be given as to the ultimate outcome of the non-settling states' challenges. The parties have been working towards converting the "term sheet" into a final settlement agreement.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

As a result of the settlement, in the first nine months of 2013, Liggett recognized income of \$6,947. Liggett received credits of \$1,733 in April 2014 from these settling states related to the 2013 NPM Adjustment. Liggett received additional credits of \$1,940 in April 2015 from these settling states related to the 2014 NPM Adjustment. The remaining NPM Adjustment accrual of \$25,809 at June 30, 2015 relates to the disputed amounts Liggett withheld from the non-settling states for 2004 - 2010, which may be subject to payment, with interest, if Liggett loses the disputes for those years. Approximately \$30,100 currently remains in the disputed payments accounts relating to the 2011, 2012, 2013 and 2014 NPM Adjustment dispute with the non-settling states.

In September 2013, the panel issued its decisions with respect to the 15 states as to which the Participating Manufacturers contested diligence but that did not enter into the Stipulated Partial Settlement and Award. The panel found that six of these states did not diligently enforce their MSA escrow statutes in 2003. As a result of this ruling Liggett recognized income of \$5,987 including interest, in the third quarter of 2013. All six of the states that were found to be non-diligent filed motions in state court seeking to vacate or reduce the amount of the arbitration award. Before the MSA payments for 2013 were due, the Pennsylvania trial court rejected the state's motion to vacate the award, but granted its motion to reduce the award. As a result, in April 2014, Liggett received a credit in the amount of \$6,441 for the 2003 NPM Adjustment (as calculated by the independent auditor). Liggett subsequently reimbursed the six states 20% of that credit pursuant to the agreement discussed above, bringing its net recovery to \$5,152, which is approximately \$1,315 lower than the amount to which Liggett believes it is entitled. Subsequent to the April 15, 2014 MSA payment date, a state court in Missouri issued a ruling similar to the ruling in Pennsylvania. As such, Liggett's 2003 NPM Adjustment credit could be reduced by an additional \$521. Subsequent to the April 15, 2014 MSA payment date, a state trial court in Maryland reached a different result from the Pennsylvania and Missouri trial courts, denying the state's motion to vacate the award and further denying its motion to reduce the amount of the award payable to Liggett. A New Mexico trial court has not yet acted on New Mexico's motion. In June 2014, Kentucky and Indiana agreed to settle the dispute and join the term sheet described above. As a result, Liggett recognized income of approximately \$1,400 in the second quarter of 2014. The Participating Manufacturers, including Liggett, appealed the Pennsylvania and Missouri decisions, while Maryland appealed the Maryland trial court decision. In April 2015, the Pennsylvania decision was affirmed by the appellate court. The Participating Manufacturers have asked the Pennsylvania Supreme Court to grant a discretionary appeal of that decision. If Liggett is unsuccessful in its appeals or if other states are successful with respect to any such appeals or motions, the amount of the 2003 NPM Adjustment and any interest or earnings to which Liggett is entitled could be lower than the amounts described above and Liggett would be obligated to pay the difference.

Disputes over the NPM Adjustments for 2004-2014 remain to be arbitrated with the states that have not joined the settlement. Further adjustments could also be due to Liggett under the settlement with 24 states for 2013 forward.

"Gross" v. "Net" Calculations. In October 2004, the independent auditor notified all Participating Manufacturers that their payment obligations under the MSA, dating from the agreement's execution in late 1998, had been re-calculated using "net" units, rather than "gross" units (which had been used since 1999). Liggett objected to this retroactive change and disputed the change in methodology.

In December 2012, the parties arbitrated the dispute. In February 2013, the arbitrators ruled that the independent auditor was precluded from recalculating Liggett's grandfathered market share ("GFMS") exemption. The arbitrators further ruled that, for purposes of calculating Liggett's payment obligations, Liggett's market share, calculated on a net basis, should be increased by a factor of 1.25%. Liggett filed a motion seeking correction of the part of the arbitrators' decision that would require the 1.25% increase in Liggett's market share. The states objected to Liggett's motion.

In October 2014, the panel issued a Corrected Final Award that eliminated the 1.25% adjustment increase. The panel further determined that the independent auditor shall compute Liggett's market share for all years after 2000 on a "net" basis, but, adjust that computation to approximate "gross" market share by using actual returned product data for each year. In July 2015, the independent auditor issued calculations purportedly based on the Corrected Final Award, which indicated that Liggett owes approximately \$16,000 for years 2001 - 2013. Liggett contends that the independent auditor's calculations are not consistent with the Corrected Final Award and Liggett has disputed them. Liggett's accrual for this matter was \$8,500 at June 30, 2015.

Other State Settlements. The MSA replaced Liggett's prior settlements with all states and territories except for Florida, Mississippi, Texas and Minnesota. Each of these four states, prior to the effective date of the MSA, negotiated and executed settlement agreements with each of the other major tobacco companies, separate from those settlements reached previously with Liggett. Except as described below, Liggett's agreements with these states remain in full force and effect. These states' settlement agreements with Liggett contained most favored nation provisions which could reduce Liggett's payment obligations based on subsequent settlements or resolutions by those states with certain other tobacco companies. Beginning in 1999, Liggett determined

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

that, based on each of these four states' settlements with United States Tobacco Company, Liggett's payment obligations to those states were eliminated. With respect to all non-economic obligations under the previous settlements, Liggett believes it is entitled to the most favorable provisions as between the MSA and each state's respective settlement with the other major tobacco companies. Therefore, Liggett's non-economic obligations to all states and territories are now defined by the MSA.

In 2003, as a result of a dispute with Minnesota regarding its settlement agreement, Liggett agreed to pay \$100 a year in any year cigarettes manufactured by Liggett are sold in that state. The Attorneys General for Florida, Mississippi and Texas previously advised Liggett that they believed that Liggett had failed to make payments under the respective settlement agreements with those states. In 2010, Liggett settled with Florida and agreed to pay \$1,200 and to make further annual payments of \$250 for a period of 21 years, starting in March 2011, with the payments from year 12 forward being subject to an inflation adjustment. These payments are in lieu of any other payments allegedly due to Florida. In 2012, Mississippi provided Liggett with a 60-day notice that the state intended to pursue its remedies if Liggett did not cure the alleged defaults. Liggett responded to Mississippi's letter denying the existence of any defaults. There can be no assurance that Liggett will be able to resolve the matters with Texas and Mississippi or that Liggett will not be required to make additional payments which could adversely affect the Company's consolidated financial position, results of operations and cash flows.

Cautionary Statement. Management is not able to reasonably predict the outcome of the litigation pending or threatened against Liggett or the Company. Litigation is subject to many uncertainties. Liggett has been found liable in multiple *Engle* progeny cases and Individual Actions, several of which were affirmed on appeal and satisfied by Liggett. It is possible that other cases could be decided unfavorably against Liggett and that Liggett will be unsuccessful on appeal. Liggett may attempt to settle particular cases if it believes it is in its best interest to do so.

Management cannot predict the cash requirements related to any future defense costs, settlements or judgments, including cash required to bond any appeals, and there is a risk that those requirements will not be able to be met. An unfavorable outcome of a pending smoking-related case could encourage the commencement of additional litigation. Except as discussed in this Note 7, management is unable to estimate the loss or range of loss that could result from an unfavorable outcome of the cases pending against Liggett or the costs of defending such cases and as a result has not provided any amounts in its consolidated financial statements for unfavorable outcomes.

The tobacco industry is subject to a wide range of laws and regulations regarding the marketing, sale, taxation and use of tobacco products imposed by local, state and federal governments. There have been a number of restrictive regulatory actions, adverse legislative and political decisions and other unfavorable developments concerning cigarette smoking and the tobacco industry. These developments may negatively affect the perception of potential triers of fact with respect to the tobacco industry, possibly to the detriment of certain pending litigation, and may prompt the commencement of additional litigation or legislation.

It is possible that the Company's consolidated financial position, results of operations and cash flows could be materially adversely affected by an unfavorable outcome in any of the smoking-related litigation.

The activity in the Company's accruals for the MSA and tobacco litigation for the six months ended June 30, 2015 were as follows:

			Curr	ent Liabilities		Non-Current Liabilities						
	ur	ayments due nder Master Settlement Agreement		Litigation Accruals	 Total	ur S	yments due Ider Master Settlement Agreement		Litigation Accruals		Total	
Balance at January 1, 2015	\$	26,322	\$	3,149	\$ 29,471	\$	25,809	\$	25,700	\$	51,509	
Expenses		53,435		2,490	55,925		—		(195)		(195)	
Change in MSA obligations capitalized as inventory		1,011		—	1,011		—		—		—	
Payments		(18,142)		(5,645)	(23,787)				—		_	
Reclassification from non-current liabilities		_		3,305	3,305		_		(3,305)		(3,305)	
Interest on withholding		_		178	178				1,244		1,244	
Balance as of June 30, 2015	\$	62,626	\$	3,477	\$ 66,103	\$	25,809	\$	23,444	\$	49,253	

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

		C	urren	t Liabilities		Non-Current Liabilities						
	unc Se	vments due ler Master ettlement greement		Litigation Accruals		Total	un S	yments due der Master ettlement greement		Litigation Accruals		Total
Balance at January 1, 2014	\$	25,348	\$	59,310	\$	84,658	\$	27,571	\$	27,058	\$	54,629
Expenses		52,510		1,769		54,279		_		_		_
NPM Settlement adjustment		_		_		_		(1,419)		_		(1,419)
Change in MSA obligations capitalized as inventory		151		_		151		_		_		_
Payments		(16,343)		(60,201)		(76,544)		—		_		—
Reclassification from non-current liabilities		343		3,575		3,918		(343)		(3,575)		(3,918)
Interest on withholding		—		83		83		_		893		893
Balance as of June 30, 2014	\$	62,009	\$	4,536	\$	66,545	\$	25,809	\$	24,376	\$	50,185

The activity in the Company's accruals for the MSA and tobacco litigation for the six months ended June 30, 2014 were as follows:

Other Matters:

Liggett's and Vector Tobacco's management are unaware of any material environmental conditions affecting their existing facilities. Liggett's and Vector Tobacco's management believe that current operations are conducted in material compliance with all environmental laws and regulations and other laws and regulations governing cigarette manufacturers. Compliance with federal, state and local provisions regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, has not had a material effect on the capital expenditures, results of operations or competitive position of Liggett or Vector Tobacco.

Liggett Vector Brands entered into an agreement with a subsidiary of the American Wholesale Marketers Association to support a program to permit certain tobacco distributors to secure, on reasonable terms, tax stamp bonds required by state and local governments for the distribution of cigarettes. The agreement expires in February 2016. Under the agreement, Liggett Vector Brands has agreed to pay a portion of losses incurred by the surety under the bond program, with a maximum loss exposure of \$500. To secure its potential obligations under the agreement, Liggett Vector Brands posted a \$100 letter of credit and agreed to fund up to an additional \$400. Liggett previously paid \$83 for obligations under this program, and therefore, is only committed to fund an additional \$317 over the letter of credit. The Company believes Liggett Vector Brands' obligation under the agreement was immaterial at June 30, 2015.

There are several other proceedings, lawsuits and claims pending against the Company or one or more of its consolidated subsidiaries unrelated to tobacco or tobacco product liability. For instance, Douglas Elliman is subject to various types of litigation in the ordinary course of its business. Management is of the opinion that the liabilities, if any, ultimately resulting from such other proceedings, lawsuits and claims should not materially affect the Company's financial position, results of operations or cash flows.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

8. INCOME TAXES

The Company's provision for income taxes in interim periods is based on an estimated annual effective income tax rate derived, in part, from estimated annual pre-tax results from ordinary operations. The annual effective income tax rate is reviewed and, if necessary, adjusted on a quarterly basis.

The Company's income tax expense consisted of the following:

	Three Months Ended					Six Months Ended				
		Jun		June 30,						
	2015			2014		2015		2014		
Income before provision for income taxes	\$	31,069	\$	19,132	\$	64,964	\$	25,603		
Income tax expense using estimated annual effective income tax rate		11,533		6,279		24,143		8,404		
Changes in effective tax rates		(78)		(178)		—		—		
Impact of discrete items, net		(91)		—		(100)		639		
Income tax expense	\$	11,364	\$	6,101	\$	24,043	\$	9,043		

The discrete item for the six months ended June 30, 2015 is primarily related to the rate differential in other comprehensive income and the results of a recent state income tax audits. The discrete item for the six months ended June 30, 2014 is primarily related to an increase in the blended state tax rate that resulted in the Company's revaluation of its deferred taxes and the results of a state income tax audit.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

9. INVESTMENTS AND FAIR VALUE MEASUREMENTS

The Company's recurring financial assets and liabilities subject to fair value measurements are as follows:

	Fair Value Measurements as of June 30, 2015											
Description		Total		oted Prices in ve Markets for entical Assets (Level 1)	Obser	ficant Other rvable Inputs Level 2)	Unob	Significant servable Inputs (Level 3)				
Assets:												
Money market funds	\$	109,209	\$	109,209	\$	_	\$	_				
Certificates of deposit		4,790		—		4,790		—				
Bonds		12,368		12,368		_		—				
Investment securities available for sale												
Equity securities		158,274		157,958		316		—				
Mutual funds invested in fixed income securities		60,441		60,441		—		—				
Fixed income securities												
U.S. Government securities		33,886				33,886		_				
Corporate securities		51,937				51,937		_				
U.S. mortgage backed securities		6,757				6,757		_				
Commercial mortgage-backed securities		15,758				15,758		_				
U.S. asset backed securities		13,393				13,393		_				
Index-linked U.S. bonds		2,131				2,131		_				
Total fixed income securities		123,862				123,862		_				
Warrants (1)		1,859		_		_		1,859				
Total	\$	470,803	\$	339,976	\$	128,968	\$	1,859				
Liabilities:												
Fair value of derivatives embedded within convertible debt	\$	156,783	\$	—	\$	—	\$	156,783				

(1) Warrants are 1,000,000 warrants to purchase Ladenburg Thalmann Financial Services Inc. ("LTS") common stock received on November 4, 2011 which were carried at \$1,859 as of June 30, 2015 and are included in "Other assets." The Company recognized a loss of \$483 for the six months ended June 30, 2015 related to the change in fair value of the Warrants.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

	Fair Value Measurements as of December 31, 2014											
Description		Total	Activ Ide	oted Prices in /e Markets for ntical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Ur	Significant tobservable Inputs (Level 3)					
Assets:												
Money market funds	\$	205,180	\$	205,180	\$ —	- \$	—					
Certificates of deposit		3,462		—	3,462	!	—					
Bonds		4,868		4,868	_		_					
Investment securities available for sale												
Equity securities		154,192		153,666	526	i	_					
Mutual funds invested in fixed income securities		59,826		59,826	_		_					
Fixed income securities												
U.S. Government securities		35,446		_	35,446	i	_					
Corporate securities		56,248		7,397	48,851		_					
U.S. Government and federal agency		4,770		_	4,770)						
Commercial mortgage-backed securities		16,508		_	16,508	;	_					
U.S. asset-backed securities		16,955		_	16,955	;	—					
Index-linked U.S. bonds		2,098		_	2,098	;						
Total fixed income securities		132,025		7,397	124,628	}	_					
Warrants (1)		2,342		_	_		2,342					
Total	\$	561,895	\$	430,937	\$ 128,616	\$	2,342					
Liabilities:												
Fair value of derivatives embedded within convertible debt	\$	169,386	\$	_	\$	- \$	169,386					

(1) Warrants include 1,000,000 of LTS Warrants received on November 4, 2011 which were carried at \$2,342 as of December 31, 2014 and are included in "Other assets." The Company recognized income of \$584 for the year ended December 31, 2014 related to the change in fair value of the Warrants. The Company recognized a loss of \$111 for the six months ended June 30, 2014.

The fair value of the Level 2 certificates of deposit are based on prices posted by the financial institutions. The fair value of investment securities available for sale included in Level 1 are based on quoted market prices from various stock exchanges. The Level 2 investment securities available for sale are based on quoted market prices of securities that are thinly traded.

The fair value of derivatives embedded within convertible debt was derived using a valuation model. These derivatives have been classified as Level 3. The valuation model assumes future dividend payments by the Company and utilizes interest rates and credit spreads based upon the implied debt rate of the 5.50% Convertible Notes due 2020 to determine the fair value of the derivatives embedded within the convertible debt. The changes in fair value of derivatives embedded within convertible debt are presented on the Condensed Consolidated Statements of Operations.

The value of the embedded derivatives is contingent on changes in implied interest rates of the convertible debt, the Company's stock price, stock volatility as well as projections of future cash and stock dividends over the term of the debt. The interest rate component of the value of the embedded derivative is computed by calculating an equivalent non-convertible, unsecured and subordinated borrowing cost. This rate is determined by calculating the implied rate on the Company's 2020 Convertible Notes when removing the embedded option value within the convertible security. This rate is based upon market observable inputs and influenced by the Company's stock price, convertible bond trading price, risk free interest rates and stock volatility.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

The fair value of the warrants was derived using the Black-Scholes model and has been classified as Level 3. The assumptions used under the Black-Scholes model in computing the fair value of the warrants are based on contractual term of the warrants, volatility of the underlying stock based on the historical quoted prices of the underlying stock, assumed future dividend payments and a risk-free rate of return.

The unobservable inputs related to the valuations of the Level 3 assets and liabilities are as follows at June 30, 2015:

		Quantitative	Information about Level 3 Fair Value	Measurements	6	
	ir Value at June 30, 2015	Valuation Technique	Unobservable Input	Range (Actual)		
Warrant	\$ 1,859	Option model	Stock price	\$	3.50	
			Exercise price	\$	1.68	
			Term (in years)		1.3	
			Volatility		39.30%	
			Dividend rate		_	
			Risk-free return		0.70%	
Fair value of derivatives embedded within convertible debt	\$ 156,783	Discounted cash flow	Assumed annual stock dividend		5%	
			Assumed annual cash dividend	\$	1.60	
			Stock price	\$	23.46	
			Convertible trading price		110.12%	
			Volatility		16%	
			Implied credit spread		6.0% - 7.0% (6.5%)	

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

The unobservable inputs related to the valuations of the Level 3 assets and liabilities are as follows at December 31, 2014:

		Quantitative	leasurements			
		Fair Value at December 31, 2014	Valuation Technique	Unobservable Input		Range (Actual)
Warrants	\$	2,342	Option model	Stock price	\$	3.95
				Exercise price	\$	1.68
				Term (in years)		1.8
				Volatility		44.42%
				Dividend rate		_
				Risk-free return		0.70%
Fair value of derivatives embedded within convertible debt	\$	169,386	Discounted cash flow	Assumed annual stock dividend		5%
				Assumed annual cash dividend	\$	1.60
				Stock price	\$	21.31
				Convertible trading price		106.8%
				Volatility		16.00%
				Implied credit spread		6.25% - 7.25% (6.75%)

In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company is required to record assets and liabilities at fair value on a nonrecurring basis. Generally, assets and liabilities are recorded at fair value on a nonrecurring basis as a result of impairment charges. The Company had no nonrecurring nonfinancial assets subject to fair value measurements as of June 30, 2015 and December 31, 2014.

10. SEGMENT INFORMATION

The Company's significant business segments for the three and six months ended June 30, 2015 and 2014 were Tobacco, E-Cigarettes and Real Estate. The Tobacco segment consists of the manufacture and sale of conventional cigarettes. The E-Cigarettes segment includes the operations of the Company's ecigarette business. The Real Estate segment includes the Company's investment in New Valley LLC, which includes Douglas Elliman, Escena, Indian Creek, Sagaponack and investments in real estate ventures. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. As a result of the amount of operating losses of Zoom as of September 30, 2014 when compared to the remaining components of our Corporate and Other segment, we have reevaluated our operating segments and have separated our E-Cigarettes operations from the Corporate and Other segment for previously reported periods as of and for the three and six months ended June 30, 2014. Thus, prior period information has been recast to conform to the current presentation. This change did not have an impact to the Company's historical consolidated results.

(Dollars in Thousands, Except Per Share Amounts) Unaudited

Financial information for the Company's operations before taxes for the three and six months ended June 30, 2015 and 2014 follows:

	,	Tobacco		E	C-Cigarettes	Real Estate	Corporate and Other	Total
Three months ended June 30, 2015			_					
Revenues	\$	254,890		\$	261	\$ 161,022	\$ _	\$ 416,173
Operating income (loss)		56,215	(1)		(2,400)	6,892	(4,667)	56,040
Equity income from real estate ventures		—			—	1,856	—	1,856
Depreciation and amortization		2,931			—	3,076	435	6,442
Three months ended June 30, 2014								
Revenues	\$	250,556		\$	2,569	\$ 153,488	\$ _	\$ 406,613
Operating income (loss)		51,506	(2)		(3,765)	15,901	(3,334)	60,308
Equity loss from real estate ventures		_			_	(1,808)	_	(1,808)
Depreciation and amortization		2,588			_	2,622	252	5,462
Six months ended June 30, 2015								
Revenues	\$	482,975		\$	680	\$ 293,278	\$ —	\$ 776,933
Operating income (loss)		105,885	(3)		(5,564)	9,043	(9,369)	99,995
Equity income from real estate ventures		—			—	2,194	—	2,194
Depreciation and amortization		5,867			—	5,984	872	12,723
Capital expenditures		2,350			—	3,029	—	5,379
Six months ended June 30, 2014								
Revenues	\$	483,948		\$	8,369	\$ 261,532	\$ —	\$ 753,849
Operating income (loss)		94,402	(4)		(4,190)	20,645	(7,827)	103,030
Equity loss from real estate ventures		—			—	(256)	—	(256)
Depreciation and amortization		5,081			_	6,969	504	12,554
Capital expenditures		6,563			_	3,570	11	10,144

⁽¹⁾ Operating income includes \$1,250 of litigation judgment expense and \$1,607 of pension settlement expense.

⁽²⁾ Operating income includes \$1,419 of income from NPM Settlement.

⁽³⁾ Operating income includes \$2,093 of litigation judgment expense and \$1,607 of pension settlement expense.
 ⁽⁴⁾ Operating income includes \$1,419 of income from NPM Settlement and \$1,500 of litigation judgment expense.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

11. CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The accompanying condensed consolidating financial information has been prepared and presented pursuant to Securities and Exchange Commission Regulation S-X, Rule 3-10, "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered." Each of the subsidiary guarantors are 100% owned, directly or indirectly, by the Company, and all guarantees are joint and several and subject to certain automatic release provisions. Relief from the financial statement requirements under Rule 3-10 is being provided because the Company's guarantee release provisions are considered customary. Such release provisions are as follows:

- the sale or other disposition of all or substantially all of the assets or all of the capital stock of any subsidiary guarantor; and
- the satisfaction of the requirements for legal defeasance or the satisfaction and discharge of the indenture.

The Company's investments in its consolidated subsidiaries are presented under the equity method of accounting.

The indenture of the 7.75% Senior Secured Notes contains covenants that restrict the payment of dividends by the Company if the Company's consolidated earnings before interest, taxes, depreciation and amortization, as defined in the indenture, for the most recently ended four full quarters is less than \$75,000 and the indenture also restricts the incurrence of debt if the Company's Leverage Ratio and its Secured Leverage Ratio, as defined in the indenture, exceed 3.0 and 1.5, respectively.

At June 30, 2015, management believed that the Company was in compliance with all covenants under the indentures of the 7.75% Senior Secured Notes.

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING BALANCE SHEETS

				J	June 30, 2015				
					Subsidiary				Consolidated
	Parent/		Subsidiary		Non-	(Consolidating		Vector Group
	Issuer		Guarantors		Guarantors		Adjustments		Ltd.
-									
\$	111,503	\$	24,020	\$	102,800	\$	_	\$	238,323
	277,483		65,094		_		_		342,577
	_		12,471		5,551		_		18,022
	1,744		_		_		(1,744)		_
	_		98,576		_		_		98,576
	2,343		_		_		(2,343)		_
	_		910		1,414		_		2,324
	910		7,078		37,248		_		45,236
	393,983		208,149		147,013		(4,087)		745,058
	2,177		57,228		20,043		_		79,448
	_				23,043		_		23,043
	45,669		_		550		_		46,219
	_		_		199,026		_		199,026
	563.658		_		_		(563,658)		_
			17,186		_		(20,220
					159.489		_		267,000
	_						_		26,635
	42 810				1 683		_		56,194
\$	·	\$		\$		\$	(567,745)	\$	1,462,843
	, ,	-	-, -	-	,-	-	(, -,	-	, - ,
¢		¢	5 788	¢	286	¢		¢	6,074
Ψ		Ψ		Ψ	200	Ψ		Ψ	931
					1 220		(1.744)		551
	/0		5,905		3		(2,343)		3,723
	-		66,103		-		-		66,103
	18,734		9,588		—		—		28,322
	34,318		54,264		36,941				125,523
	53,130		143,064		38,569		(4,087)		230,676
	864,399		8,583		17		_		872,999
	156,783		_		_		—		156,783
	33,381		16,324		_		—		49,705
	24,155		34,560		39,465		—		98,180
	2,469		49.460		4.237		_		56,166
	1,134,317		251,991				(4,087)		1,464,509
	, ,-								, , , , , , , , , , , , , , , , , , , ,
	(82.986)		176.419		387.239		(563.658)		(82.986)
	(82,986)		176,419		387,239 81.320		(563,658)		(82,986) 81,320
	(82,986)		176,419 176,419		387,239 81,320 468,559		(563,658)	_	(82,986) 81,320 (1,666)
	\$	Issuer Issuer Introve Introve	Issuer \$ \$ \$ 111,503 277,483 1,744 1,744 2,343 2,343 1,744 1,744 1,744 1,744 1,744 1,744 1,744 1,744 1,744 1,744	Issuer Guarantors S 111,503 \$ 24,020 277,483 65,094 277,483 65,094 277,483 65,094 1,744 12,471 1,744 98,576 2,343 2,343 2,343 208,149 910 7,078 393,983 208,149 2,177 57,228 3,034 208,149 45,669 45,669 563,658 3,034 17,186 - 53,058 42,810 11,701 5 42,810 11,701 5 5 5 4 931 - 5 42,810 11,701 5	Parent/ Subsidiary Guarantors Subsidiary Guarantors \$ 111,503 \$ 24,020 \$ 277,483 65,094 1 277,483 65,094 1 1,744 12,471 1 1,744 98,576 1 2,343 98,576 1 2,343 910 7,078 910 7,078 1 1 910 7,078 1 1 2,177 57,228 1 1 393,983 208,149 1 1 2,177 57,228 1 1 3,034 17,186 1 1 - - 26,635 1 - 107,511 1 1 - 26,635 1 1 - 107,511 1 1 - 107,511 1 1 - <	Parent/ Issuer Subsidiary Guarantors Non- Guarantors \$ 111,503 \$ 24,020 \$ 102,800 277,483 65,094 — — 277,483 65,094 — — 11,744 — — — 2,343 — — — 2,343 — — — 2,343 — — — 393,983 208,149 147,013 2,177 57,228 20,043 3,177 57,228 20,043 45,669 — — — — — 3,034 17,186 — — — — 3,034 17,186 — — — — 3,034 17,186 — — — — 42,810 \$ \$50,847 — — — — — —	Parent/ Subsidiary Subsidiary Non- Curantors Issuer Guarantors Guarantors Guarantors Guarantors \$ 111,503 \$ 24,020 \$ 102,800 \$ 277,483 65,094 - - - 12,471 5,551 - - 1,744 - - 2,343 - - 2,343 - - - 910 7,078 37,248 - 393,983 208,149 147,013 - - - - - 23,043 - - 2,177 57,228 20,043 - - - 3,034 17,186 - - - 3,034 17,186 - - - 42,810 11,701 1,683 - - </td <td>Parent/ Subsidiary Guarantors Subsidiary Guarantors Non- Guarantors Consolidating Adjustments \$ 111.503 \$ 24,020 \$ 102,800 \$ 277,483 65,094 277,483 65,094 1,744 (1,741) 2,343 (2,343) 2,171 57,228 20,043 393,983 208,149 147,013 (4,087) 2,177 57,228 20,043 393,983 208,149 147,013 (4,087) 2,177 57,228 20,043 53,058 <t< td=""><td>Subsidiary Subsidiary Non- Consolidating Issuer Guarantors Adjustments Adjustments \$ 111,503 \$ 24,020 \$ 102,800 \$ - \$ 277,483 65,094 - - - \$ - 12,471 5,551 - - \$ - 98,576 - - - \$ 2,343 - - (1,744) - - - 98,576 - - - - 2,343 - - (2,343) - - - 910 7,078 37,248 - - 2,177 57,228 20,043 - - 2,177 57,228 20,043 - - 3033,983 208,149 147,013 (4,087) - - - - 199,026 - - - -</td></t<></td>	Parent/ Subsidiary Guarantors Subsidiary Guarantors Non- Guarantors Consolidating Adjustments \$ 111.503 \$ 24,020 \$ 102,800 \$ 277,483 65,094 277,483 65,094 1,744 (1,741) 2,343 (2,343) 2,171 57,228 20,043 393,983 208,149 147,013 (4,087) 2,177 57,228 20,043 393,983 208,149 147,013 (4,087) 2,177 57,228 20,043 53,058 <t< td=""><td>Subsidiary Subsidiary Non- Consolidating Issuer Guarantors Adjustments Adjustments \$ 111,503 \$ 24,020 \$ 102,800 \$ - \$ 277,483 65,094 - - - \$ - 12,471 5,551 - - \$ - 98,576 - - - \$ 2,343 - - (1,744) - - - 98,576 - - - - 2,343 - - (2,343) - - - 910 7,078 37,248 - - 2,177 57,228 20,043 - - 2,177 57,228 20,043 - - 3033,983 208,149 147,013 (4,087) - - - - 199,026 - - - -</td></t<>	Subsidiary Subsidiary Non- Consolidating Issuer Guarantors Adjustments Adjustments \$ 111,503 \$ 24,020 \$ 102,800 \$ - \$ 277,483 65,094 - - - \$ - 12,471 5,551 - - \$ - 98,576 - - - \$ 2,343 - - (1,744) - - - 98,576 - - - - 2,343 - - (2,343) - - - 910 7,078 37,248 - - 2,177 57,228 20,043 - - 2,177 57,228 20,043 - - 3033,983 208,149 147,013 (4,087) - - - - 199,026 - - - -

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING BALANCE SHEETS

				De	ecember 31, 2014			
					Subsidiary			Consolidated
		Parent/	Subsidiary		Non-	C	Consolidating	Vector Group
		Issuer	Guarantors		Guarantors	1	Adjustments	Ltd.
ASSETS:								
Current assets:								
Cash and cash equivalents	\$	211,751	\$ 9,724	\$	104,890	\$	—	\$ 326,365
Investment securities available for sale		278,010	68,033		—		—	346,043
Accounts receivable - trade, net		—	18,024		5,304		—	23,328
Intercompany receivables		795	267		—		(1,062)	—
Inventories		—	90,323		—		—	90,323
Income taxes receivable, net		1,055	463		21		1,743	3,282
Restricted assets		—	1,181		1,414		_	2,595
Other current assets		899	 9,133		26,686			 36,718
Total current assets		492,510	197,148		138,315		681	828,654
Property, plant and equipment, net		2,648	61,149		20,315		_	84,112
Real estate held for sale, net		_	—		10,643		_	10,643
Long-term investments		39,594	_		698		_	40,292
Investments in real estate ventures		—	—		163,460		—	163,460
Investments in consolidated subsidiaries		518,963	_		_		(518,963)	_
Restricted assets		1,707	10,306		—		—	12,013
Goodwill and other intangible assets, net		_	107,511		162,461		-	269,972
Prepaid pension costs		—	25,032		—		—	25,032
Other assets		45,904	 10,743		2,246			 58,893
Total assets	\$	1,101,326	\$ 411,889	\$	498,138	\$	(518,282)	\$ 1,493,071
LIABILITIES AND STOCKHOLDERS' EQUITY:								
Current liabilities:								
Current portion of notes payable and long-term debt	\$	25,000	\$ 27,248	\$	392	\$	_	\$ 52,640
Current portion of fair value of derivatives embedded within convertible debt		884	_		_		_	884
Current portion of employee benefits		_	931		_		_	931
Intercompany payables		_	_		1,062		(1,062)	_
Income taxes payable, net		_	_		_		1,743	1,743
Litigation accruals and current payments due under the Master Settlement Agreement			29,471					29,471
Deferred income taxes, net		17,452	11,027					23,471 28,479
Other current liabilities		36,653	58,677		31,425			126,755
Total current liabilities		79,989	 127,354	·	32,879		681	 240,903
Notes payable, long-term debt and other obligations, less current portion		852,560	8,120		32,079		001	860,711
Fair value of derivatives embedded within convertible debt		168,502	0,120		51			168,502
Non-current employee benefits		32,842	16,472					49,314
Deferred income taxes, net		23,539	32,301		38,670			43,514 94,510
Other liabilities, primarily litigation accruals and payments due under the			52,501		50,070			
Master Settlement Agreement		921	 51,775		4,383			 57,079
Total liabilities		1,158,353	236,022		75,963		681	1,471,019
Commitments and contingencies								
Stockholders' (deficiency) equity attributed to Vector Group Ltd.		(57,027)	175,867		343,096		(518,963)	(57,027)
Non-controlling interest	_	_	_		79,079	_		 79,079
Total stockholders' (deficiency) equity	-	(57,027)	 175,867		422,175	-	(518,963)	 22,052
Total liabilities and stockholders' equity	\$	1,101,326	\$ 411,889	\$	498,138	\$	(518,282)	\$ 1,493,071

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS

		 Thre				
			Consolidated			
	Parent/	Subsidiary	Non-	Consolidating		Vector Group
	Issuer	Guarantors	Guarantors	Adjustments		Ltd.
Revenues	\$ _	\$ 255,291	\$ 161,022	\$ (140)	\$	416,173
Expenses:						
Cost of sales	_	175,334	103,870	_		279,204
Operating, selling, administrative and general expenses	6,937	22,555	50,327	(140)		79,679
Litigation settlement and judgment expense	_	1,250	—	_		1,250
Management fee expense		2,563	_	(2,563)		
Operating (loss) income	(6,937)	53,589	6,825	2,563		56,040
Other income (expenses):						
Interest expense	(30,880)	(879)	(2)	_		(31,761)
Change in fair value of derivatives embedded within convertible debt	5,256	_	_	_		5,256
Equity income from real estate ventures	_	_	1,856	—		1,856
Equity loss on long-term investments	(1,657)	—	—	—		(1,657)
Loss on sale of investment securities available for sale	(190)	_	—	—		(190)
Equity income in consolidated subsidiaries	35,754	—	—	(35,754)		—
Management fee income	2,563	_	—	(2,563)		_
Other, net	896	200	429			1,525
Income before provision for income taxes	4,805	52,910	9,108	(35,754)		31,069
Income tax benefit (expense)	 13,063	 (21,226)	 (3,201)			(11,364)
Net income	17,868	31,684	5,907	(35,754)		19,705
Net income attributed to non-controlling interest			(1,837)			(1,837)
Net income attributed to Vector Group Ltd.	 17,868	31,684	4,070	(35,754)		17,868
Comprehensive income attributed to non-controlling interest	 _	 _	 (1,837)			(1,837)
Comprehensive income attributed to Vector Group Ltd.	\$ 15,087	\$ 31,933	\$ 4,070	\$ (36,003)	\$	15,087

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS

		 Thre	e Mo	onths Ended June 30,	2014	4	
				Subsidiary			Consolidated
	Parent/	Subsidiary		Non-		Consolidating	Vector Group
	Issuer	Guarantors		Guarantors		Adjustments	Ltd.
Revenues	\$ —	\$ 253,125	\$	153,488	\$	_	\$ 406,613
Expenses:							
Cost of sales	_	181,517		97,765		_	279,282
Operating, selling, administrative and general expenses	4,933	22,190		39,900		—	67,023
Management fee expense		 2,468				(2,468)	_
Operating (loss) income	(4,933)	46,950		15,823		2,468	60,308
Other income (expenses):							
Interest expense	(43,190)	(1,284)		(3)		294	(44,183)
Change in fair value of derivatives embedded within convertible debt	1,970	_		_		_	1,970
Acceleration of interest expense related to debt conversion	(439)	_		_		_	(439)
Equity loss from real estate ventures	_	_		(1,808)		_	(1,808)
Equity loss on long-term investments	(273)	_		—		—	(273)
Loss on sale of investment securities available for sale	(18)	_		—		—	(18)
Equity income in consolidated subsidiaries	32,408			_		(32,408)	_
Management fee income	2,468			_		(2,468)	—
Other, net	 1,068	 224		2,577		(294)	 3,575
(Loss) income before provision for income taxes	(10,939)	45,890		16,589		(32,408)	19,132
Income tax benefit (expense)	 18,864	 (19,716)		(5,249)		—	 (6,101)
Net income	7,925	26,174		11,340		(32,408)	13,031
Net income attributed to non-controlling interest	 	 		(5,106)			 (5,106)
Net income attributed to Vector Group Ltd.	 7,925	26,174		6,234		(32,408)	 7,925
Comprehensive income attributed to non-controlling interest	 	 		(5,106)			 (5,106)
Comprehensive income attributed to Vector Group Ltd.	\$ 9,436	\$ 25,464	\$	6,234	\$	(31,698)	\$ 9,436

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS

		 Six					
					Consolidated		
	Parent/	Subsidiary	Non-	Consolidating			Vector Group
	 Issuer	 Guarantors	 Guarantors		Adjustments		Ltd.
Revenues	\$ —	\$ 483,914	\$ 293,278	\$	(259)	\$	776,933
Expenses:							
Cost of sales	—	332,994	188,228		_		521,222
Operating, selling, administrative and general expenses	13,894	43,892	96,096		(259)		153,623
Litigation settlement and judgment expense	_	2,093	_		_		2,093
Management fee expense	_	5,125			(5,125)		
Operating (loss) income	(13,894)	99,810	8,954		5,125		99,995
Other income (expenses):							
Interest expense	(61,634)	(1,870)	(3)		_		(63,507)
Change in fair value of derivatives embedded within convertible debt	11,716	_	_		_		11,716
Equity income from real estate ventures	_		2,194				2,194
Equity loss on long-term investments	(1,694)		_		_		(1,694)
(Loss) gain on sale of investment securities available for sale	(336)	13,175	_				12,839
Equity income in consolidated subsidiaries	71,748	_	—		(71,748)		—
Management fee income	5,125	_	_		(5,125)		—
Other, net	1,920	520	981		—		3,421
Income before provision for income taxes	12,951	111,635	 12,126		(71,748)		64,964
Income tax benefit (expense)	25,873	(45,407)	(4,509)		_		(24,043)
Net income	 38,824	 66,228	 7,617		(71,748)		40,921
Net income attributed to non-controlling interest	_	—	(2,097)		_		(2,097)
Net income attributed to Vector Group Ltd.	38,824	66,228	 5,520		(71,748)		38,824
Comprehensive income attributed to non-controlling interest	 _	 	 (2,097)				(2,097)
Comprehensive income attributed to Vector Group Ltd.	\$ 38,042	\$ 65,589	\$ 5,520	\$	(71,109)	\$	38,042

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS

			Six	Mor	nths Ended June 30, 2	014		
	Parent/		Subsidiary		Non-		Consolidating	Vector Group
	Issuer		Guarantors		Guarantors		Adjustments	 Ltd.
Revenues	\$ —	\$	492,317	\$	261,532	\$	_	\$ 753,849
Expenses:								
Cost of sales			353,230		165,089		_	518,319
Operating, selling, administrative and general expenses	11,216		43,875		75,909		—	131,000
Litigation judgment expense			1,500		_		—	1,500
Management fee expense		. <u> </u>	4,935				(4,935)	
Operating (loss) income	(11,216)	88,777		20,534		4,935	103,030
Other income (expenses):								
Interest expense	(77,972)	(2,239)		(37)		612	(79,636)
Change in fair value of derivatives embedded within convertible debt	320		_		_		—	320
Acceleration of interest expense related to debt conversion	(4,118)	_		_		_	(4,118)
Equity loss from real estate ventures	—		—		(256)		—	(256)
Loss on sale of investment securities available for sale	(71)	_				_	(71)
Equity income on long-term investments	633		_		_		—	633
Equity income in consolidated subsidiaries	60,126		_		_		(60,126)	_
Management fee income	4,935		_		_		(4,935)	
Other, net	1,766		484		4,063		(612)	5,701
(Loss) income before provision for income taxes	(25,597)	87,022		24,304		(60,126)	25,603
Income tax benefit (expense)	36,102		(36,355)		(8,790)		—	(9,043)
Net income	10,505		50,667		15,514		(60,126)	16,560
Net income attributed to non-controlling interest					(6,055)		_	(6,055)
Net income attributed to Vector Group Ltd.	10,505		50,667	_	9,459		(60,126)	 10,505
Comprehensive income attributed to non-controlling interest			_		(6,055)		—	 (6,055)
Comprehensive income attributed to Vector Group Ltd.	\$ 17,324	\$	50,659	\$	9,459	\$	(60,118)	\$ 17,324

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS

		Six			
			Subsidiary		Consolidated
	Parent/	Subsidiary	Non-	Consolidating	Vector Group
	Issuer	Guarantors	Guarantors	Adjustments	Ltd.
Net cash provided by operating activities	\$ 42,679	\$ 99,159	\$ 13,057	\$ (71,010)	\$ 83,885
Cash flows from investing activities:					
Sale of investment securities	103,846	14,415	_	_	118,261
Maturities of investment securities	1,737	_	—	—	1,737
Purchase of investment securities	(112,119)	(1,476)	_	_	(113,595)
Proceeds from sale or liquidation of long-term investments	—	_	148	—	148
Purchase of long-term investments	(5,000)	_	—	—	(5,000)
Investments in real estate ventures	—	_	(34,857)	—	(34,857)
Increase in cash surrender value of life insurance policies	(717)	(401)	_	_	(1,118)
Increase in restricted assets	(1,327)	(6,607)	—	—	(7,934)
Issuance of notes receivable	—	_	(4,410)	—	(4,410)
Investments in subsidiaries	(42,808)	_	—	42,808	—
Proceeds from sale of fixed assets	—	3	_	_	3
Capital expenditures	—	(2,350)	(3,029)	—	(5,379)
Repayments of notes receivable	1,106	_	_	_	1,106
Pay downs of investment securities	3,530	_		_	3,530
Proceeds from sale of preferred securities	—	_	1,000	—	1,000
Investments in real estate held for sale, net			(12,502)		(12,502)
Net cash (used in) provided by investing activities	(51,752)	3,584	(53,650)	42,808	(59,010)
Cash flows from financing activities:					
Proceeds from issuance of debt	_	22		_	22
Deferred financing costs	_	(625)	_	_	(625)
Repayments of debt	_	(3,254)	(120)	_	(3,374)
Borrowings under revolver	—	126,727	—	_	126,727
Repayments on revolver	_	(144,492)	_	_	(144,492)
Capital contributions received	—	2,250	40,558	(42,808)	—
Intercompany dividends paid	_	(69,075)	(1,935)	71,010	_
Dividends and distributions on common stock	(92,778)	_	—	—	(92,778)
Distributions to non-controlling interest	—	_	_	_	—
Proceeds from exercise of Vector options	1,219	_	—	—	1,219
Tax benefit of options exercised	384				384
Net cash (used in) provided by financing activities	(91,175)	(88,447)	38,503	28,202	(112,917)
Net (decrease) increase in cash and cash equivalents	(100,248)	14,296	(2,090)		(88,042)
Cash and cash equivalents, beginning of period	211,751	9,724	104,890	_	326,365
Cash and cash equivalents, end of period	\$ 111,503	\$ 24,020	\$ 102,800	\$	\$ 238,323

(Dollars in Thousands, Except Per Share Amounts) <u>Unaudited</u>

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS

ParterStubilityStubilityStubilityStubilityConcolledVectorIssueCuaratoroCuaratoroAdjuturentLatNet calu provided by opening activitiesS1,520S3,202S(1,120)Stel direstment securitiesParceals formsale or lipolation of long-term investments								
IssuerGuarantosCaractorosAdjustmentsInduNet cash provided by operating activities\$17,371\$46,294\$32,279\$(41,352)\$53,095Cath flows from investing activities42,20542,205Sale of investment securities(108,839)(1,560)42,20542,205Purchase of investment securities(108,839)(1,560)42,20542,20542,205 <th></th> <th></th> <th></th> <th></th> <th>Subsidiary</th> <th></th> <th>Сс</th> <th>onsolidated</th>					Subsidiary		Сс	onsolidated
s 17.374 5 46.294 5 32.279 5 (41,952) 5 Cash flows from investing activitie: Sale of investment securities 49.296 — — — 49.206 Purchase of investment securities (108.057) (1500) — — 49.206 Purchase of long-term investments (500) — — — (7.000) Purchase of long-term investments (7.000) — — — (7.000) Durchase of long-term investments — — — (7.000) — — (7.000) Durchase of long-term investments — — — (7.000) — — (7.000) Dustibutions from investment in real estate ventures — — .			Parent/	Subsidiary	Non-	Consolidating	Ve	ctor Group
Net cash provided by operating activities 5 5.395 Sake of investing activities 49,296 — — 49,296 Purchase of investing activities (108,839) (1,560) — — 49,296 Purchase of investing activities (100,839) (1,560) — — 49 — (101,419) Purchase of indep-term investments (7000) — — — (12,534) — (12,534) Purchase of indep-term investment in real state ventures — — (200) — (220) … (220) Distributions from investment in real state ventures — … 3.533 … …			Issuer	Guarantors	Guarantors	Adjustments]	Ltd.
Sale of investment securities 49,296 49,296 Purchase of investment securities (108,859) (1,500) (10,149) Purchase of logidation of log-term investments 500 49 (7,000) Investments in rail estate ventures (12,534) (22,534) Purchase of subsidiaries (350) (22,534) Distributions from investment in rail estate ventures (350) (230) Distributions from investingent in real estate ventures (350) (350) (350) Decrease (increase) in cestricted assets 299 19 (889) (371) Issuance of notes receivable 35,393 (35,000) (250) Repayments of notes receivable 35,393 (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) (35,000) <th>Net cash provided by operating activities</th> <th>\$</th> <th>17,374</th> <th>\$ 46,294</th> <th>\$ 32,279</th> <th>\$ (41,952)</th> <th>\$</th> <th>53,995</th>	Net cash provided by operating activities	\$	17,374	\$ 46,294	\$ 32,279	\$ (41,952)	\$	53,995
Purchase of investment securities (1108,859) (1,560) — — (110,119) Purchase of long-term investments 500 — 49 — 549 Purchase of long-term investments (7,000) — — (7,000) Investments in real estate ventures — — (12,534) — (22,50) Distributions from investment in real estate ventures — — 3,539 — 3,539 Increase in cash surender value of life insurance policies — — 3,539 — 3,539 Decrease (increase) in antricited assets 299 19 (689) — (371) Issuance of notes receivable (35,000) — (250) 35,000 (250) Repayments of notes receivable (55,67) — — (4 — 4 4 — (10,144) Net cash used in investing activities (90,109) (8,455) (13,705) 25,267 (10,144) Net cash used in investing activities (90,109) (8,455) (3,570)	Cash flows from investing activities:							
Proceeds from sale or liquidation of long-term investments 500 — 49 — 599 Purchase of long-term investments (7,000) — — — (7,000) Investments in real estate ventures — — (253) — (253) Purchase of subsidiaries — — (250) — (250) Distributions from investment in real estate ventures — — 3359 — 3.539 Increase in cash surrender value of life insurance policies — (395) — — (395) Decrease (increase) in restricted assets 299 19 (669) — (371) Issuance of notes receivable (35,000) — (250) 35,000 (250) Repayments of notes receivable (25,267) — — 4 — — 4 Investing activities (11) (5,563) (3,570) — (10,14) Net cash used in investing activities: — — — (42,160) — (43,702)	Sale of investment securities		49,296	_	_	—		49,296
Purchase of long-term investments $(7,000)$ $ (7,000)$ Investments in real estate ventures $ (2,34)$ $ (2,534)$ Purchase of subsidiaries $ (2,530)$ $ (2,530)$ Distributions from investment in real estate ventures $ 3,539$ $ (2,50)$ Distributions from investment in real estate ventures $ (3,500)$ $ (2,50)$ Decrease (increase) in restricted assets 299 19 (689) $ (2,51)$ Repayments of notes receivable $(35,000)$ $ (2,50)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $ (2,52,67)$ $-$ </td <td>Purchase of investment securities</td> <td></td> <td>(108,859)</td> <td>(1,560)</td> <td>_</td> <td>_</td> <td></td> <td>(110,419)</td>	Purchase of investment securities		(108,859)	(1,560)	_	_		(110,419)
Investments in real estate ventures $ (12,534)$ $ (12,534)$ Purchase of subsidiaries $ (250)$ $ (250)$ Distributions from investment in real estate ventures $ 3,539$ $ 3,539$ Increase in cash surender value of life insurance policies $ (350)$ $ (350)$ Decrease (increase) in restricted assets 299 19 (689) $ (371)$ Issuance of notes receivable $(35,000)$ $ (250)$ $35,000$ (250) Repayments of notes receivable $35,933$ $ (35,000)$ 933 Proceeds from sale of fixed assets $ 4$ $ (41,10)$ Investments in subsidiaries $(25,267)$ $ (0,144)$ Net cash used in investing activities $(90,109)$ $(8,495)$ $(13,705)$ $25,267$ $-$ Capital expenditores (11) $(6,563)$ $(3,70)$ $ (0,144)$ Net cash used in investing activities $(90,109)$ $(8,495)$ $(13,705)$ $25,267$ $-$ Proceeds from issuance of debt $408,750$ $40,166$ $ (35,000)$ $413,216$ Deferred financing activities $ (32,739)$ $35,000$ $(80,51)$ Borrowings under revolver $ (32,736)$ $ -$ Proceeds from issuance of debt $408,750$ $ (427,736)$ $-$ Deferred financing activities <td>Proceeds from sale or liquidation of long-term investments</td> <td></td> <td>500</td> <td>_</td> <td>49</td> <td>—</td> <td></td> <td>549</td>	Proceeds from sale or liquidation of long-term investments		500	_	49	—		549
Purchase of subsidiaries — — — — — (250) Distributions from investment in real estate ventures — — 3,539 — 3,539 Increase in cash surender value of life insurance policies — (395) — — (395) Decrease (increase) in restricted assets 299 19 (689) — (371) Issuance of notes receivable (35,000) — (250) 35,000 (35,000) 933 Proceeds from sale of fixed assets — 4 — — 44 Investments in subsidiaries (25,267) — — 25,267 — Capital expenditures (11) (6,553) (3,570) — (10,144) Net shows from financing activities: (90,109) 64,455 (13,705) 25,267 — Proceeds from issuance of debt 408,750 40,166 — (10,144) Net shows from financing activities: — — (42,300) (35,000) 413,916 Deforced fin	Purchase of long-term investments		(7,000)	—	—	—		(7,000)
Distributions from investment in real estate ventures - - 3.53 - 3.53 Increase in cash surreade value of life insurance policies - (395) - - (395) Decrease (increase) in restricted assets 299 19 (669) - (371) Issunce of notes receivable (35,000) - (250) 35,000 (250) Repayments of notes receivable 35,933 - - (35,000) 933 Proceeds from sale of fixed asers - 4 - - 44 Investing activities (25,267) - - 25,267 - Capital expenditures (11) (6,563) (3570) - (10,144) Net cash used in investing activities (90,109) (8,495) (13,705) 25,267 (87,042) Cashid expenditures (11) (6,563) (3,570) - (10,144) Net cash susance of debt 408,750 40,166 - (35,000) (8,051) Defrered financing costs	Investments in real estate ventures		_	_	(12,534)	—		(12,534)
Increase in cash surrender value of life insurance policies(395)(395)Decrease (increase) in restricted assets29919(689)(371)Issuance of notes receivable(35,000)(250)35,000(250)Repayments of notes receivable35,933(35,000)933Proceeds from sale of fixed assets44Investments in subsidiaries(25,267)(10,144)Net cash used in investing activities(90,109)(8,495)(13,705)25,267(07,442)Net cash used in investing activities(11)(6,563)(3,570)(10,144)Net cash used in investing activities(12,360)(11,49)Proceeds from issuance of debt408,75040,166(35,000)413,916Deferred financing costs(12,360)(22,360)Repayments of tebt(37,736)(437,736)Borrowings under revolver(337,736)(437,736)Capital contributions received(30,000)(11,952)Intercompany dividends paidDividends and distributions on common stock(80,963)	Purchase of subsidiaries		—	_	(250)	_		(250)
Decrease (increase) in restricted assets29919(689)(371)Issuance of notes receivable $(35,000)$ (250) $35,000$ (250)Repayments of notes receivable $35,933$ (35,000)933Proceeds from sale of fixed assets44Investments in subsidiaries $(25,267)$ 25,267Capital expenditures(11) (6563) (3570) (10,144)Net cash used in investing activities(900) (8495) (13,05)25,267(87,042)Cash flows from financing activities:(35,000)413,916(12,360)413,916Deferred financing costs(12,360)(12,360)(8,651)Borrowings under revolver(437,736)(437,736)Capital expenditions received(30,000)(11,952)41,952Intercompany dividends paid(30,000)(11,952)41,952Dividends and distributions on common stock(80,963)(30,075)-(30,075)Proceeds from exercise of Vector options $3,405$ (30,075)-(30,075)Proceeds from exercise of vector options $3,405$ (30,075)-(30,075)Proceeds from exercise of vector options $3,405$ (30,075)Proceeds from exercise of vector options $3,405$ </td <td>Distributions from investment in real estate ventures</td> <td></td> <td>—</td> <td>—</td> <td>3,539</td> <td>_</td> <td></td> <td>3,539</td>	Distributions from investment in real estate ventures		—	—	3,539	_		3,539
Issuance of notes receivable $(35,000)$ — (250) $35,000$ (250) Repayments of notes receivable $35,933$ — — $(35,000)$ 933 Proceeds from sale of fixed assets — 4 — — 44 Investments in subsidiaries $(25,267)$ — — 44 Investments in subsidiaries $(25,267)$ — — $25,267$ — Capital expenditures (11) $(6,563)$ $(3,570)$ — $(10,144)$ Net cash used in investing activities: $(90,109)$ $(8,495)$ $(13,705)$ $25,267$ $(07,42)$ Cash flows from financing activities: $(90,109)$ $(8,495)$ $(13,705)$ $25,267$ $(07,42)$ Proceeds from issuance of debt $408,750$ $40,166$ — $(35,000)$ $413,916$ Deferred financing activities: $(12,360)$ — — $(12,360)$ $(13,759)$ $35,000$ $(8,051)$ Borrowings under revolver — $(39,293)$ $(3,759)$ $35,000$ $(8,051)$ Dividends and istributions on common stock	Increase in cash surrender value of life insurance policies		—	(395)	_	_		(395)
Repayments of notes receivable $35,933$ $ (35,000)$ 933 Proceeds from sale of fixed assets $ 4$ $ 4$ Investments in subsidiaries $(25,267)$ $ 25,267$ $-$ Capital expenditures (11) $(6,563)$ $(3,570)$ $ (10,144)$ Net cash used in investing activities $(90,109)$ $(8,495)$ $(13,705)$ $25,267$ $(87,042)$ Cash flows from financing activities: $ (35,000)$ $413,916$ Deferred financing costs $(12,360)$ $ (12,360)$ Repayments of debt $ (39,293)$ $(3,758)$ $35,000$ $(8,051)$ Borrowings under revolver $ (437,736)$ $ (437,736)$ Capital contributions received $ (30,000)$ $(11,952)$ $(11,952)$ $-$ Intercompany dividends paid $ (30,076)$ $ (80,963)$ Dividends and distributions on common stock $(80,963)$ $ (80,963)$ Proceeds from exercise of Vector options $3,405$ $ (80,963)$ Net cash provided by (used in) financing activities $319,512$ $(34,525)$ $3,332$ $16,685$ $305,004$ Net cash provided by (used in) financing activities $246,777$ $3,274$ $21,906$ $ 271,957$ Cash and cash equivalents, beginning of period $151,342$ $11,812$ $71,312$ $ 2$	Decrease (increase) in restricted assets		299	19	(689)	_		(371)
Proceeds from sale of fixed assets $ 4$ $ 4$ Investments in subsidiaries $(25,267)$ $ 25,267$ $-$ Capital expenditures (11) $(6,563)$ $(3,570)$ $ (10,144)$ Net cash used in investing activities $(90,109)$ $(8,495)$ $(13,705)$ $25,267$ $(87,042)$ Cash flows from financing activities: $ (0,166)$ $ (35,000)$ $413,916$ Deferred financing costs $(12,360)$ $ (12,360)$ Repayments of debt $ (39,293)$ $(3,758)$ $35,000$ $(8,051)$ Borrowings under revolver $ (437,736)$ $ 429,188$ Repayments on revolver $ (437,736)$ $ (437,736)$ Capital contributions received $ 3,150$ $22,117$ $(25,267)$ $-$ Intercompany dividends paid $ (3,075)$ $ (80,963)$ Dividends and distributions on common stock $(80,963)$ $ (80,963)$ Proceeds from exercise of Vector options $3,405$ $ (3,075)$ $ (80,963)$ Net cash provided by (used in) financing activities $319,512$ $(34,525)$ $3,332$ $16,685$ $305,004$ Net increase in cash and cash equivalents $246,777$ $3,274$ $21,906$ $ 27,1957$ Cash and cash equivalents, beginning of period $151,342$ $11,812$ <td>Issuance of notes receivable</td> <td></td> <td>(35,000)</td> <td>—</td> <td>(250)</td> <td>35,000</td> <td></td> <td>(250)</td>	Issuance of notes receivable		(35,000)	—	(250)	35,000		(250)
Investments in subsidiaries $(25,267)$ $ 25,267$ $-$ Capital expenditures(11) $(6,563)$ $(3,570)$ $ (10,144)$ Net cash used in investing activities $(90,109)$ $(8,495)$ $(13,705)$ $25,267$ $(87,042)$ Cash flows from financing activities: $408,750$ $40,166$ $ (35,000)$ $413,916$ Deferred financing costs $(12,360)$ $ (12,360)$ Repayments of debt $ (39,293)$ $(3,758)$ $35,000$ (8051) Borrowings under revolver $ 429,188$ $ 429,188$ Repayments on revolver $ (437,736)$ $ (437,736)$ Capital contributions received $ 3,150$ $22,117$ $(25,267)$ $-$ Intercompany dividends paid $ (30,000)$ $(11,952)$ $41,952$ $-$ Dividends and distributions on common stock $(80,963)$ $ (30,075)$ $ (30,075)$ Proceeds from exercise of Vector options $3,405$ $ 3,405$ Tax benefit of options exercised 680 $ 680$ Net cash provided by (used in financing activities $319,512$ $(34,525)$ $3,332$ $16,685$ $305,004$ Net increase in cash and cash equivalents $246,777$ $3,274$ $21,906$ $ 27,1957$ <tr <td="">Cash and cash equivalents, b</tr>	Repayments of notes receivable		35,933	_	_	(35,000)		933
Capital expenditures (11) (6,563) (3,570) — (10,144) Net cash used in investing activities (90,19) (8,495) (13,705) 25,267 (87,042) Cash flows from financing activities: (11,2,360) - (12,360) 413,916 Deferred financing costs (12,360) - - (12,360) (13,75) (12,360) (11,37) (12,360) (12,360) (13,75) (12,360) (13,75) (12,360) (13,75) (12,360) (13,75) (13,75) (13,75) (13,75) (13,75) (13,75) (14,37,736) <td< td=""><td>Proceeds from sale of fixed assets</td><td></td><td>—</td><td>4</td><td>_</td><td>_</td><td></td><td>4</td></td<>	Proceeds from sale of fixed assets		—	4	_	_		4
Net cash used in investing activities (90,109) (8,495) (13,705) 25,267 (87,042) Cash flows from financing activities:	Investments in subsidiaries		(25,267)	_	_	25,267		—
Cash flows from financing activities: Proceeds from issuance of debt 408,750 40,166 (35,000) 413,916 Deferred financing costs (12,360) (12,360) Repayments of debt (39,293) (3,758) 35,000 (8,051) Borrowings under revolver 429,188 429,188 Repayments on revolver (437,736) (437,736) Capital contributions received 3,150 22,117 (25,267) Intercompany dividends paid (30,000) (11,952) 41,952 Dividends and distributions on common stock (80,963) (80,963) 3,075) Proceeds from exercise of Vector options 3,405 3,405 680 Net cash provided by (used in) financing activities 319,512 (34,525) 3,332 16,685 305,004 Net increase in cash and cash equivalents 246,777 3,274 21,906 271,957 </td <td>Capital expenditures</td> <td></td> <td>(11)</td> <td>(6,563)</td> <td>(3,570)</td> <td>_</td> <td></td> <td>(10,144)</td>	Capital expenditures		(11)	(6,563)	(3,570)	_		(10,144)
Proceeds from issuance of debt $408,750$ $40,166$ $$ $(35,000)$ $413,916$ Deferred financing costs $(12,360)$ $$ $$ $ (12,360)$ Repayments of debt $$ $(39,293)$ $(3,758)$ $35,000$ $(8,051)$ Borrowings under revolver $$ $429,188$ $$ $$ $429,188$ Repayments on revolver $$ $(437,736)$ $$ $ (437,736)$ Capital contributions received $$ $3,150$ $22,117$ $(25,267)$ $$ Intercompany dividends paid $$ $(30,000)$ $(11,952)$ $41,952$ $$ Dividends and distributions on common stock $(80,963)$ $$ $$ $(30,075)$ $$ Proceeds from exercise of Vector options $3,405$ $$ $$ $(3,075)$ $$ Tax benefit of options exercised 680 $$ $$ -680 Net cash provided by (used in) financing activities $319,512$ $(34,525)$ $3,332$ $16,685$ $305,004$ Net increase in cash and cash equivalents $246,777$ $3,274$ $21,906$ $ 234,466$	Net cash used in investing activities		(90,109)	 (8,495)	(13,705)	25,267		(87,042)
Deferred financing costs(12,360)———(12,360)Repayments of debt—(39,293)(3,758)35,000(8,051)Borrowings under revolver—429,188——429,188Repayments on revolver—(437,736)——429,188Repayments on revolver—(437,736)——(437,736)Capital contributions received—3,15022,117(25,267)—Intercompany dividends paid—(30,000)(11,952)41,952—Dividends and distributions on common stock(80,963)———(80,963)Distributions to non-controlling interest——(3,075)—(3,075)Proceeds from exercise of Vector options3,405———680Net cash provided by (used in) financing activities319,512(34,525)3,33216,685305,004Net increase in cash and cash equivalents246,7773,27421,906—21,1957Cash and cash equivalents, beginning of period151,34211,81271,312—234,466	Cash flows from financing activities:							
Repayments of debt — (39,293) (3,758) 35,000 (8,051) Borrowings under revolver — 429,188 — — 429,188 Repayments on revolver — (437,736) — — 429,188 Repayments on revolver — (437,736) — — (437,736) Capital contributions received — 3,150 22,117 (25,267) — Intercompany dividends paid — (30,000) (11,952) 41,952 — Dividends and distributions on common stock (80,963) — — — (80,963) Distributions to non-controlling interest — — (3,075) — (3,075) Proceeds from exercise of Vector options 3,405 — — — 34,055 Tax benefit of options exercised 680 — — — 680 Net cash provided by (used in) financing activities 319,512 (34,525) 3,332 16,685 305,004 Net increase in cash and cash equivalents	Proceeds from issuance of debt		408,750	40,166	_	(35,000)		413,916
Borrowings under revolver — 429,188 — — 429,188 Repayments on revolver — (437,736) — — (437,736) Capital contributions received — 3,150 22,117 (25,267) — Intercompany dividends paid — (30,000) (11,952) 41,952 — Dividends and distributions on common stock (80,963) — — — (80,963) Distributions to non-controlling interest — — (3,075) — (3,075) Proceeds from exercise of Vector options 3,405 — — — 680 Net cash provided by (used in) financing activities 319,512 (34,525) 3,332 16,685 305,004 Net increase in cash and cash equivalents 246,777 3,274 21,906 — 271,957 Cash and cash equivalents, beginning of period 151,342 11,812 71,312 — 234,466	Deferred financing costs		(12,360)	_	_	_		(12,360)
Repayments on revolver—(437,736)——(437,736)Capital contributions received—3,15022,117(25,267)—Intercompany dividends paid—(30,000)(11,952)41,952—Dividends and distributions on common stock(80,963)———(80,963)Distributions to non-controlling interest——(3,075)—(3,075)Proceeds from exercise of Vector options3,405———3,405Tax benefit of options exercised680———680Net cash provided by (used in) financing activities319,512(34,525)3,33216,685305,004Net increase in cash and cash equivalents246,7773,27421,906—271,957Cash and cash equivalents, beginning of period151,34211,81271,312—234,466	Repayments of debt		—	(39,293)	(3,758)	35,000		(8,051)
Capital contributions received — 3,150 22,117 (25,267) — Intercompany dividends paid — (30,000) (11,952) 41,952 — Dividends and distributions on common stock (80,963) — — — (80,963) Distributions to non-controlling interest — — (3,075) — (3,075) Proceeds from exercise of Vector options 3,405 — — — 3,405 Tax benefit of options exercised 680 — — — 680 Net cash provided by (used in) financing activities 319,512 (34,525) 3,332 16,685 305,004 Net increase in cash and cash equivalents 246,777 3,274 21,906 — 271,957 Cash and cash equivalents, beginning of period 151,342 11,812 71,312 — 234,466	Borrowings under revolver		—	429,188	_	_		429,188
Intercompany dividends paid—(30,000)(11,952)41,952—Dividends and distributions on common stock(80,963)———(80,963)Distributions to non-controlling interest——(3,075)—(3,075)Proceeds from exercise of Vector options3,405———3,405Tax benefit of options exercised680———680Net cash provided by (used in) financing activities319,512(34,525)3,33216,685305,004Net increase in cash and cash equivalents246,7773,27421,906—271,957Cash and cash equivalents, beginning of period151,34211,81271,312—234,466	Repayments on revolver		_	(437,736)	_	_		(437,736)
Dividends and distributions on common stock(80,963)(80,963)Distributions to non-controlling interest(3,075)(3,075)Proceeds from exercise of Vector options3,4053,405Tax benefit of options exercised680680Net cash provided by (used in) financing activities319,512(34,525)3,33216,685305,004Net increase in cash and cash equivalents246,7773,27421,906271,957Cash and cash equivalents, beginning of period151,34211,81271,312234,466	Capital contributions received		_	3,150	22,117	(25,267)		_
Distributions to non-controlling interest——(3,075)—(3,075)Proceeds from exercise of Vector options3,405———3,405Tax benefit of options exercised680———680Net cash provided by (used in) financing activities319,512(34,525)3,33216,685305,004Net increase in cash and cash equivalents246,7773,27421,906—271,957Cash and cash equivalents, beginning of period151,34211,81271,312—234,466	Intercompany dividends paid		—	(30,000)	(11,952)	41,952		—
Proceeds from exercise of Vector options3,4053,405Tax benefit of options exercised680680Net cash provided by (used in) financing activities319,512(34,525)3,33216,685305,004Net increase in cash and cash equivalents246,7773,27421,906271,957Cash and cash equivalents, beginning of period151,34211,81271,312234,466	Dividends and distributions on common stock		(80,963)	—	_	_		(80,963)
Tax benefit of options exercised680———680Net cash provided by (used in) financing activities319,512(34,525)3,33216,685305,004Net increase in cash and cash equivalents246,7773,27421,906—271,957Cash and cash equivalents, beginning of period151,34211,81271,312—234,466	Distributions to non-controlling interest		—	—	(3,075)	_		(3,075)
Net cash provided by (used in) financing activities 319,512 (34,525) 3,332 16,685 305,004 Net increase in cash and cash equivalents 246,777 3,274 21,906 — 271,957 Cash and cash equivalents, beginning of period 151,342 11,812 71,312 — 234,466	Proceeds from exercise of Vector options		3,405	_	_	_		3,405
Net increase in cash and cash equivalents 246,777 3,274 21,906 — 271,957 Cash and cash equivalents, beginning of period 151,342 11,812 71,312 — 234,466	Tax benefit of options exercised		680	—	_	_		680
Cash and cash equivalents, beginning of period 151,342 11,812 71,312 — 234,466	Net cash provided by (used in) financing activities		319,512	(34,525)	3,332	16,685		305,004
	Net increase in cash and cash equivalents		246,777	3,274	21,906	_		271,957
Cash and cash equivalents, end of period \$ 398,119 \$ 15,086 \$ 93,218 \$ — \$ 506,423	Cash and cash equivalents, beginning of period		151,342	11,812	71,312			234,466
	Cash and cash equivalents, end of period	\$	398,119	\$ 15,086	\$ 93,218	\$	\$	506,423

(Dollars in Thousands, Except Per Share Amounts)

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of Vector Group Ltd.'s financial statements with a narrative from our management's perspective. Our MD&A is divided into the following sections:

- Overview and Recent Developments
- Results of Operations
- Summary of Real Estate Investments
- Liquidity and Capital Resources

Please read this discussion along with our MD&A and audited financial statements as of and for the year ended December 31, 2014 and Notes thereto, included in our 2014 Annual Report on Form 10-K, and our Consolidated Condensed Financial Statements and related Notes as of and for the quarterly period ended June 30, 2015.

Overview

We are a holding company and are engaged principally in:

- the manufacture and sale of cigarettes in the United States through our Liggett Group LLC ("Liggett") and Vector Tobacco Inc. ("Vector Tobacco") subsidiaries,
- the sale of electronic cigarettes ("e-cigarettes") in the United States through our Zoom E-Cigs LLC ("Zoom") subsidiary, and
- the real estate business through our New Valley LLC ("New Valley") subsidiary, which is seeking to acquire additional operating companies and real estate properties. New Valley owns 70.59% of Douglas Elliman Realty, LLC ("Douglas Elliman Realty"), which operates the largest residential brokerage company in the New York metropolitan area.

Zoom entered the United States e-cigarette market in limited retail distribution outlets in 2013. Zoom's operations are included in our "E-Cigarettes" reporting segment. Our exposure to Zoom, as of June 30, 2015, was approximately \$3,411, which was primarily comprised of Zoom's inventory and point of sale marketing material. We have seen significant changes in the e-cigarette market over the past year with apparent declines in the sales of disposable and rechargeable e-cigarettes while open system vapor products that feature refillable tanks and use low-cost flavored liquids have demonstrated mixed results. Additionally, we believe uncertainties exist related to the regulation of e-cigarettes, including open system vapor products. Given this backdrop, our primary focus on e-cigarettes is to stay prepared to pursue opportunities if they occur.

Recent Developments

Liggett Credit Facility. On January 14, 2015, our subsidiaries, Liggett and 100 Maple LLC ("Maple"), entered into a Third Amended and Restated Credit Agreement (the "Credit Agreement"), dated as of January 14, 2015, with Wells Fargo Bank, National Association ("Wells Fargo"), as agent and lender. The Credit Agreement governs a \$60,000 credit facility (the "Credit Facility") that consists of a revolving credit facility of up to \$60,000 borrowing capacity (the "Revolver") and a \$3,600 term loan (the "Term Loan") that is within the \$60,000 commitment under the Credit Facility and reduces the amount available under the Revolver. All borrowings under the Credit Facility (other than the Term Loan) are limited to a borrowing base equal to roughly (1) the lesser of (a) 85% of the net amount of eligible accounts receivable and (b) \$10,000 plus (2) the lesser of (a) the sum of (I) 80% of the value of eligible inventory consisting of packaged cigarettes plus (II) the lesser of (x) 60% multiplied by Liggett's eligible cost of eligible inventory consisting of leaf tobacco and (b) \$60,000, less (3) certain reserves against accounts receivable, inventory, bank products or other items which Wells Fargo, as agent, may establish from time to time in its permitted discretion. The obligations under the Credit Facility are collateralized on a first priority basis by all inventories, receivables and certain other personal property of Liggett and Maple, a mortgage on Liggett's manufacturing facility and certain real property of Maple, subject to certain permitted liens. The Credit Facility amended and restated Liggett's existing \$3,600 credit facility with Wells Fargo and Maple's existing \$3,600 term loan with Wells Fargo.

The term of the Credit Facility expires on March 31, 2020. Prime rate loans under the Credit Facility bear interest at a rate equal to the greatest of (i) the Federal Funds rate plus 0.50%, (ii) LIBOR plus 1.0% and (ii) the prime rate of Wells Fargo. LIBOR rate loans under the Credit Facility bear interest at a rate equal to LIBOR plus 2.25%. Monthly principal payments of \$25 are due under the Term Loan on the first day of each month with the unpaid principal balance due at maturity on March 31, 2020. The Credit Facility contains customary affirmative and negative covenants, including covenants that limit Liggett's, Maple's and their subsidiaries' ability to incur, create or assume certain indebtedness, to incur or assume certain liens, to purchase, hold or acquire certain investments, to declare or make certain dividends and distributions and to engage in certain mergers, consolidations and asset sales. The Credit Facility also requires us to comply with specified financial covenants, including that Liggett's earnings before interest, taxes, depreciation and amortization, as defined under the Credit Facility, on a trailing twelve month basis, shall not be less than \$100,000 if Liggett's excess availability, as defined under the Credit Facility (before a maximum carryover amount of \$10,000), shall not exceed \$20,000 during any fiscal year. The Credit Facility also contains customary events of default.

Vector 6.75% Variable Interest Senior Convertible Note due 2015. In February 2015, the holder of the 6.75% Variable Interest Senior Convertible Note due 2015, converted the remaining \$25,000 principal balance of the Note into 2,227,552 of our common shares.

Liggett Retirement Window. Liggett recorded a charge of \$1,607 for the three and six months ended June 30, 2015 in connection with a window offered to terminated participants in two Defined Benefit Plans in 2015.

Recent Developments in Smoking-Related Litigation

There are no material changes from the Recent Developments in Smoking-Related Litigation set forth in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," of our Annual Report on Form 10-K, for the year ended December 31, 2014. Please refer to that section and the information below for disclosures regarding the critical accounting policies related to our business.

Critical Accounting Policies

There are no material changes from the critical accounting policies set forth in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," of our Annual Report on Form 10-K, for the year ended December 31, 2014. Please refer to that section and the information below for disclosures regarding the critical accounting policies related to our business.

Results of Operations

The following discussion provides an assessment of our results of operations, capital resources and liquidity and should be read in conjunction with our condensed consolidated financial statements included elsewhere in this report. The condensed consolidated financial statements include the accounts of VGR Holding, Liggett, Vector Tobacco, Liggett Vector Brands, New Valley and other less significant subsidiaries.

For purposes of this discussion and other consolidated financial reporting, our significant business segments for the three and six months ended June 30, 2015 and 2014 were Tobacco, E-Cigarettes and Real Estate. The Tobacco segment consists of the manufacture and sale of cigarettes. The E-Cigarettes segment includes the operations of Zoom. The Real Estate segment includes our investment in New Valley LLC, which includes Douglas Elliman, Escena, Indian Creek and investments in real estate ventures. As a result of the amount of operating losses of Zoom as of September 30, 2014 when compared to the remaining components of our Corporate and Other segment, we reevaluated our operating segments and have separated our E-Cigarettes operations from the Corporate and Other segment for previously reported periods as of and for the three and six months ended June 30, 2014. Thus, prior period information has been recast to conform to the current presentation. This change did not have an impact to the Company's historical consolidated results.

	Three Months Ended					Six Months Ended					
		June	30,								
		2015	2014			2015		2014			
Revenues:											
Торассо	\$	254,890	\$	250,556	\$	482,975	\$	483,948			
E-Cigarettes		261		2,569		680		8,369			
Real Estate		161,022		153,488		293,278		261,532			
Total revenues	\$	416,173	\$	406,613	\$	776,933	\$	753,849			
<u>Operating income (loss)</u> :											
Tobacco	\$	56,215 ⁽¹⁾	\$	51,506 ⁽²⁾	\$	105,885 ⁽³⁾	\$	94,402 (4)			
E-Cigarettes		(2,400)		(3,765)		(5,564)		(4,190)			
Real Estate		6,892		15,901		9,043		20,645			
Corporate and Other		(4,667)		(3,334)		(9,369)		(7,827)			
Total operating income	\$	56,040	\$	60,308	\$	99,995	\$	103,030			

⁽¹⁾ Operating income includes \$1,250 of litigation judgment expense and \$1,607 of pension settlement expense.

⁽²⁾ Operating income includes \$1,419 of income from NPM Settlement.

⁽³⁾ Operating income includes \$2,093 of litigation judgment expense and \$1,607 of pension settlement expense.

⁽⁴⁾ Operating income includes \$1,419 of income from NPM Settlement and \$1,500 of litigation judgment expense.

Three Months Ended June 30, 2015 Compared to Three Months Ended June 30, 2014

<u>*Revenues*</u>. Total revenues were \$416,173 for the three months ended June 30, 2015 compared to \$406,613 for the three months ended June 30, 2014. Total revenues increased by \$9,560 (2.4%) due to an increase in Real Estate revenues of \$7,534. which was primarily related to Douglas Elliman's brokerage revenues, and an increase in Tobacco revenues of \$4,334. This was offset by a decline in Zoom e-cigarette revenues of \$2,308.

<u>Cost of Sales</u>. Total cost of sales were \$279,204 for the three months ended June 30, 2015 compared to \$279,282 for the three months ended June 30, 2014. The \$78 (0.03%) decline in cost of sales was due to a \$4,906 decline in Tobacco cost of sales primarily related to the elimination of the Federal Tobacco Quota Buyout program and a \$1,279 decline in Zoom e-cigarette brand cost of sales. This was offset by an increase in real estate cost of sales of \$6,107 related to an increase of real estate commission expense at Douglas Elliman.

Expenses. Operating, selling, general and administrative expenses were \$79,679 for the three months ended June 30, 2015 compared to \$67,023 for the same period last year. This was an increase of \$12,656 (18.9%) of which \$10,438 was primarily related to the operating, selling and administrative expenses of Real Estate, \$3,281 of Tobacco operating, selling, general and administrative expenses and an increase in Corporate and Other expense of \$1,331. This was offset by a decline in Zoom operating, selling, general and administrative expenses of \$2,394.

<u>Operating income (loss)</u>. Operating income was \$56,040 for the three months ended June 30, 2015 compared to \$60,308 for the same period last year, a decline of \$4,268 (7.1%). Real Estate operating income declined by \$9,009 and Corporate and Other expenses increased by \$1,333. This was offset by an increase in Tobacco operating income of \$4,709 and a decline in operating losses related to Zoom of \$1,365.

<u>Other income (expenses)</u>. Other expenses were \$24,971 and \$41,176 for the three months ended June 30, 2015 and 2014, respectively. For the three months ended June 30, 2015, other expenses primarily consisted of interest expense of \$31,761, a loss on sale of investment securities available for sale of \$190 and equity losses on long-term investments of \$1,657. This was offset by income of \$5,256 from changes in fair value of derivatives embedded within convertible debt, equity income from real estate ventures of \$1,856 and other income of \$1,525. For the three months ended June 30, 2014, other expenses primarily consisted of interest expense related to the debt conversion of the 6.75% Variable Interest Senior Convertible Exchange Notes of \$439, equity losses on long-term investments of \$273, equity loss from non-consolidated real estate businesses of \$1,808 and a loss on sale of investment securities available for sale of \$18. The increase in interest expense in 2014 was primarily attributable to higher average debt balances. This was offset by income of \$1,970 from changes in fair value of derivatives embedded within convertible debt and interest and other income of \$3,575.

Income before provision for income taxes. Income before income taxes for the three months ended June 30, 2015 was \$31,069 compared to \$19,132 for the three months ended June 30, 2014. The increase is attributable to the items discussed above.

Income tax expense. Income tax expense was \$11,364 for the three months ended June 30, 2015 compared to \$6,101 for the three months ended June 30, 2014. Our provision for income taxes in interim periods is based on an estimated annual effective income tax rate derived, in part, from estimated annual income before provision for income taxes in accordance with guidance on accounting for income taxes on interim periods. For the three months ended June 30, 2015, our income tax expense decreased by \$91 due primarily to the results of a recent state income tax audit.

Tobacco.

Tobacco Revenues. Liggett increased the list price of PYRAMID, LIGGETT SELECT, EVE and GRAND PRIX by \$0.70 per carton in May 2015, \$0.70 per carton in November 2014 and \$0.60 per carton in May 2014.

All of our Tobacco sales were in the discount category in 2015 and 2014. For the three months ended June 30, 2015, tobacco revenues were \$254,890 compared to \$250,556 for the three months ended June 30, 2014. Revenues increased by \$4,334 (1.7%) due to a favorable price variance of \$9,308 offset by a decline in sales volume of \$4,974 (approximately 15.4 million units).

Tobacco Cost of Sales. Our Tobacco cost of sales declined from \$179,773 for the three months ended June 30, 2014 to \$174,867 for the three months ended June 30, 2015. The major components of our Tobacco cost of sales are as follows:

	Th	Three Months Ended June 30,				
	2015		2014			
Manufacturing overhead, raw materials and labor	\$ 32	,301 \$	32,196			
Federal Excise Taxes, net	108	,912	109,695			
Tobacco quota buyout expense (1)		664	6,922			
FDA expense	4	,315	4,413			
MSA expense, net of market share exemption	28	,675	26,547			
Total cost of sales	\$ 174	,867 \$	179,773			

⁽¹⁾ The quarterly assessments due under the Fair and Equitable Tobacco Reform Act (shown as "Tobacco quota buyout expense" above) expired at the end of 2014. The \$664 for the three months ended June 30, 2015 represents a final assessment for Q4 2014, which was received in Q2 2015.

Tobacco gross profit was \$80,023 for the three months ended June 30, 2015 compared to \$70,783 for the three months ended June 30, 2014. The \$9,240 (13.1%) increase was due to higher margins associated with price increases primarily on the PYRAMID brand and the absence of the tobacco quota buyout expense. This increase was partially offset by increased MSA and FDA expense, both of which increased in 2015 on a per-unit basis. As a percentage of revenues (excluding Federal Excise Taxes), Tobacco gross profit was 54.8% in the 2015 period compared to 50.3% in the comparable 2014 period.

Tobacco expenses. Tobacco operating, selling, general and administrative expenses were \$23,808 and \$19,277 for the three months ended June 30, 2015 and 2014, respectively. The increase of \$4,531 primarily related to an increase in tobacco product liability settlement expenses and a pension settlement charge of \$1,607. Tobacco product liability legal expenses were \$3,158 and \$1,817 for the three months ended June 30, 2015 and 2014, respectively.

Tobacco operating income. Tobacco operating income was \$56,215 for the three months ended June 30, 2015 compared to \$51,506 for the same period last year. The Tobacco operating income increase of \$4,709 (9.1%) was primarily due to higher margins associated with price increases primarily on the PYRAMID brand and the absence of the tobacco quota buyout expense, partially offset by increased manufacturing, MSA and FDA unit costs and increased operating, selling, general and administrative expenses.

E-Cigarettes.

E-Cigarettes revenues were \$261 for the three months ended June 30, 2015 compared to \$2,569 for three months ended June 30, 2014. Revenues declined because of lower sales volume and increased per unit promotional spending.

Our E-Cigarettes cost of sales were \$467 for the three months ended June 30, 2015 compared to \$1,746 for the three months ended June 30, 2014. Cost of sales declined due to lower sales volumes.

E-Cigarettes operating, selling, general and administrative expenses were \$2,194 and \$4,588 for the three months ended June 30, 2015 and 2014, respectively. The decline was due to lower advertising and marketing expenses. E-Cigarettes operating losses were \$2,400 and \$3,765 for the three months ended June 30, 2015 and 2014, respectively.

Real Estate.

Real Estate Revenues. Real Estate revenues were \$161,022 and \$153,488 for the three months ended ended June 30, 2015 and 2014, respectively. Real Estate revenues increased by \$7,534, the increase is primarily related to Douglas Elliman's Commission and other brokerage income offset by the absence of the revenue from the sale of Indian Creek in 2014 of \$14,400.

Real Estate revenues and cost of sales for the three months ended June 30, 2015 and 2014 were as follows:

	Three Months Ended June 30,				
	2015		2014		
Real Estate Revenues:					
Commission and other brokerage income	\$ 151,020	\$	129,395		
Property management income	7,473		7,796		
Title fees	1,123		729		
Indian Creek	_		14,400		
Sales on facilities primarily from Escena	1,179		1,168		
Other	227		—		
Total real estate revenues	\$ 161,022	\$	153,488		
Real Estate Cost of Sales:					
Commission and other brokerage income	\$ 102,767	\$	86,713		
Indian Creek cost of sales	_		9,987		
Cost of sales on facilities primarily from Escena	934		971		
Title fees	169		92		
Total real estate cost of sales	\$ 103,870	\$	97,763		

Brokerage Cost of sales. Douglas Elliman commission cost of sales increased by \$16,054 due to increased sales volume.

Real Estate expenses. Real Estate operating, selling, general and administrative expenses were \$50,260 and \$39,822 for the three months ended June 30, 2015 and 2014, respectively. Real Estate operating, selling, general and administrative expenses increased by \$10,438 primarily related to an increase of expenses at Douglas Elliman related to its strategic investments fueled by its expansion into new markets, its development marketing division and increased advertising and marketing expenses to strengthen the long-term value of the Douglas Elliman brand name.

Real Estate operating income. The Real Estate segment had operating income of \$6,892 for the three months ended June 30, 2015 and \$15,901 for the three months ended June 30, 2014. The decline of \$9,009 was primarily related to an increase in Douglas Elliman operating, selling, general and administrative expenses offset by higher profits and the absence of the operating income related to the 2014 sale of Indian Creek.

Corporate and Other.

Corporate and Other operating loss. Corporate and Other operating loss was \$4,667 for the three months ended June 30, 2015 compared to \$3,334 for 2014. Corporate and Other operating losses increased by \$1,333 primarily as a result of increased non-cash compensation expense for the three months ended June 30, 2015.

Six Months Ended June 30, 2015 Compared to Six Months Ended June 30, 2014

<u>Revenues</u>. Total revenues were \$776,933 for the six months ended June 30, 2015 compared to \$753,849 for the six months ended June 30, 2014. The \$23,084 (3.1%) increase in revenues was due to an increase in Real Estate revenues of \$31,746 primarily related to Douglas Elliman, offset by a \$7,689 decline in revenues from E-Cigarettes and a \$973 decline in Tobacco revenues.

<u>Cost of Sales</u>. Total cost of sales were \$521,222 for the six months ended June 30, 2015 compared to \$518,319 for the six months ended June 30, 2014. The \$2,903 (0.6%) increase in cost of sales was due to an increase in Real Estate cost of sales of \$23,141 related to the Douglas Elliman real estate commissions expense, offset by a \$16,042 decline in Tobacco cost of sales primarily related to the elimination of the Federal Tobacco Quota Buyout program and \$4,196 decline in cost of sales from E-Cigarettes.

Expenses. Operating, selling, general and administrative expenses were \$153,623 for the six months ended June 30, 2015 compared to \$131,000 for the same period last year. This was an increase of \$22,623 (17.3%) of which \$20,207 was related to the operating, selling and administrative expenses of Real Estate, \$2,994 to Tobacco operating, selling and administrative expenses and an increase in Corporate and Other expenses of \$1,542. This was offset by a decline in operating, selling, general and administrative expenses in the E-Cigarettes segment of \$2,120.

<u>Operating income (loss)</u>. Operating income was \$99,995 for the six months ended June 30, 2015 compared to \$103,030 for the same period last year, a decline of \$3,035 (2.9%). Tobacco operating income increased by \$11,483. This was offset by a \$11,602 decline in Real Estate operating income, a \$1,374 increase in operating losses related to E-Cigarettes and a \$1,542 increase in Corporate and Other expenses.

<u>Other income (expenses)</u>. Other expenses were \$35,031 and \$77,427 for the six months ended June 30, 2015 and 2014, respectively. For the six months ended June 30, 2015, other expenses primarily consisted of interest expense of \$63,507 and an equity loss on long-term investments of \$1,694. This was offset by a gain on sale of investment securities available for sale of \$12,839, income of \$11,716 from changes in fair value of derivatives embedded within convertible debt, equity income on real estate ventures of \$2,194 and interest and other income of \$3,421. For the six months ended June 30, 2014, other expenses primarily consisted of interest expense of \$79,636, acceleration of interest expense related to the debt conversion of the 6.75% Variable Interest Senior Convertible Exchange Notes of \$4,118, equity loss on real estate ventures of \$256 and a loss on sale of investment securities available for sale of \$71. The increase in interest expense in 2014 was primarily attributable to higher average debt balances. This was offset by equity income on long-term investments of \$633, interest and other income of \$5,701 and income of \$320 from changes in fair value of derivatives embedded within convertible debt.

Income before provision for income taxes. Income before income taxes was \$64,964 and \$25,603 for the six months ended June 30, 2015 and 2014, respectively. The increase is attributable to the items discussed above.

<u>Income tax expense</u>. Income tax expense was \$24,043 and \$9,043 for the six months ended June 30, 2015 and 2014, respectively. Our provision for income taxes in interim periods is based on an estimated annual effective income tax rate derived, in part, from estimated annual income before provision for income taxes in accordance with guidance on accounting for income taxes on interim periods. For the six months ended June 30, 2015, our income tax expense was decreased by \$100 due primarily to the rate differential in other comprehensive income and the results of a recent state income tax audits.

Tobacco.

Tobacco Revenues. Liggett increased the list price of PYRAMID, LIGGETT SELECT, EVE and GRAND PRIX by \$0.70 per carton in May 2015, \$0.60 per carton in May 2014 and \$0.70 per carton in November 2014.

All of our Tobacco sales were in the discount category in 2015 and 2014. For the six months ended June 30, 2015, Tobacco revenues were \$482,975 compared to \$483,948 for the six months ended June 30, 2014. Revenues declined by \$973 (0.2%) due to a decline in sales volume of \$19,403 (approximately 115.8 million units), offset by a favorable price variance of \$18,430.

Tobacco Cost of Sales. Our Tobacco cost of sales declined from \$347,939 for the six months ended June 30, 2014 to \$331,897 for the six months ended June 30, 2015. The major components of our Tobacco cost of sales are as follows:

	Six Months Ended				
	June 30,				
	 2015		2014		
Manufacturing overhead, raw materials and labor	\$ 61,963	\$	61,464		
Federal Excise Taxes, net	206,271		212,108		
Tobacco quota buyout expense (1)	664		14,272		
FDA expense	9,564		9,005		
MSA expense, net of market share exemption	53,435		51,090		
Total cost of sales	\$ 331,897	\$	347,939		

⁽¹⁾ The quarterly assessments due under the Fair and Equitable Tobacco Reform Act (shown as "Tobacco quota buyout expense" above) expired at the end of 2014. The \$664 for the six months ended June 30, 2015 represents a final assessment for Q4 2014, which was received in Q2 2015.

Tobacco gross profit was \$151,078 for the six months ended June 30, 2015 compared to \$136,009 for the six months ended June 30, 2014. The \$15,069 (11.1%) increase was due to higher margins associated with the absence of the tobacco quota buyout expense as well as price increases. This increase was partially offset by increased MSA and FDA expense, both of which increased in 2015 on a per-unit basis. As a percentage of revenues (excluding Federal Excise Taxes), Tobacco gross profit was 54.6% in the 2015 period and 50.0% in the 2014 period.

Tobacco expenses. Tobacco operating, selling, general and administrative expenses were \$45,194 for the six months ended June 30, 2015 compared to \$41,607 for the six months ended June 30, 2014. The \$3,587 increase in expenses primarily relates to an increase in tobacco product liability settlement expenses in addition to a pension settlement charge of \$1,607. Tobacco product liability legal expenses were \$5,713 and \$5,174 for the six months ended June 30, 2015 and 2014, respectively.

Tobacco operating income. Tobacco operating income was \$105,885 for the six months ended June 30, 2015 compared to \$94,402 for the same period last year. The Tobacco operating income increase of \$11,483 (12.2%) was due to higher margins associated with price increases and the absence of the tobacco quota buyout expense, which was partially offset by increased manufacturing, MSA and FDA expense, both of which increased in 2015 on a per-unit basis and increased operating, selling, general and administrative expenses.

E-Cigarettes.

E-Cigarettes revenues were \$680 for the six months ended June 30, 2015 compared to \$8,369 for six months ended June 30, 2014. Revenues declined because of lower sales volume and increased per unit promotional spending.

Our E-Cigarettes cost of sales were \$1,097 for the six months ended June 30, 2015 compared to \$5,293 for the six months ended June 30, 2014. Cost of sales decreased by \$4,196 due to lower sales volumes.

E-Cigarettes operating, selling, general and administrative expenses were \$5,146 and \$7,266 for the six months ended June 30, 2015 and 2014, respectively. The decline was due to lower advertising and marketing expenses. Operating losses from E-Cigarettes were \$5,564 and \$4,190 for the six months ended June 30, 2015 and 2014, respectively.

Real Estate.

Real Estate Revenues. Real Estate revenues were \$293,278 and \$261,532 for the six months ended ended June 30, 2015 and 2014, respectively. Real Estate revenues increased by \$31,746 (12.1%), primarily related to an increase of \$45,395 in Douglas Elliman's Commission and other brokerage income and offset by the absence of the \$14,400 revenue from the sale of Indian Creek in 2014.

Real Estate revenues and cost of sales for the six months ended ended June 30, 2015 were as follows:

	Six Months Ended June 30,			
	2015		2014	
Real Estate Revenues:				
Commission and other brokerage income	\$ 272,726	\$	227,331	
Property management income	14,686		15,113	
Title fees	1,951		1,334	
Indian Creek	_		14,400	
Sales on facilities primarily from Escena	3,524		3,354	
Other	391		_	
Total real estate revenues	\$ 293,278	\$	261,532	
Real Estate Cost of Sales:				
Commission and other brokerage income	\$ 185,864	\$	152,779	
Indian Creek cost of sales	—		9,987	
Cost of sales on facilities primarily from Escena	2,055		2,147	

Title fees

Total real estate cost of sales

Brokerage Cost of sales. Douglas Elliman commission cost of sales increased by \$33,085 due to increased sales volume.

Real Estate expenses. Real Estate operating, selling, general and administrative expenses were \$96,007 and \$75,800 for the six months ended June 30, 2015 and 2014, respectively. The increase of \$20,207 was primarily due to an increase of expenses at Douglas Elliman related to its strategic investments fueled by its expansion into new markets, its development marketing division and increased advertising and marketing expenses to strengthen the long-term value of the Douglas Elliman brand name.

309

\$

188,228

\$

174

165,087

Real Estate operating income. The Real Estate segment had operating income of \$9,043 and \$20,645 for the six months ended June 30, 2015 and 2014, respectively. The decrease in operating income of \$11,602 was primarily related to an increase in in Douglas Elliman operating, selling, general and administrative expenses, offset by higher profits and the absence of the operating income related to the 2014 sale of Indian Creek .

Corporate and other.

Corporate and other loss. The operating loss at the corporate segment was \$9,369 for the six months ended June 30, 2015 compared to \$7,827 for the same period in 2014. The increase was primarily due to increased non-cash compensation expense for the six months ended June 30, 2015.

Summary of Real Estate Investments

We own, and seek to acquire investment interests in various domestic and international real estate projects through debt and equity investments. Our current real estate investments primarily include the following projects as of June 30, 2015:

	(Dollars in Thousands. Area and Unit Information in Ones)																	
	Location	Date of Initial Investment	Percentage Owned	Net Cash Invested	Cumu Earn (Los	ings	Carry Value a June 30,	as of	Fut Cap Com mer from Valle	oital mit- nts New	Projec Residentia Hotel A	l and/or	Projec Comme Spac	rcial	Proje Numb Reside Lots, U and/or Roo	er of ntial Units Hotel	Projected Construction Start Date	Projected Construction End Date
Sagaponack	Sagaponack, NY	April 2015	100% \$	§ 12,502	\$	_	\$ 12	2,502	s	_	TBD		N/A		TBD		N/A	N/A
Escena, net	Master planned community, golf course, restaurant and shop in Palm Springs, CA	March 2008	100%	1,975	8,	566	10),541		_	450	Acres			667 450	R Lots H	N/A	N/A
Real estate held for sale, net			5	\$ 14,477	\$8,	566	\$ 23	3,043	\$	_								
10 Madison Square Park West (1107 Broadway)	Flatiron District/NoMad neighborhood, Manhattan, NY	October 2011	5.0% \$	\$ 5,232	\$2,	175	\$ 7	,407		_	260,000	SF	20,000	SF	124	R	August 2012	May 2016
The Marquand	Upper East Side, Manhattan, NY	December 2011	18.0%	7,000	6,	500	13	,500		_	90,000	SF	_		29	R	June 2012	August 2015
11 Beach Street	TriBeCa, Manhattan, NY	June 2012	49.5%	12,328	(324)	12	,004		_	97,000	SF	_		27	R	May 2014	July 2016
20 Times Square (701 Seventh Avenue)	Times Square, Manhattan, NY	August 2012	11.5%	12,737		—	12	,737		—	280,000	SF	80,000	SF	452	Н	September 2013	January 2018
111 Murray Street	TriBeCa, Manhattan, NY	May 2013	25.0%	27,319	(116)	27	,203		_	330,000	SF	TBD		157	R	September 2014	September 201
357 West (160 Leroy Street) (2)	West Greenwich Village, Manhattan, NY	March 2013	5.0%	1,753		_	1	,753		_	130,000	SF	_		50	R	Fall2015	March 2018
PUBLIC Chrystie House (f/k/a Chrystie Street)	Lower East Side, Manhattan, NY		18.4%	5,297		_		i,297		_	217,000		43,000	SF	11 367	R H	June 2014	March 2017
The Dutch (25-19 43rd Avenue)	Long Island City, NY	May 2014	9.9%	980		_		980			63,000	SF	_		86	R	September 2014	January 2017
Queens Plaza (23-10 Queens Plaza South)	Long Island City, NY	December 2012	45.4%	11,082		64	11	,146		_	260,000	SF	25,000		391	R	March 2014	April 2016
87 Park (8701 Collins Avenue)	Miami Beach, FL	December 2013	15.0%	6,000	(264)	5	,736		_	160,000	SF	TBD		70		October 2015	August 2017
125 Greenwich Street (2) West Hollywood Edition (9040 Sunset	Financial District, Manhattan, NY	August 2014	10.4%	9,308	(198)	9	9,110		_	306,000	SF	16,000		TBD 20	R R	March 2015	March 2018
Boulevard)	West Hollywood, CA	October 2014	48.5%	5,604		_	5	,604		_	295,000	SF	TBD		190	H	May 2015	April 2018
76 Eleventh Avenue	West Chelsea, Manhattan, NY	May 2015	5.1%	17,000		—	17	,000		—	620,000	SF	48,000	SF	250	Н	September 2016	March 2019
Monad Terrace	Miami Beach, FL	May 2015	33.3%	6,200		_	6	i,200		-	160,000	SF	-		TBD	R	May 2016	May 2018
Condominium and Mixed Use Development			5	\$ 127,840	\$7,	837	\$ 135	677	\$	—								
Maryland Portfolio	Primarily Baltimore County, MD	July 2012	7.5% \$	\$ 3,334	\$ (418)	\$ 2	916		_	N/A		N/A		5,517	R	N/A	N/A
ST Portfolio	Houston, TX; Phoenix, AZ; and Stamford, CT	November 2013	16.3%	15,542	1,	368	16	i,910		_	1,018,404	SF	24,987	SF	761	R	N/A	N/A
Apartment Buildings			5	\$ 18,876	\$	950	\$ 19	,826	\$	_								
Park Lane Hotel	Central Park South, Manhattan, NY	November 2013	5.0% 5	\$ 22,806	\$ (3,	277)	\$ 19	,529		_	445,600	SF	_		628	Н	N/A	N/A
Hotel Taiwana	St. Barthelemy, French West Indies	October 2011	17.0%	7,942	:	264	8	,206		_	61,300	SF	4,300	SF	22	н	N/A	N/A
Coral Beach and Tennis Club	Coral Beach, Bermuda	December 2013	49.0%	5,156	(2,	131)	3	,025		_	52	Acres			87	н	N/A	N/A
Hotels			5	\$ 35,904	\$ (5,	144)	\$ 30	,760	\$	_								
The Plaza at Harmon Meadow	Secaucus, NJ	March 2015	49.0% \$	5,931	\$	27	\$ 5	,958		_	_	_	217,613	SF	_	_	N/A	N/A
Commercial			5	5,931	\$	27	\$ 5	,958										
Milanosesto Holdings (Sesto Holdings)	Milan, Italy	October 2010	7.2% \$	\$ 5,037	\$	_	\$ 5	6,037		_	322	Acres	TBD		TBD		2014	2024
Land Development				5,037		_	\$ 5	i,037	\$	_								

(1) This column only represents capital commitments required under the various joint venture agreements. However, many of the operating agreements provide for the operating partner to call capital. If a joint venture partner, such as New Valley, declines to fund the capital call, then the partner's ownership percentage could either be diluted or, in some situations, the character of a funding member's contribution would be converted from a capital contribution to a member loan.

(2) Carrying value as of June 30, 2015, includes non-controlling interest of \$876 and \$2,000, respectively.

N/A - Not applicable SF - Square feet H - Hotel rooms

TBD -To be determined R - Residential Units R Lots - Residential lots

Other investments in real estate ventures relate to an investment in a mortgage company and an insurance company by Douglas Elliman with a carrying value of \$1,768 as of June 30, 2015.

Liquidity and Capital Resources

Cash and cash equivalents decreased by \$88,042 for the six months ended June 30, 2015 and increased by \$271,957 for the six months ended June 30, 2014.

Cash provided from operations was \$83,885 and \$53,995 for the six months ended June 30, 2015 and 2014, respectively. The change primarily related to increased operating income and the absence of payments for the *Engle* progeny settlement payment in the 2015 period, offset by increased cash interest payments and income taxes in the same period.

Cash used in investing activities was \$59,010 and \$87,042 for the six months ended June 30, 2015 and 2014, respectively. In the first six months of 2015, cash used in investing activities was for the purchase of investment securities of \$113,595, investment in real estate ventures of \$34,857, investment in real estate held for sale, net of \$12,502, purchase of long-term investments of \$5,000, capital expenditures of \$5,379, an increase in restricted assets of \$7,934, issuance of notes receivable of \$4,410 and an increase in cash surrender value of corporate-owned life insurance policies of \$1,118. This was offset by the sale of investment securities of \$1,737, proceeds from the sale or liquidation of long-term investments of \$148, collections of notes receivable of \$1,106, pay-downs of investment securities of \$3,530, proceeds from sale of preferred securities of \$1,000 and proceeds from the sale of fixed assets of \$3. In the first six months of 2014, cash used in investing activities was for the purchase of investment securities of \$10,144, purchase of long-term investments of \$110,419, investment in real estate ventures of \$12,534, capital expenditures of \$10,144, purchase of long-term investments of \$250 and purchase of subsidiaries of \$250. This was offset by the sale of investment securities of \$49,296, distributions from investments in real estate ventures of \$3,539, proceeds from the sale or liquidation of long-term investments of \$45,399, proceeds from the sale or liquidation of long-term investment securities of \$49,296, distributions from investments in real estate ventures of \$250. This was offset by the sale of investment securities of \$49,296, distributions from investments in real estate ventures of \$3,539, proceeds from the sale or liquidation of long-term investments of \$49,296, distributions from investments in real estate ventures of \$3,539, proceeds from the sale or liquidation of long-term investments of \$49,296, distributions from investments in real estate ventures of \$3,539, proceeds from

Our investment philosophy is to maximize return on investments using a reasonable expectation for return. For example, we expect our investment returns to exceed the comparable return on cash or short-term U.S. Treasury Bills when investing in equity and debt securities and more than our weighted average cost of capital when investing in non-consolidated real estate businesses and capital expenditures. In accordance with this philosophy, our investing activities increased in 2014 and we will continue to monitor our investment philosophy in the future.

Cash used in financing activities was \$112,917 for the six months ended June 30, 2015 compared to cash provided by financing activities of \$305,004 for the six months ended June 30, 2014. In the first six months of 2015, cash was used for the distributions on common stock of \$92,778, payment of deferred financing costs of \$625, repayments of debt of \$3,374 and net repayments of debt under the revolver of \$17,765. This was offset by proceeds from the exercise of Vector options of \$1,219, the tax benefit of options exercised of \$384 and proceeds from issuance of debt of \$22. In the first six months of 2014, cash was provided by the proceeds from issuance of debt of \$413,916, proceeds from the exercise of Vector options of \$3,405 and tax benefit of options exercised of \$680. This was offset by cash used for the distributions on common stock of \$80,963, payment of deferred financing costs of \$12,360, repayment of debt of \$8,051, net repayments of debt under the revolver of \$8,548 and distributions to non-controlling interest of \$3,075.

In recent years, we have taken advantage of historically low interest rates and lowered our weighted average cost of capital by issuing debt at lower interest rates than our historical borrowing levels. We will continue to evaluate current market conditions related to our capital structure. For example, based on quoted market prices, our 7.75% Senior Secured Notes were yielding approximately 5.7% on a "yield to worst" basis, or approximately 3.9% more than the comparable U.S. Treasury Bond at June 30, 2015. The Company is able to redeem such bonds at price of 105.813% beginning on February 15, 2016. The redemption price declines to 103.875% on February 15, 2017, 101.938% on February 15, 2018 and 100% on February 15, 2019. We have no current intentions or plans to undertake any capital markets activities, and there can be no assurance that we would be able to issue debt at a lower interest rate than our historical borrowing levels in the future. In the event we pursue any capital markets activities, our ability to complete any offering would be subject to market conditions.

Liggett Credit Facility and Liggett Term Loan Under Credit Facility. As discussed in Recent Developments, Liggett and Maple entered into an amended and restated Credit Agreement on January 14, 2015, with Wells Fargo. The credit facility increased from \$50,000 to \$60,000 and expires on March 31, 2020. As of June 30, 2015, \$3,442 was outstanding under the revolving and term loan portions of the credit facility. Availability as determined under the Credit Facility was approximately \$56,558 based on eligible collateral at June 30, 2015. At June 30, 2015, management believed that Liggett was in compliance with all covenants under the credit facility; Liggett's EBITDA, as defined, were approximately \$203,621 for the last twelve months ended June 30, 2015.

Vector. On February 3, 2015, the holder of the 6.75% Variable Interest Senior Convertible Note due 2015, converted the remaining \$25,000 principal balance of the \$50,000 Note into 2,227,552 of our common shares. The debt conversion resulted in a reduction of debt and an increase to equity in the amount of \$25,000.

The indenture of our 7.75% senior secured notes due 2021 contains covenants that restrict the payment of dividends if our consolidated earnings before interest, taxes, depreciation and amortization ("Consolidated EBITDA"), as defined in the indenture, for the most recently ended four full quarters is less than \$75,000. The indenture also restricts the incurrence of debt if our Leverage Ratio and our Secured Leverage Ratio, as defined in the indenture, exceed 3.0 and 1.5, respectively. Our Leverage Ratio is defined in the indenture as the ratio of our guaranteeing subsidiaries' total debt less the fair market value of our cash, investments in marketable securities and long-term investments to Consolidated EBITDA, as defined in the indenture. Our Secured Leverage Ratio is defined in the indenture in the same manner as the Leverage Ratio, except that secured indebtedness is substituted for indebtedness. The following table summarizes the requirements of financial covenants and the results of the calculation, as defined by the indenture.

	Indenture		December 31,
Covenant	Requirement	2015	2014
Consolidated EBITDA, as defined	\$75,000	\$268,542	\$244,100
Leverage ratio, as defined	<3.0 to 1	1.29 to 1	1.23 to 1
Secured leverage ratio, as defined	<1.5 to 1	0.3 to 1	0.1 to 1

We and our subsidiaries have significant indebtedness and debt service obligations. At June 30, 2015, we and our subsidiaries had total outstanding indebtedness of \$1,103,423. Approximately \$230,000 of our 7.5% convertible notes mature in 2019, \$258,750 of our 5.5% variable interest senior convertible notes mature in 2020, and \$600,000 of our 7.75% senior secured notes mature in 2021. In addition, subject to the terms of any future agreements, we and our subsidiaries will be able to incur additional indebtedness in the future. There is a risk that we will not be able to generate sufficient funds to repay our debt. If we cannot service our fixed charges, it would have a material adverse effect on our business and results of operations.

We believe that our cigarette and real estate operations are positive cash-flow-generating units and will continue to be able to sustain their operations without any significant liquidity concerns.

In order to meet the above liquidity requirements as well as other anticipated liquidity needs in the normal course of business, we had cash and cash equivalents of approximately \$238,300, investment securities available for sale of approximately \$342,600, long-term investments with an estimated value of approximately \$56,000 and availability under Liggett's credit facility of approximately \$56,600 at June 30, 2015. Management currently anticipates that these amounts, as well as expected cash flows from our operations, management fees and other payments from subsidiaries should be sufficient to meet our liquidity needs over the next 12 months. We may acquire or seek to acquire additional operating businesses through merger, purchase of assets, stock acquisition or other means, or to make other investments, which may limit our liquidity otherwise available.

On a quarterly basis, we evaluate our investments to determine whether an impairment has occurred. If so, we also make a determination if such impairment is considered temporary or other-than-temporary. We believe that the assessment of temporary or other-than-temporary impairment is facts and circumstances driven. However, among the matters that are considered in making such a determination are the period of time the investment has remained below its cost or carrying value, the likelihood of recovery given the reason for the decrease in market value and our original expected holding period of the investment.

Market Risk

We are exposed to market risks principally from fluctuations in interest rates, foreign currency exchange rates and equity prices. We seek to minimize these risks through our regular operating and financing activities and our long-term investment strategy. Our market risk management procedures cover all market risk sensitive financial instruments.

As of June 30, 2015, approximately \$3,400 of our outstanding debt at face value had variable interest rates determined by various interest rate indices, which increases the risk of fluctuating interest rates. Our exposure to market risk includes interest rate fluctuations in connection with our variable rate borrowings, which could adversely affect our cash flows. As of June 30, 2015, we had no interest rate caps or swaps. Based on a hypothetical 100 basis point increase or decrease in interest rates (1%), our annual interest expense could increase or decrease by approximately \$34.

In addition, as of June 30, 2015, \$255,744 (\$488,750 principal amount) of outstanding debt had a variable interest rate determined by the amount of the dividends on our common stock. The difference between the stated value of the debt and carrying value is due principally to certain embedded derivatives, which were separately valued and recorded upon issuance. Changes to the estimated fair value of these embedded derivatives are reflected within our statements of operations as "Changes in fair value of derivatives embedded within convertible debt." The value of the embedded derivative is contingent on changes in interest rates of debt instruments maturing over the duration of the convertible debt as well as projections of future cash and stock dividends

over the term of the debt and changes in the closing stock price at the end of each quarterly period. Based on a hypothetical 100 basis point increase or decrease in interest rates (1%), our annual "Changes in fair value of derivatives embedded within convertible debt" could increase or decrease by approximately \$2,998 with approximately \$1,323 resulting from the embedded derivative associated with the 7.5% variable interest senior convertible notes, and the remaining \$1,675 resulting from the embedded derivative associated with our 5.5% variable interest senior convertible debentures due 2020. An increase in our quarterly dividend rate by \$0.10 per share would increase interest expense by approximately \$9,800 per year.

We have estimated the fair market value of the embedded derivatives based principally on the results of a valuation model. The value of the embedded derivatives is contingent on changes in interest rates of debt instruments maturing over the duration of the convertible debt, our stock price as well as projections of future cash and stock dividends over the term of the debt. The interest rate component of the value of the embedded derivative is computed by calculating an equivalent non-convertible, unsecured and subordinated borrowing cost. This rate is determined by calculating the implied rate on our 7.5% Convertible Notes when removing the embedded option value within the convertible security. This rate is based upon market observable inputs and influenced by our stock price, convertible bond trading price, risk-free interest rates and stock volatility. The range of estimated fair market values of our embedded derivatives was between \$158,324 and \$155,272. We recorded the fair market value of our embedded derivatives at the midpoint of the range at \$156,783 as of June 30, 2015. The estimated fair market value of our embedded derivatives could change significantly based on future market conditions.

We and New Valley also hold long-term investments in various investment partnerships. These investments are illiquid, and their ultimate realization is subject to the performance of the underlying entities.

New Accounting Pronouncements

Refer to Note 1, Summary of Significant Accounting Policies, to our financial statements for further information on New Accounting Pronouncements.

Legislation and Regulation

There are no material changes from the Legislation and Regulation section set forth in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," of our Annual Report on Form 10-K, for the year ended December 31, 2014. Please refer to that section and the information below for disclosures regarding the critical accounting policies related to our business.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical information, this report contains "forward-looking statements" within the meaning of the federal securities law. Forward-looking statements include information relating to our intent, belief or current expectations, primarily with respect to, but not limited to:

- economic outlook,
- capital expenditures,
- cost reduction,
- legislation and regulations,
- cash flows,
- operating performance,
- litigation,
- · impairment charges and cost saving associated with restructurings of our tobacco operations, and
- related industry developments (including trends affecting our business, financial condition and results of operations).

We identify forward-looking statements in this report by using words or phrases such as "anticipate," "believe," "estimate," "expect," "intend," "may be," "objective," "plan," "seek," "predict,", "project" and "will be" and similar words or phrases or their negatives.

The forward-looking information involves important risks and uncertainties that could cause our actual results, performance or achievements to differ materially from our anticipated results, performance or achievements expressed or implied by the forward-

looking statements. Factors that could cause actual results to differ materially from those suggested by the forward-looking statements include, without limitation, the following:

- general economic and market conditions and any changes therein, due to acts of war and terrorism or otherwise,
- governmental regulations and policies,
- effects of industry competition,
- impact of business combinations, including acquisitions and divestitures, both internally for us and externally in the tobacco industry,
- impact of legislation on our competitors' payment obligations, results of operations and product costs, i.e. the impact of federal legislation eliminating the federal tobacco quota system and providing for regulation of tobacco products by the FDA,
- impact of substantial increases in federal, state and local excise taxes,
- uncertainty related to product liability litigation including the *Engle* progeny cases pending in Florida; and,
- potential additional payment obligations for us under the MSA and other settlement agreements with the states.

Further information on the risks and uncertainties to our business include the risk factors discussed above in "Management's Discussion and Analysis of Financial Condition and Results of Operations" and under Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission.

Although we believe the expectations reflected in these forward-looking statements are based on reasonable assumptions, there is a risk that these expectations will not be attained and that any deviations will be material. The forward-looking statements speak only as of the date they are made.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The information under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations - Market Risk" is incorporated herein by reference.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports the Company files or submits under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

In connection with the preparation of this Quarterly Report on Form 10-Q, the Company carried out an evaluation under the supervision of and with the participation of the Company's management, including the Chief Executive Officer and Chief Financial Officer, as of June 30, 2015, of the effectiveness of the design and operation of the Company's disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2015, the Company's disclosure controls and procedures were not effective because of the material weaknesses in internal control over financial reporting described in Part II, Item 9A of the 2014 Form 10-K. Management has concluded that the material weaknesses that were present at December 31, 2014 continued to exist as of June 30, 2015, as discussed below.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

In 2014, management was required to include in its assessment of internal control over financial reporting the controls of Douglas Elliman Realty, LLC ("Douglas Elliman"), which became a consolidated subsidiary of the Company on December 13, 2013. In connection with management's assessment of the Company's internal control over financial reporting as of December 31, 2014, management identified control deficiencies that constituted material weaknesses in internal control over financial reporting at the Company's Douglas Elliman subsidiary as follows:

- i. The Company did not maintain effective monitoring of controls in certain areas relating to the period-end financial reporting process at Douglas Elliman. This material weakness contributed to additional material weaknesses related to the analysis and review of significant account reconciliations and the interim and annual financial statements, segregation of duties of finance and accounting personnel, processing and recording of recurring and non-recurring journal entries and supervision of access of rights and privileges of users of Douglas Elliman's information technology system for finance and accounting as described below.
- ii. The Company did not maintain effective controls over Douglas Elliman's period-end financial reporting processes, including controls over the preparation, analysis and review of certain significant account reconciliations required to assess the appropriateness of account balances at period-end, as well as controls over the preparation and review of the interim and annual financial statements. This lack of controls over the preparation and review of interim and annual financial statements impacted the Company's ability to identify and accumulate all information required to determine the completeness and accuracy of the financial statements and disclosures.
- iii. The Company did not maintain effective controls over the segregation of duties of finance and accounting personnel at Douglas Elliman. Specifically, finance and accounting personnel at Douglas Elliman were authorized to perform interrelated functions that could have resulted in either erroneous or inappropriate actions that could have affected the Company's financial statements.
- iv. The Company did not maintain effective controls over the processing and recording of recurring and non-recurring journal entries at Douglas Elliman. Specifically, effective controls did not exist to ensure that journal entries were either prepared with sufficient documentation or were reviewed and approved to verify the accuracy and completeness of the journal entries.
- v. The Company did not maintain effective controls over access to Douglas Elliman's information technology system for finance and accounting ("IT System"). Specifically, access review controls to Douglas Elliman's IT System were not effectively designed to restrict access to certain financial applications and data. This impacted controls over financial reporting at Douglas Elliman that depended on the effective operation of restricted access.

These material weaknesses did not result in any material misstatements to the financial statements in any accounting periods ending prior to January 1, 2015 or for the three and six months ended June 30, 2015. However, these material weaknesses could result in misstatement of the aforementioned account balances or disclosures that would result in material misstatements to the annual or interim consolidated financial statements that would not be prevented or detected.

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the Company's consolidated interim unaudited financial statements were prepared in accordance with U.S. GAAP. Based on the performance of additional procedures by management designed to ensure the reliability of the Company's financial reporting, the Company's management believes that the consolidated interim unaudited financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, the Company's financial condition, results of operations and cash flows for

the periods presented and that this Quarterly Report on Form 10-Q does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report.

Remediation Plan

The Company's management has engaged in and is continuing to engage in efforts to remediate the underlying causes of the material weaknesses described above. Specifically, the following steps have been taken by management of the Douglas Elliman subsidiary:

- i. Hiring additional personnel, including a new Chief Financial Officer, in Douglas Elliman's finance department and restructuring titles and duties in Douglas Elliman' finance department.
- ii. Adding or strengthening new controls to ameliorate the processing and review of transactions and segregation of duties. The new controls are being tested and testing will continue in the third and fourth quarters of 2015.

The Company's management and the Board of Directors believe that these remediation efforts represent significant improvements in the Company's control environment and in its controls over the financial reporting of Douglas Elliman. Additional controls may also be required over time. The identified material weaknesses in internal control will not be considered fully addressed until the internal controls over these areas have been in operation for a sufficient period of time for management to conclude that the material weaknesses have been fully remediated. Management continues to work on implementing and testing the new controls in order to make this final determination.

Changes in Internal Control Over Financial Reporting

As discussed above, during the quarter ended June 30, 2015, management continued to implement certain remediation measures to improve the Company's internal controls over financial reporting and to remediate previously identified material weaknesses. However, there were no changes that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. Furthermore, neither the design nor the operating effectiveness of additional changes in internal control over financial reporting has been evaluated in the Company's remediation process.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

Reference is made to Note 7, incorporated herein by reference, to our condensed consolidated financial statements included elsewhere in this report which contains a general description of certain legal proceedings to which our company, or its subsidiaries are a party and certain related matters. Reference is also made to Exhibit 99.1 for additional information regarding the pending smoking-related legal proceedings to which Liggett or us is a party. A copy of Exhibit 99.1 will be furnished without charge upon written request to us at our principal executive offices, 4400 Biscayne Boulevard, 10th Floor, Miami, Florida 33137, Attn. Investor Relations.

Item 1A. Risk Factors

Except as set forth below, there are no material changes from the risk factors set forth in Item 1A, "Risk Factors," of our Annual Report on 10-K for the year ended December 31, 2014.

Liggett faces intense competition in the domestic tobacco industry.

Liggett is considerably smaller and has fewer resources than its major competitors, and, as a result, has a more limited ability to respond to market developments. Management Science Associates' data indicate that in 2014 Philip Morris, RJ Reynolds and Lorillard Tobacco Company, then the three largest cigarette manufacturers, controlled approximately 84.9% of the United States cigarette market. Philip Morris is the largest manufacturer in the market, and its profits are derived principally from its sale of premium cigarettes. Philip Morris had approximately 60.8% of the premium segment and 47.3% of the total domestic market during 2014. During 2014, all of Liggett's sales were in the discount segment, and its share of the total domestic cigarette market was 3.4%. Philip Morris and RJ Reynolds, the two largest cigarette manufacturers, historically, because of their dominant market share, have been able to determine cigarette prices for the various pricing tiers within the industry.

Consolidation in the industry could adversely affect our ability to compete in the U.S. cigarette market. For example, RJ Reynolds' merger with Lorillard Tobacco Company, which consolidates more than 80% of the United States cigarette market within the control of two cigarette manufacturers, could make it more difficult for Liggett and Vector Tobacco to compete for shelf space in retail outlets and could impact price competition in the market, either of which could have a material adverse effect on our sales volume, operating income and cash flows. Further, as part of the merger, RJ Reynolds and Lorillard Tobacco Company divested four of their brands to Imperial Tobacco PLC, our largest competitor for the sale of deep discount cigarettes.

Liggett's business is highly dependent on the discount cigarette segment.

Liggett depends more on sales in the discount cigarette segment of the market, relative to the full-price premium segment, than its major competitors. Since 2004, all of Liggett's unit volume was generated in the discount segment. The discount segment is highly competitive, with consumers having less brand loyalty and placing greater emphasis on price. While Philip Morris ,RJ Reynolds, and Imperial compete with Liggett in the discount segment of the market, the strongest competition for market share has come from a group of smaller manufacturers and importers, most of which sell low quality, deep discount cigarettes. While Liggett's share of the discount market was 11.8% in 2014,11.6% in 2013 and 12.1% in 2012, Management Science Associates' data indicate that the discount market share of these other smaller manufacturers and importers was approximately 24.6% in 2014, 24.2% in 2013, and 22.2% in 2012. If pricing in the discount market continues to be impacted by these smaller manufacturers and importers, margins in Liggett's only current market segment could be negatively affected, which in turn could negatively affect the value of our common stock.

Liggett's market share is susceptible to decline.

For a number of years prior to 2000, Liggett suffered a substantial decline in market share. Liggett's market share increased in 2014, after having declined in 2013 and 2012. Liggett's market share increased during each of the years between 2000 and 2011 (except for 2008, which was unchanged). This earlier market share erosion resulted in part from Liggett's highly leveraged capital structure that existed until December 1998 and its limited ability to match other competitors' wholesale and retail trade programs, obtain retail shelf space for its products and advertise its brands. These declines also resulted from adverse developments in the tobacco industry, intense competition and changes in consumer preferences which have continued up to the current time. According to Management Science Associates' data, Liggett's overall domestic market share during 2014 was 3.4% compared to 3.3% during 2013, and 3.5% during 2012. Liggett's share of the discount segment was 11.8% during 2014, 11.6% during 2013 and 12.1% during 2012. Liggett's overall market share increased by 0.1% in 2014 after declining by 0.2% in 2013. If it were to decline substantially in the future, Liggett's sales volume, operating income and cash flows would be materially adversely affected, which in turn would negatively affect the value of our common stock.

The domestic cigarette industry has experienced declining unit sales in recent periods.

Industry-wide shipments of cigarettes in the United States have been declining for a number of years, with Management Science Associates' data indicating that domestic industry-wide shipments decreased by approximately 3.0% in 2014 as compared to 2013, and by approximately 4.7% in 2013 as compared to 2012. We believe that industry-wide shipments of cigarettes in the United States will continue to decline as a result of numerous factors. These factors include health considerations, diminishing social acceptance of smoking, and a wide variety of federal, state and local laws limiting smoking in restaurants, bars and other public places, as well as increases in federal and state excise taxes and settlement-related expenses which have contributed to high cigarette price levels in recent years . If this decline in industry-wide shipments continues and Liggett is unable to capture market share from its competitors, or if the industry as a whole is unable to offset the decline in unit sales with price increases, Liggett's sales volume, operating income and cash flows could be materially adversely affected, which in turn could negatively affect the value of our common stock.

The Family Smoking Prevention and Tobacco Control Act may adversely affect our sales and operating profit.

On June 22, 2009, the President signed into law the Family Smoking Prevention and Tobacco Control Act (the "Tobacco Control Act"). The law grants FDA broad authority over the manufacture, sale, marketing and packaging of tobacco products, although FDA is prohibited from banning all cigarettes or all smokeless tobacco products. Among other measures, the law (under various deadlines):

- increases the number of health warnings required on cigarette and smokeless tobacco products, increases the size of warnings on packaging and in advertising, requires FDA to develop graphic warnings for cigarette packages, and grants FDA authority to require new warnings;
- imposes new restrictions on the sale and distribution of tobacco products, including significant new restrictions on tobacco product advertising and
 promotion, as well as the use of brand and trade names;
- bans the use of "light," "mild," "low" or similar descriptors on tobacco products;
- bans the use of "characterizing flavors" in cigarettes other than tobacco or menthol;
- gives FDA the authority to impose tobacco product standards that are appropriate for the protection of the public health (by, for example, requiring reduction or elimination of the use of particular constituents or components, requiring product testing, or addressing other aspects of tobacco product construction, constituents, properties or labeling);
- requires manufacturers to obtain FDA review and authorization for the marketing of certain new or modified tobacco products;
- requires pre-market approval by FDA for tobacco products represented (through labels, labeling, advertising, or other means) as presenting a lower risk of harm or tobacco-related disease;
- requires manufacturers to report ingredients and harmful constituents and requires FDA to disclose certain constituent information to the public;
- mandates that manufacturers test and report on ingredients and constituents identified by FDA as requiring such testing to protect the public health, and allows FDA to require the disclosure of testing results to the public;
- requires manufacturers to submit to FDA certain information regarding the health, toxicological, behavioral or physiological effects of tobacco products;
- prohibits use of tobacco containing a pesticide chemical residue at a level greater than allowed under federal law;
- requires FDA to establish "good manufacturing practices" to be followed at tobacco manufacturing facilities;
- requires tobacco product manufacturers (and certain other entities) to register with FDA;
- authorizes FDA to require the reduction of nicotine (although it may not require the reduction of nicotine yields of a tobacco product to zero) and the potential reduction or elimination of other constituents, including menthol;
- imposes (and allows FDA to impose) various recordkeeping and reporting requirements on tobacco product manufacturers; and
- grants FDA the regulatory authority to impose broad additional restrictions.

The Tobacco Control Act requires premarket review of "new tobacco products." A "new tobacco product" is one that was not commercially marketed in the U.S. as of February 15, 2007 or that was modified after that date. In general, before a company may commercially market a "new tobacco product," it must either (a) submit an application and obtain an order from FDA permitting the product to be marketed; or (b) submit a report and receive an FDA order finding the product to be "substantially equivalent" to a "predicate" tobacco product that was commercially marketed in the U.S. prior to February 15, 2007. A "substantially equivalent" tobacco product is one that has the "same characteristics" as the predicate or one that has "different characteristics" but does not raise "different questions of public health."

Manufacturers of products first introduced after February 15, 2007 and before March 22, 2011 who submitted a substantial equivalence report to FDA prior to March 23, 2011 may continue to market the tobacco product unless FDA issues an order that the product is not substantially equivalent. Failure to timely submit the report, or FDA's conclusion that such a "new tobacco product" is not substantially equivalent, will cause the product to be deemed misbranded and/or adulterated. After March 22, 2011, a "new tobacco product" may not be marketed without an FDA substantial equivalence determination. Prior to the deadline, Liggett and Vector Tobacco submitted substantial equivalence reports to FDA for numerous products. It is possible that FDA could determine some, or all, of these products are not "substantially equivalent" to a preexisting tobacco product. Such a determination could prevent us from marketing these products in the United States and could have a material adverse effect on us.

Liggett and Vector Tobacco have begun to receive feedback from FDA regarding certain of their substantial equivalence reports, including "Preliminary Finding" letters and other FDA correspondence requesting additional information that would support FDA's determinations of substantial equivalence. Liggett and Vector Tobacco have timely responded to FDA's requests. Liggett and Vector Tobacco cannot predict whether FDA will deem these responses sufficient to support determinations of substantial equivalence for the products covered by these substantial equivalence reports.

It is likely that the new tobacco law could result in a decrease in cigarette sales in the United States, including sales of Liggett's and Vector Tobacco's brands. Total compliance and related costs are not possible to predict and depend substantially on the future requirements imposed by FDA under the new tobacco law. Costs, however, could be substantial and could have a material adverse affect on the companies' financial condition, results of operations, and cash flows. In addition, FDA has a number of investigatory and enforcement tools available to it. Failure to comply with the new tobacco law and with FDA regulatory requirements could result in significant financial penalties and could have a material adverse effect on the business, financial condition and results of operation of both Liggett and Vector Tobacco. At present, we are not able to predict whether the new tobacco law will impact Liggett and Vector Tobacco to a greater degree than other companies in the industry, thus affecting our competitive position.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

No securities of ours which were not registered under a private offering of the Securities Act of 1933 have been issued or sold by us during the three months ended June 30, 2015.

- **12.1** Computation of Ratio of Earnings to Fixed Charges for each of the five years within the period ended December 31, 2014 and for each of the six months within the periods ended June 30, 2015 and 2014.
- **31.1** Certification of Chief Executive Officer, Pursuant to Exchange Act Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- **31.2** Certification of Chief Financial Officer, Pursuant to Exchange Act Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- **32.1** Certification of Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- **32.2** Certification of Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 99.1 Material Legal Proceedings
- **101.INS** XBRL Instance Document
- 101.SCH XBRL Taxonomy Extension Schema
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase
- **101.DEF** XBRL Taxonomy Extension Definition Linkbase
- 101.LAB XBRL Taxonomy Extension Label Linkbase
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

VECTOR GROUP LTD. (Registrant)

By: /s/ J. Bryant Kirkland III

J. Bryant Kirkland III Vice President, Treasurer and Chief Financial Officer

Date: July 29, 2015

VECTOR GROUP LTD.

Computation of Ratio of Earnings to Fixed Charges

(Dollars in Thousands, Except Ratios)

(Unaudited)

	Six Months Er	ided June 30,		Year Ended December 31,					
	2015	2014	2014	2013	2012	2011	2010		
Earnings as defined:									
Pre-tax income	64,964	25,603	82,487	63,487	53,717	123,157	85,570		
Distributions from investees	1,629	3,279	5,152	4,251	19,169	9,322	12,212		
Interest expense	51,791	83,434	146,787	147,084	132,538	93,939	72,572		
(Income) loss in equity of affiliate	(2,194)	256	(4,103)	(22,925)	(29,764)	(19,966)	(23,963)		
Interest portion of rental expense (1)	3,854	3,596	7,505	2,174	1,367	1,438	1,223		
Total earnings	120,044	116,168	237,828	194,071	177,027	207,890	147,614		
Fixed charges as defined:									
Interest expense	51,791	83,434	146,787	147,084	132,538	93,939	72,572		
Interest portion of rent expense (1)	3,854	3,596	7,505	2,174	1,367	1,438	1,223		
Total fixed charges	55,645	87,030	154,292	149,258	133,905	95,377	73,795		
Ratio of earnings to fixed charges	2.16	1.33	1.54	1.30	1.32	2.18	2.00		

(1) One third of rent expense is the portion deemed representative of the interest factor.

RULE 13a-14(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Howard M. Lorber, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Vector Group Ltd.;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 29, 2015

/s/ Howard M. Lorber

Howard M. Lorber President and Chief Executive Officer

I, J. Bryant Kirkland III, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Vector Group Ltd.;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 29, 2015

/s/ J. Bryant Kirkland III

J. Bryant Kirkland III Vice President, Treasurer and Chief Financial Officer

SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

In connection with the Quarterly Report of Vector Group Ltd. (the "Company") on Form 10-Q for the quarter ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Howard M. Lorber, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

July 29, 2015

/s/ Howard M. Lorber

Howard M. Lorber President and Chief Executive Officer

SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

In connection with the Quarterly Report of Vector Group Ltd. (the "Company") on Form 10-Q for the quarter ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, J. Bryant Kirkland III, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

July 29, 2015

/s/ J. Bryant Kirkland III

J. Bryant Kirkland III Vice President, Treasurer and Chief Financial Officer Pursuant to the Florida Supreme Court's ruling in *Engle v. Liggett Group Inc.*, which decertified the *Engle* class on a prospective basis, former class members had until January 2008 to file individual lawsuits. Lawsuits by individuals requesting the benefit of the *Engle* ruling are referred to as the "*Engle* progeny" cases. In October 2013, the Company announced a settlement of the claims of over 4,900 *Engle* progeny plaintiffs. Notwithstanding the settlement, the claims of approximately 300 *Engle* progeny plaintiffs remain pending. For more information on the *Engle* case and on the settlement, see "Note 7. Contingencies."

(i) <u>Engle Progeny Cases with trial dates through June 30, 2016.</u>

<u>Alvarez, *et al.* v. R.J. Reynolds, *et al.*, Case No. 07-030302 CA 32, Circuit Court of the 11th Judicial Circuit, Miami-Dade County (case filed 09/17/14). Two individuals suing. The case is scheduled for trial in 11/15.</u>

<u>Cannon v. R.J. Reynolds, *et al.*</u>, Case No. 2007 CA 2774, Circuit Court of the 1st Judicial Circuit, Escambia County (case filed 11/19/07). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled as the back up trial starting 05/02/16 and it is the primary case scheduled for trial starting 06/27/16.

<u>Chernofsky v. Philip Morris, *et al.*</u>, Case No. 07-46345, Circuit Court of the 11th Judicial Circuit, Miami-Dade County (case filed 12/28/07). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled for trial starting 03/07/16.

<u>Collar v. R.J. Reynolds, *et al.*</u>, Case No. 31 2011 CA 000115, Circuit Court of the 19th Judicial Circuit, Indian River County (case filed 02/08/11). One individual suing. Trial commenced on 07/08/15. The jury returned a defense verdict on 07/30/15.

<u>Cooper v. R.J. Reynolds, *et al.*</u>, Case No. 08-26350, Circuit Court of the 17th Judicial Circuit, Broward County (case filed 06/09/08). One individual suing. Liggett has no smoking history. The only claim remaining against Liggett is for conspiracy. The case is scheduled for trial starting 08/12/15.

<u>Dibble v. R.J. Reynolds, *et al.*</u>, Case No. 502008CA03543, Circuit Court of the 15th Judicial Circuit, Palm Beach County (case filed 11/14/08). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled for trial starting 02/01/16.

<u>Durrance v. R.J. Reynolds, *et al.*</u>, Case No. 11-00026-GS, Circuit Court of the 10th Judicial Circuit, Highlands County (case filed 01/12/11). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled for trial starting 05/23/16.

<u>Ewing v. R.J. Reynolds, *et al.*</u>, Case No. 2009-CA-002791, Circuit Court of the 1st Judicial Circuit, Escambia County (case filed 08/21/09). One individual suing. The case is scheduled as the back up case for trial starting 10/19/15 and it is the primary case scheduled for trial starting 01/11/16.

<u>Hull v. R.J. Reynolds, *et al.*</u>, Case No. 14-17702CA08, Circuit Court of the 11th Judicial Circuit, Miami-Dade County (case filed 07/07/14). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled for trial in 05/16.

<u>Kersey v. R.J. Reynolds, *et al.*</u>, Case No. 2008 CA 2142, Circuit Court of the 1st Judicial Circuit, Escambia County (case filed 07/11/08). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled for trial starting 03/07/16.

<u>Manassa v. R.J. Reynolds, *et al.*</u>, Case No. 15-008515, Circuit Court of the 11th Judicial Circuit, Miami Dade County (case filed 04/14/15). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled for trial in 06/16.

<u>Pijuan, *et al.* v. R.J. Reynolds, *et al.*, Case No. 10-8359, Circuit Court of the 11th Judicial Circuit, Miami-Dade County (case filed 02/08/10). Two individuals suing. The case is scheduled for trial 12/01/15.</u>

Shulman, *et al.* v. R.J. Reynolds, *et al.*, Case No. 2007 CA 023832 MB AF, Circuit Court of the 15th Judicial Circuit, Palm Beach County (case filed 01/04/08). One individual suing. The case is scheduled for trial starting 10/16/15.

<u>Vasquez v. R.J. Reynolds, *et al.*</u>, Case No. 07-45313-CA-02, Circuit Court of the 11th Judicial Circuit, Miami-Dade County (case filed 12/20/07). One individual suing on behalf of the estate and survivors of a deceased smoker. The case is scheduled for trial starting 06/13/16.

(ii) Post-Trial Engle Progeny Cases.

<u>Boatright, *et al.* v. R.J. Reynolds, *et al.*, Case No. 53-2011-CA-000158-000-WH, Circuit Court of the 10th Judicial Circuit, Polk County (case filed 01/12/11). This was a personal injury action filed by a smoker and his spouse that proceeded to jury trial in October 2014. At the close of plaintiff's case, the court granted directed verdict to Liggett on all claims other than the claim for conspiracy to conceal. In November 2014, the jury returned a verdict in favor of plaintiffs and awarded compensatory damages in the amount of \$15,000,000. The jury apportioned fault as follows: Plaintiff - 15%, Philip Morris - 85%. While the jury determined that Liggett's participation in an agreement to conceal was a legal cause of injury to plaintiffs, the court refused to allow the jury to consider apportioning fault to Liggett. The jury assessed punitive damages against Philip Morris for \$19,700,000 and Liggett for \$300,000. Post-trial motions were denied. In January 2015, a joint and several judgment was entered against the defendants for \$12,750,000 for the compensatory damages. An additional \$300,000 in punitive damages was awarded against Liggett. In February 2015, the defendants filed a notice of appeal to the Second District Court of Appeal. In March 2015, plaintiffs' motion for attorneys' fees was denied by the court. Plaintiff appealed that ruling. Briefing is underway on both appeals.</u>

<u>Buchanan v. R.J. Reynolds, *et al.*</u>, Case No. 2007-CA-3565, Circuit Court of the 2nd Judicial Circuit, Leon County (case filed 12/17/07). This was a wrongful death action that proceeded to jury trial in November 2012. In December 2012, the jury returned a verdict in favor of the plaintiff and awarded compensatory damages in the amount of \$5,500,000. The jury apportioned fault as follows: Decedent - 26%, Philip Morris - 37% and Liggett - 37% (\$2,035,000). In April 2012, a joint and several judgment for \$5,500,000 was entered against the defendants. In July 2014, the First District Court of Appeal affirmed the lower court, but certified to the Florida Supreme Court the issue of the statute of repose, which is currently before the court in *Hess*. In August 2014, defendants filed a notice to invoke the discretionary jurisdiction of the Florida Supreme Court. In September 2014, the Florida Supreme Court stayed the case pending the outcome of *Hess*. The parties reached a confidential settlement agreement regarding the amount of plaintiff's trial level attorneys' fees and costs in the event plaintiff prevails on appeal.

<u>Calloway v. R.J. Reynolds, *et al.*</u>, Case No. 08-21770, Circuit Court of the17th Judicial Circuit, Broward County (case filed 05/15/08). This was a wrongful death action that proceeded to jury trial in April 2012. In May 2012, the jury returned a verdict in favor of the plaintiff and awarded compensatory damages in the amount of \$20,500,000. The jury apportioned fault as follows: Decedent - 20.5%, R.J. Reynolds - 27%, Philip Morris - 25%, Lorillard - 18% and Liggett - 9.5% (\$1,947,500). In August 2012, a joint and several judgment for compensatory damages of \$16,100,000 was entered against the defendants. In addition, the judgment awarded plaintiff \$7,600,000 in punitive damages against Liggett. An order of entitlement to attorneys' fees and costs was also entered against the defendants. In September 2012, the defendants filed a notice of appeal to the

Fourth District Court of Appeal. The plaintiffs filed a notice of cross-appeal. Briefing is complete. Oral argument occurred on June 16, 2015.

<u>Caprio v. R.J. Reynolds, *et al.*</u>, Case No. 2007-CV-036719, Circuit Court of the17th Judicial Circuit, Broward County (case filed 12/28/07). This was a personal injury action that proceeded to jury trial in February 2015. At trial, the court directed verdict in Liggett's favor on all of plaintiff's claims other than conspiracy. The jury answered certain questions on the verdict form and awarded economic damages in the amount of \$559,172, but were deadlocked as to other questions on the verdict form. In May 2015, over Defendants' objections, the court entered a partial verdict on class membership, product use causation, and economic damages and ordered a new trial on the remaining issues, including comparative fault and punitive damages. Defendants post-trial motions were denied. Defendants appealed to the Fourth District Court of Appeal.

<u>Cohen, D. v. R.J. Reynolds, *et al.*</u>, Case No. 09-004042, Circuit Court of the 15th Judicial Circuit, Palm Beach County (case filed 02/04/09). This was a wrongful death action that proceeded to jury trial in April 2013. In May 2013, the jury returned a verdict in favor of the plaintiff and awarded compensatory damages in the amount of \$2,055,000. The jury apportioned fault as follows: Decedent - 40%, RJR - 30%, Lorillard - 20% and Liggett - 10% (\$205,500). In June 2013, the trial court granted defendants' motion for a new trial. The new trial date has not been scheduled. Plaintiff filed a notice of appeal and the defendants filed a notice of cross appeal. Briefing is underway.

Irimi v. R.J. Reynolds, *et al.*, Case No. 08-26337 19, Circuit Court of the 17th Judicial Circuit, Broward County (case filed 06/30/08). This was a wrongful death action that proceeded to jury trial in July 2014. On August 28, 2014 the jury returned a verdict in favor of plaintiff and awarded compensatory damages in the amount of \$3,123,426. The jury apportioned fault as follows: Decedent - 70%, R.J. Reynolds - 14.5%, Lorillard - 14.5% and Liggett - 1% (\$31,234). In January 2015, the court granted defendants' motion for a new trial. Plaintiff filed a notice of appeal to the Fourth District Court of Appeal. Briefing is underway.

Lambert v. R.J. Reynolds, *et al.*, Case No. 2007-013530-CI-19, Circuit Court of the 6th Judicial Circuit, Pinellas County (case filed 02/05/08). This was a wrongful death action that proceeded to jury trial in September 2014. Liggett was the only defendant at trial. On October 1, 2014, the jury returned a verdict in favor of plaintiff and awarded compensatory damages in the amount of \$3,600,000. In addition, \$9,500,000 in punitive damages were awarded by the jury. The jury apportioned fault as follows: Decedent - 70% and Liggett - 30%. Because Liggett was found liable for an intentional tort, the court refused to reduce the compensatory award by the decedent's comparative fault and final judgment was entered against Liggett for \$13,100,000. In February 2015, Liggett filed a notice of appeal to the Second District Court of Appeal. Briefing is underway.

<u>Putney v. R.J. Reynolds, *et al.*</u>, Case No. 07-36668, Circuit Court of the 17th Judicial Circuit, Broward County (case filed 12/28/07). This was a wrongful death action that proceeded to jury trial in March 2010. In April 2010, the jury returned a verdict in favor of the plaintiff and awarded compensatory damages in the amount of \$15,000,000. The jury apportioned fault as follows: Decedent - 35%, R.J. Reynolds - 30%, Liggett - 20% (\$3,008,138) and Philip Morris - 15%. No punitive damages were awarded against Liggett. Defendants appealed the final judgment. The Fourth District Court of Appeal reversed and remanded the case for further proceedings, however, because it found that the trial court erred in entering summary judgment against defendants' on their statute of repose defense and in denying Defendants' Motion for *Remittitur* of the compensatory damage award for loss of consortium, it ruled that the award was excessive. Plaintiff filed a motion for rehearing which was denied. Both parties filed notices to invoke the discretionary jurisdiction of the Florida Supreme Court. In December 2013, the Florida Supreme Court stayed the appeal pending the outcome of *Hess*. Plaintiff also moved for an award of attorneys' fees against Liggett pursuant to the fee shifting provisions of Florida's proposal for settlement statute based on a settlement offer that was not accepted by Liggett. Entitlement to an attorney fee award has been entered, and the amount of such award will be determined in a separate proceeding.

<u>Tullo v. R.J. Reynolds, *et al.*</u>, Case No. 2008-CA-035457, Circuit Court of the 15th Judicial Circuit, Palm Beach County (case filed 11/14/08). This was a wrongful death action that proceeded to jury trial in March 2011. In April 2011, the jury returned a verdict in favor of the plaintiff and awarded compensatory damages in the amount of \$4,500,000. The jury apportioned damages as follows: Plaintiff - 45%, Philip Morris - 45%, Liggett - 5% (\$225,000) and Lorillard - 5%. No punitive damages were awarded. In August 2013, the Fourth District Court of Appeal affirmed. Defendants' notice to invoke the discretionary jurisdiction of the Florida Supreme Court was denied. Liggett satisfied the merits judgment in October 2014 and other than an issue regarding the calculation of interest on the judgment and Liggett's share of plaintiff's taxable costs, this matter is concluded.

<u>Ward v. R.J. Reynolds, *et al.*</u>, Case No. 2008-CA-2135, Circuit Court of the 1st Judicial Circuit, Escambia County (case filed 12/13/07). This was a wrongful death action that proceeded to jury trial in January 2012. In January 2012, the jury returned a verdict in favor of the plaintiff and awarded compensatory damages in the amount of \$1,000,000. The jury apportioned fault as follows: Decedent - 50%, R.J. Reynolds - 30%, Philip Morris - 10%, Lorillard - 9.9% and Liggett - 0.1% (\$1,000). No punitive damages were awarded against Liggett. A joint and several judgment was entered against the defendants for \$487,000. In September 2013, the First District Court of Appeal affirmed. Liggett satisfied the merits judgment in January 2014. Plaintiff moved for an award of attorneys' fees against Liggett pursuant to the fee shifting provisions of Florida's proposal for settlement statute based on a settlement offer that was not accepted by Liggett. Defendants appealed the trial court's ruling that plaintiff was entitled to an attorney fee award. On June 24, 2014, the appellate court reversed the trial court's award of attorneys' fees and remanded the case to the trial court to consider an award of attorneys' fees to which plaintiff may be entitled.

B. <u>Other Individual Cases</u>.

<u>Bagshaw v. R.J. Reynolds, *et al.*</u>, Case No. 06-CA-004768, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 06/01/06). One individual suing. There has been no recent activity in this case.

<u>Calhoun, et al., v. Brown & Williamson Tobacco Co., et al.</u>, Case No. 02-CA-007970, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 08/27/02). Three individuals suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Capone v. Philip Morris Inc., et al.</u>, Case No. 05-10312-CA-24, Circuit Court of the 11th Judicial Circuit, Miami-Dade County (case filed 05/12/14). One individual suing. There has been no recent activity in this case.

<u>Colic v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 03-CA-010844, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 11/18/03). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Cotto v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 03-CA-000748, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 01/22/03). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Cowart v. Liggett Group Inc., *et al.*</u>, Case No. 98-01483-CA, Circuit Court of the 4th Judicial Circuit, Duval County (case filed 03/16/98). One individual suing. Liggett is the only tobacco company defendant in this case. The case is dormant.

<u>Cox v. R.J. Reynolds, *et al.*</u>, Case No. 05-CA-000677, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 01/21/05). One individual suing. There has been no recent activity in this case.

<u>Diamond v. R.J. Reynolds, *et al.*</u>, Case No. 08-24533, Circuit Court of the 17th Judicial Circuit, Broward County (case filed 05/30/08). One individual suing. There has been no recent activity in this case.

<u>Ditslear v. R.J. Reynolds, *et al.*</u>, Case No. 05-CA-000899, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 01/28/05). One individual suing. There has been no recent activity in this case.

<u>Fine v. Philip Morris, Inc., *et al.*</u>, Case No. 08-000383 (AA), Circuit Court of the 15th Judicial Circuit, Palm Beach County (case filed 01/07/08). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Fuchs v. R.J. Reynolds, *et al.*</u>, Case No. 05-CA-000681, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 01/21/05). One individual suing. There has been no recent activity in this case.

<u>Gentile v. R.J. Reynolds, *et al.*</u>, Case No. 50215CA-005405XXXXMB, Circuit Court of the 15th Judicial Circuit, Palm Beach County (case filed 05/26/15). One individual suing on behalf of the estate and survivors of a deceased smoker.

<u>Grant v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 03-CA-002673, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 03/17/03). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Grose v. R.J. Reynolds, *et al.*</u>, Case No. 08-38276, Circuit Court of the 17th Judicial Circuit, Broward County (case filed 08/15/08). One individual suing on behalf of the estate and survivors of a deceased smoker. In addition to Liggett, Vector Tobacco is named as a defendant. In October 2008, defendants filed a motion to dismiss the complaint. A hearing has not been scheduled.

<u>Hearne v. R.J. Reynolds, *et al.*</u>, Case No. 06-CA-000550, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 01/20/06). One individual suing. There has been no recent activity in this case.

<u>Hecker v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 03-CA-009336, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 10/07/03). One individual suing. There has been no recent activity in this case.

Laschke, *et al.* v. R.J. Reynolds, *et al.*, Case No. 96-8131-CI-008, Circuit Court of the 6th Judicial Circuit, Pinellas County (case filed 12/20/96). Two individuals suing. The dismissal of the case was reversed on appeal, and the case was remanded to the trial court. An amended complaint was filed by the plaintiffs. In January 2006, defendants filed motions to dismiss the amended complaint. A hearing has not been scheduled.

<u>Lewis v. R.J. Reynolds, *et al.*</u>, Case No. 05-CA-002167, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 03/09/05). One individual suing. There has been no recent activity in this case.

<u>McDonald v. Brown & Williamson Tobacco Co., *et al.*, Case No. 03-CA-004767, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 05/19/03). One individual suing. In January 2008, plaintiff filed a motion to amend the complaint alleging that plaintiff is a member of the *Engle* class. There has been no further activity in the case.</u>

<u>Meckler v. Liggett Group Inc.</u>, Case No. 97-03949-CA, Circuit Court of the 4th Judicial Circuit, Duval County (case filed 07/10/97). One individual suing. Liggett is the only defendant in this case. The case is dormant.

<u>Morgan v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 02-CA-007084, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 08/02/02). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Quinn v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 03-CA-004768, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 05/19/03). One individual suing. There has been no recent activity in this case.

<u>Schuman v. R.J. Reynolds, *et al.*</u>, Case No. 04-CA-009409, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 10/18/04). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Shaw v. R.J. Reynolds, *et al.*</u>, Case No. 05-CA-002863, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 03/30/05). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

<u>Spivak v. Philip Morris Inc., *et al.*</u>, Case No. 08-19309 (AH), Circuit Court of the 15th Judicial Circuit, Palm Beach County (case filed 06/26/08). One individual suing on behalf of the estate and survivors of a deceased smoker. There has been no recent activity in this case.

Swindells v. R.J. Reynolds, *et al.*, Case No. 06-CA-007837, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 09/01/06). One individual suing. There has been no recent activity in this case.

<u>Ward v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 03-CA-008480, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 09/11/03). One individual suing. There has been no recent activity in this case.

<u>Witt v. Brown & Williamson Tobacco Co., *et al.*</u>, Case No. 04-CA-008530, Circuit Court of the 13th Judicial Circuit, Hillsborough County (case filed 09/21/04). One individual suing. There has been no recent activity in this case.

<u>Louisiana</u>

<u>Oser v. The American Tobacco Co., *et al.*</u>, Case No. 97-9293, Circuit Court of the Civil District Court, Parish of Orleans (case filed 05/27/97). One individual suing. There has been no recent activity in this case.

<u>Reese, *et al.* v. R. J. Reynolds, *et al.*</u>, Case No. 2003-12761, Circuit Court of the 22nd Judicial District Court, St. Tammany Parish (case filed 06/10/03). Five individuals suing. There has been no recent activity in this case.

Maryland

<u>Bearman, *et al.* v. Union Carbide Corporation, *et al.*, Case No. 24-X-14-000303, Circuit Court, Baltimore City (case filed 07/13/15). Two individuals suing. Plaintiff and his wife seek damages allegedly caused by exposure to asbestos and cigarettes, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants, including Liggett Group, LLC.</u>

<u>Cook, *et al.* v. Union Carbide Corporation, *et al.*, Case No. 24-X-13-000445, Circuit Court, Baltimore City (case filed 09/12/13). Two individuals suing. Plaintiff and his wife seek damages allegedly caused by exposure to asbestos and cigarettes, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants. In November 2013, defendants moved to dismiss the complaint. The motion is pending.</u>

<u>Cowens, *et al.* v. John Crane-Houdaille Inc., *et al.*, Case No. 24-X-11-000335, Circuit Court, Baltimore City (case filed 09/12/13). Three individuals suing. Plaintiffs are the surviving children of decedent Frank E. Cowens. Plaintiffs seek damages allegedly caused to decedent by exposure to asbestos and cigarette smoke, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants,</u>

including Vector Tobacco Inc. In January 2014, defendants moved to dismiss the complaint. The motion is pending.

<u>Culotta, *et al.* v. Union Carbide Corporation, *et al.*, Case No. 24-X-12-000690, Circuit Court, Baltimore City (case filed 06/20/13). One individual suing. Plaintiff seeks damages allegedly caused to decedent by exposure to asbestos and cigarette smoke, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants. In July 2013, defendants moved to dismiss the complaint. The motion is pending.</u>

<u>Fales Jr., *et al.* v. John Crane-Houdaille, Inc., *et al.*, Case No. 24-X-11-000326, Circuit Court, Baltimore City (case filed 06/10/13). One individual suing. Plaintiff is the surviving child of decedent Lolita Fales. Plaintiff seeks damages allegedly caused to decedent by exposure to asbestos and cigarette smoke, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants. In July 2013, defendants moved to dismiss the complaint. The motion is pending.</u>

Lively, Jr., *et al.* v. Union Carbide Corporation, *et al.*, Case No. 24-X-13-000710, Circuit Court, Baltimore City (case filed 03/20/15). One individual suing. Plaintiff seeks damages allegedly caused to decedent by exposure to asbestos and cigarette smoke, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants, including Liggett Group LLC and Vector Tobacco Inc. In April 2015, defendants moved to dismiss the complaint. The motion is pending.

<u>Sapp, *et al.* v. Union Carbide Corporation, *et al.*, Case No. 24-X-14-000310, Circuit Court, Baltimore City (case filed 07/13/15). Four individuals suing. Plaintiffs seek damages allegedly caused by exposure to asbestos and cigarettes, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants, including Liggett Group.</u>

<u>Schwartz, et al. v. Union Carbide Corporation, et al.</u>, Case No. 24-X-15-000074, Circuit Court, Baltimore City (case filed 05/22/15). One individual suing. Plaintiff seeks damages allegedly caused to decedent by exposure to asbestos and cigarette smoke, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants, including Liggett Group LLC. In June 2015, defendants moved to dismiss the complaint. The motion is pending.

<u>Thorpe, et al.</u> v. Union Carbide Corporation, et al., Case No. 24-X-14-000225, Circuit Court, Baltimore City (case 05/16/14). Two individuals suing. Plaintiffs are the surviving children of decedent Alice P. Thorpe. Plaintiffs seek damages allegedly caused to decedent by exposure to asbestos and cigarette smoke, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants, including Liggett Group LLC. In July 2014, defendants moved to dismiss the complaint. The motion is pending.

<u>Wilt, *et al.* v. Union Carbide Corporation, *et al.*, Case No. 24-X-12-000529, Circuit Court, Baltimore City (case filed 04/24/14). Two individuals suing. Plaintiff and his wife seek damages allegedly caused by exposure to asbestos and cigarettes, with claims against certain asbestos manufacturer defendants and certain tobacco company defendants. In July 2014, defendants moved to dismiss the complaint. The motion is pending.</u>

<u>Missouri</u>

<u>Nuzum, *et al.* v. Brown & Williamson Tobacco Corporation, *et al.*, Case No. 03-cv-237237, Circuit Court, Jackson County (case filed 05/21/03). Two individuals suing. A status conference is scheduled for June 24, 2016.</u>

<u>New York</u>

<u>Brantley v. The American Tobacco Company, *et al.*, Case No. 114317/01, Supreme Court of New York, New York County (case filed 07/23/01). One individual suing. The case is stayed by stipulation of the parties.</u>

<u>Debobes v. The American Tobacco Company, *et al.*, Case No. 29544/92, Supreme Court of New York, Nassau County (case filed 10/17/97). One individual suing. There has been no recent activity in this case.</u>

<u>Hausrath, *et al.* v. Liggett Group LLC</u>, Case No. I2001-09526, Supreme Court of New York, Erie County (case filed 01/24/02). Two individuals suing. Liggett is the only remaining defendant. In July 2013, the court granted plaintiffs' motion to restore the case to the active docket calendar. Liggett appealed, and the intermediate appellate court affirmed the lower court's decision. There has been no further activity at the trial level at this time.

James v. The American Tobacco Company, *et al.*, Case No. 103034/02, Supreme Court of New York, New York County (case filed 04/04/97). One individual suing. There has been no recent activity in this case.

<u>Shea, *et al.* v. The American Tobacco Company, *et al.*, Case No. 008938/03, Supreme Court of New York, Nassau County (case filed 10/17/97). Two individuals suing. In December 2008, the trial court granted defendants' motion to dismiss plaintiffs' claims for punitive damages as barred by the industry's 1998 settlement with the New York Attorney General, but denied the defendants' motion to dismiss the case. The dismissal of the punitive damages claim was affirmed by the intermediate appellate court in May 2010. Plaintiffs' motion to reargue the decision was denied by the appellate court.</u>

<u>Standish v. The American Tobacco Company, *et al.*</u>, Case No. 18418-97, Supreme Court of New York, Bronx County (case filed 07/28/97). One individual suing. There has been no recent activity in this case.

Tomasino, *et al.* v. The American Tobacco Company, *et al.*, Case No. 027182/97, Supreme Court of New York, Nassau County (case filed 09/23/97). Two individuals suing. In June 2009, the trial court granted defendants' motion to dismiss plaintiffs' claims for punitive damages as barred by the industry's 1998 settlement with the New York Attorney General, but denied the defendants' motion to dismiss the case. The dismissal of the punitive damages claim was affirmed by the intermediate appellate court in May 2010. Plaintiffs' motion to reargue the decision was denied by the appellate court.

<u>Yedwabnick v. The American Tobacco Company, *et al.*</u>, Case No. 20525/97, Supreme Court of New York, Queens County (case filed 09/19/97). One individual suing. There has been no recent activity in this case.

<u>Ohio</u>

<u>Croft, *et al.* v. Akron Gasket & Packing, *et al.*, Case No. CV04541681, Court of Common Pleas, Cuyahoga County (case filed 08/25/05). Two individuals suing. There has been no recent activity in this case.</u>

West Virginia

<u>Brewer, et al. v. The American Tobacco Company, et al.</u>, Case No. 01-C-82, Circuit Court, Ohio County (case filed 03/20/01). Two individuals suing. There has been no recent activity in this case.

<u>Little v. The American Tobacco Company, *et al.*</u>, Case No. 01-C-235, Circuit Court, Ohio County (case filed 06/04/01). One individual suing. There has been no recent activity in this case.

II. CLASS ACTION CASES

A. Smoking Related.

In Re: Tobacco Litigation (Personal Injury Cases), Case No. 00-C-5000, Circuit Court, West Virginia, Ohio County (case filed 01/18/00). Although not technically a class action, the court consolidated approximately 750 individual smoker actions that were pending prior to 2001 for trial on some common related issues. Liggett was severed from trial of the consolidated action. After two mistrials, in May 2013, the jury rejected all but

one of the plaintiffs' claims, finding in favor of plaintiffs on the claim that ventilated filter cigarettes between 1964 and July 1, 1969 should have included instructions on how to use them. The issue of damages was reserved for further proceedings. The court entered judgment in October 2013, dismissing all claims except the ventilated filter claim. The judgment was affirmed on appeal and remanded to the trial court for further proceedings. In April 2015 the plaintiffs filed a petition for writ of certiorari to the United States Supreme Court and the Supreme Court declined review. On July 13, 2015, the trial court ruled on the scope of the remaining ventilated cigarette filter claim and determined that only 30 plaintiffs have viable claims against the non-Liggett defendants and the trial court requested that Liggett and plaintiffs brief whether any claims against Liggett survive given the outcome of the first phase of the trial. Briefing of that issue is underway. When the case proceeds against Liggett, it is estimated that Liggett could be a defendant in less than 25 of the remaining individual cases.

<u>Parsons, *et al.* v. A C & S Inc., *et al.*, Case No. 98-C-388, Circuit Court, West Virginia, Ohio County (case filed 02/09/98). This class action is brought on behalf of plaintiff's decedent and all West Virginia residents who allegedly have personal injury claims arising from their exposure to cigarette smoke and asbestos fibers. The complaint seeks to recover unspecified compensatory and punitive damages for all potential members of the class. The plaintiff alleges that Parsons' use of tobacco products and exposure to asbestos products caused her to develop lung cancer and to become addicted to tobacco. The case is stayed as a result of the December 2000 bankruptcy petitions filed by three defendants (Nitral Liquidators, Inc., Desseaux Corporation of North America and Armstrong World Industries) in the United States Bankruptcy Court for the District of Delaware.</u>

<u>Young, et al.</u> v. American Brands Inc., et al., Case No. 97-19984cv, Civil District Court, Louisiana, Orleans Parish (case filed 11/12/97). This purported personal injury class action is brought on behalf of plaintiff and all similarly situated residents in Louisiana who, though not themselves cigarette smokers, were exposed to secondhand smoke from cigarettes that were manufactured by the defendants, including Liggett, and suffered injury as a result of that exposure. No class certification hearing has been held. The plaintiffs sought to recover an unspecified amount of compensatory and punitive damages. No class certification hearing has been held. In October 2004, the trial court stayed the *Young* case pending the outcome of an appeal in *Scott v. American Tobacco Co.*, a case seeking medical monitoring for Louisiana smokers in which Liggett was not a party. The *Scott* case was tried to a jury which denied the medical monitoring claim but determined instead that the defendants must establish a smoking cessation program. That program is ongoing. The *Scott* case is now final.

In 2013, plaintiffs' filed a motion to stay the case. The defendants did not oppose and the stay was entered by the court.

B. Price Fixing.

<u>Smith, *et al.* v. Philip Morris, Inc., *et al.*, Case No. 00-cv-26, District Court, Kansas, Seward County (case filed 02/07/00). In this class action, plaintiffs allege that defendants conspired to fix, raise, stabilize, or maintain prices for cigarettes in Kansas. The court granted class certification in November 2001. In November 2010, codefendants filed a motion for summary judgment. In addition to joining that summary judgment motion, Liggett filed a summary judgment motion in June 2011. In March 2012, the court granted the defendants' motions and dismissed the plaintiffs' claims with prejudice. In July 2014, the court of appeals affirmed the lower court's decision. On August 18, 2014, plaintiffs submitted a petition for review to the Kansas Supreme Court. A decision is pending. On June 29, 2015, the Kansas Supreme Court denied plaintiffs' petition for review.</u>

III. HEALTH CARE COST RECOVERY ACTIONS

<u>Crow Creek Sioux Tribe v. The American Tobacco Company, *et al.*, Case No. cv-97-09-082, Tribal Court of the Crow Creek Sioux Tribe, South Dakota (case filed 09/26/97). The plaintiff seeks to recover actual and punitive damages, restitution, funding of a clinical cessation program, funding of a corrective public education program and disgorgement of unjust profits from alleged sales to minors. The case is dormant.</u>